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1.	Introduction	
1.1	7-Transmembrane	receptors	
	
Since	the	description	of	the	first	7-transmembrane	receptor	(7TMR)	in	1983,1	the	importance	of	this	
class	 of	 receptors,	 in	 drug	 research	 and	 development,	 has	 constantly	 increased	 and	 could	 not	 be	
overestimated.	 Fredriksson	 et	 al.	 identified	 802	 human	 7TMR	 (also	 termed	 G	 protein-coupled	
receptors	 or	 GPCR)	 genes	 and	 divided	 them	 into	 five	 families	 based	 on	 phylogenetic	 criteria.	 The	
families	 were	 termed	 Glutamate,	 Rhodopsin,	 Adhesion,	 Frizzled/Taste2	 and	 Secretin	 (this	
classification	 is	 shortened	 to	 GRAFS).2	 These	 proteins	 share	 two	 features;	 first	 they	 all	 have	 7	
stretches	of	25-35	amino	acids	with	high	degree	of	hydrophobicity,	which	enables	them	to	span	the	
cell	membrane.	The	second	feature	 is	their	ability	to	 interact	with	heterotrimeric	G	proteins.2,3	The	
Secretin	 receptor	 family	 consists	 of	 15	 members.	 All	 deorphanized	 members	 of	 this	 family	 bind	
peptide	 hormones.	 The	Adhesion	 receptor	 family	 consists	 of	 33	members	 and	 can	 be	 divided	 into	
eight	subgroups.	The	members	of	this	family	have	diverse	and	long	N-termini	with	a	proteolytic	site	
and	several	functional	domains.	Only	three	members	of	this	class	have	been	deorphanized	so	far.	The	
Glutamate	 receptor	 family	 consists	 of	 22	 7TMRs,	 8	 metabotropic	 glutamate	 receptors,	 2	 GABA	
receptors,	 one	 calcium-sensing	 receptor	 as	 well	 as	 7	 orphan	 receptors.	 The	 ligand-binding	 was	
compared	to	a	Venus	 flytrap	mechanism,	 in	which	the	two	 lobes	of	 the	extracellular	 region	form	a	
cavity	where	glutamate	binds	and	thereby	activates	the	receptor.	The	Frizzeld/Taste2	receptor	family	
consists	of	36	members.	The	Frizzeld	receptors	bind	the	family	of	Wnt	glycoproteins	and	control	cell	
fate,	 proliferation	 and	 polarity.	 With	 672	 members,	 the	 Rhodopsin	 receptor	 family	 is	 by	 far	 the	
biggest	7TMR	receptor	family.	This	family	has	been	further	divided	into	α,	β,	γ	and	δ	branches.	The	α	
branch	contains	many	important	drug	targets	like	histamine,	dopamine,	and	serotonin	receptors.	The	
β	 branch	 includes	mainly	 peptide-binding	 receptors	 like	 endothelin	 and	 oxytocin	 receptors.	 The	 γ	
branch	has	several	members	that	are	of	 interest	for	drug	development	 like	angiotensin,	opioid	and	
somatostatin	receptors.	The	δ	branch	contains	a	variety	of	receptors,	activated	by	nucleotides,	lipids	
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or	 peptides,	 e.g.	 P2Y	 receptors,	 protease	 activated	 receptors	 (PAR),	 leukotriene	 as	 well	 as	 the	
olfactory	and	many	orphan	receptors.2,4	
The	 importance	of	 the	7TMRs	could	be	evident	by	their	ability	 to	bind	to	a	broad	range	of	 ligands,	
including	inorganic	ions,	small	organic	compounds,	lipid	metabolites,	peptides	and	even	proteins	and	
translate	the	binding	 into	 intracellular	 information.	This	class	of	proteins	has	 its	origins	 in	the	early	
evolution	 of	 eukaryotes.	 During	 evolution	 7TMRs	 underwent	 substantial	 expansion	 and	
pseudogenization.	This	made	some	7TMRs	essential	for	eukaryotic	life	and	enabled	many	organisms	
to	 readily	 adapt	 to	new	 sensory	 functions,	which	may	 represent	 an	evolutionary	 advantage.5,6	Not	
only	 is	 the	 physiological	 role	 of	 this	 protein	 family	 outstanding	 but	 also	 its	 current	 share	 in	 the	
druggable	human	genome.	Approximately	30%	of	the	marketed	drugs	target	a	7TMR,	which	makes	it	
the	most	successfully	addressed	protein	family	of	drug	targets.7,8	Nevertheless,	the	assumption	that	
7TMRs	 have	 achieved	 their	 full	 potential	 as	 drug	 targets	 cannot	 be	more	misleading.	 Taking	 into	
consideration	 that	 the	 pharmacology	 of	 7TMRs	 is	 complex	 and	 that	 the	 currently	 available	 drugs	
exert	 their	 effect	 via	 only	 few	 receptors	 of	 this	 large	 family	 (e.g.	 less	 than	 30%	 of	 non-olfactory	
7TMRs	are	targeted	with	aminergic	receptors	being	heavily	drugged),	there	is	still	a	huge	untapped	
potential	for	this	class	of	proteins	in	the	development	of	novel	drugs.9,10		
1.2	Neuropathic	pain	
Neuropathic	pain,	according	to	the	international	association	for	the	study	of	pain	(IASP),	is	defined	as	
“pain	caused	by	a	lesion	or	disease	of	the	somatosensory	nervous	system”.	Neuropathic	pain	affects	
up	to	10%	of	the	population	according	to	community-based	surveys	and	causes	substantial	disability,	
but	 current	 treatment	 is	 inadequate.	 It	 is	associated	with	 sensory	abnormalities,	 including	ongoing	
pain	 and	 paraesthesia	 (an	 abnormal	 sensation	 of	 tingling,	 prickling	 or	 burning	 of	 the	 skin	without	
apparent	physical	effect),	and	altered	stimulus–response	function,	including	allodynia	(such	that	low	
threshold	 stimuli,	 e.g.	 brushing	 of	 the	 skin,	 can	 evoke	 pain),	 hyperalgesia	 (increased	 sensitivity	 to	
noxious	stimuli),	and	loss	of	sensation	in	some	areas.11-13	The	most	common	etiologies	of	neuropathic	
pain	 in	 humans	 are	 metabolic	 diseases	 (diabetes),	 viral	 diseases	 (herpes	 zoster),	 immunological	
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mechanisms	 (multiple	 sclerosis),	 spinal	 cord	 injuries	 and	 alcoholism.14	 Itch	 (pruritus)	 is	 another	
unpleasant	 sensation,	which	was	 given	 a	 still-valid	 definition	more	 than	 340	 years	 ago	 by	 Samuel	
Hafenreffer	as	“unpleasant	sensation	that	elicits	the	desire	or	reflex	to	scratch”.	Clinical	relevance	is	
obviously	highest	in	chronic	itch	conditions	that	last	longer	than	3	months.	In	many	cases	such	as	dry	
skin,	 atopic	 eczema,	psoriasis,	 urticaria,	 scabies	 and	other	 inflammatory	 skin	diseases,	 chronic	 itch	
comprises	more	complex	skin-associated	symptoms	than	are	seen	in,	for	example,	acute	insect	bite	
reactions	(see	table	1).15	
Table	1:	Clinical	classification	of	itch	
Clinical	classification	 Mediators	and	mechanisms	 Diagnosis	 Therapy	
Itch	caused	by	skin	
disorders	
Histamine,	interleukins,	
prostaglandin	and	
proteases	
Inflammatory	
dermatoses	(atopic	
dermatitis,	psoriasis,	
drug	reactions,	mites	and	
urticaria)	and	dry	skin	
Antihistamines,	anti-
inflammatory,	immuno-
modulatory	topical	and	
systemic	therapy	
(cyclosporine	A,	
pimecrolimus,	tacrolimus	
and	corticosteroids)	
Itch	caused	by	systemic	
disorders	 Opiates,	interleukins?	
Chronic	liver	disease	and	
chronic	renal	failure	
Naltrexone,	 -opioid	
receptor	agonists	and	
gabapentin	
Neuropathic	itch	
Damage	to	nerve	fibres,	
neuropeptides	(such	as	
substance	P)	and	
proteases	
Postherpetic	pruritus,	
notalgia	paresthetica	and	
brachioradial	pruritus		
Gabapentin,	pregabalin	
and	capsaicin	
Psychogenic	itch	 Serotonin,	noradrenaline	 Delusions	of	parasitosis,	stress	and	depression	
Olanzapine,	pimozide	
and	SSRI	antidepressants	
Although	 pain	 and	 itch	 are	 universal	 sensations,	 elucidating	 the	molecular	 underpinnings	 of	 these	
processes	 is	 far	 from	being	 complete.	 Itch	 can	be	 reduced	by	painful	 stimuli;	 analgesia	 can	 reduce	
this	inhibition	and	so	enhance	itch.	This	phenomenon	is	particularly	relevant	to	spinally	administered	
μ-opioid	receptor	agonists,	which	induce	segmental	analgesia	that	is	often	combined	with	segmental	
pruritus.	Given	that	μ-opioids	can	induce	itch,	 it	 is	not	surprising	that	μ-opioid	receptor	antagonists	
have	antipruritic	effects	in	experimental	itch	studies.	Interestingly,	buprenorphine,	a	drug	combining	
μ-opioid	antagonistic	and	ĸ-opioid	agonistic	effects,	has	been	used	therapeutically	to	fight	intractable	
itch.15	Intriguingly,	an	accumulating	evidence	suggests	that	itch-specific	neurons	constitute	a	subset	
of	TRPV1-positive	(transient	receptor	potential	V1)	neurons,	which	were	initially	presumed	to	be	all	
nociceptors.16	In	recent	years	several	proteins	involved	in	sensory	functions	like	purinergic	receptors,	
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tetrodotoxin	 (TTX)	 insensitive	 sodium	channels	 consolidated	our	understanding	of	 nociception	 and	
itch,	but	the	discovery	of	mas-related	gene	receptors	in	2001	opened	new	avenues	in	the	elucidation	
of	 neuropathic	 pain	 as	 well	 as	 itch.	 It	 also	 represents	 a	 novel	 possibility	 to	 develop	 powerful	
pharmacological	tools	and	drugs	for	several	clinical	cases.17	
1.3	MAS-related	gene	receptors	
 
Mas-related	 gene	 receptors	 (MRGs)	 belong	 to	 the	 7	 transmembrane	 receptors	 (7TMRs).	 These	
receptors	 are	 in	 the	δ	branch	of	 the	Rhodopsin	 receptor	 family	 together	with	purine,	 glycoprotein	
and	olfactory	receptors.2	This	receptor	family	was	discovered	independently	by	two	groups.	Dong	et	
al.	exploited	the	fact	that	mouse	embryos	lacking	the	transcription	factor	neurogenin1	fail	to	develop	
sensory	 neurons.	 By	 subtracting	 the	 cDNA	 from	 neonatal	 wild-type	 and	 deficient	 mice,	 signaling	
molecules	 involved	 in	 nociception	 emerged.	 In	 their	 first	 paper	 they	 reported	 31	 murine	 and	 8	
human	 intact	 coding	 sequences	 belonging	 to	 7TMR,	 which	 they	 designated	 mas-related	 gene	
receptors	(MRGs)	due	to	their	relatedness	to	the	mas	oncogene.17		Lembo	et	al.	discovered	the	same	
7TMR	 family	 during	 search	 in	 the	 RNA	 isolated	 from	 a	 primary	 culture	 of	 rat	 dorsal	 root	 ganglia	
(DRG).	 Due	 to	 their	 unique	 expression	 in	 small	 nociceptive	 sensory	 neurons,	 they	 were	 named	
sensory	 neuron-specific	 receptors	 (SNSRs).18	 In	 order	 to	 avoid	 any	 confusion,	 the	 HUGO	 Gene	
Nomenclature	 Committee	 refers	 to	 these	 proteins	 as	 MAS-related	 G	 protein-coupled	 receptors	
(MRGPR).	This	abbreviation	will	be	adopted	from	now	on	in	this	thesis	and	capital	letter	abbreviation	
(MRGPR)	will	be	used	for	proteins	and	small	letter	one	(mrgpr)	would	be	used	to	refer	to	the	gene	or	
mRNA.	MRGPRs	represent	the	nonodorant	7TMR	family	with	the	largest	number	of	members	known	
so	 far	 as	 shown	 in	 figure	 1.19	 The	 MRGPR	 family	 consists	 of	 38	 members	 (see	 table	 2)	 that	 are	
grouped	 into	nine	distinct	 subfamilies	 (MRGPRA	to	–H	and	–X)	and	belongs	 to	 the	δ	branch	of	 the	
Rhodopsin	 receptor	 family.	 According	 to	 our	 current	 knowledge,	 the	mrgprA	 subfamily	 consists	 of	
one	member	in	the	rat	and	18	protein-coding	genes	in	the	mouse	as	well	as	many	pseudogenes.	The	
mrgprB	subfamily	comprises	7	 in	the	rat,	9	 in	the	mouse	and	several	pseudogenes	 in	both	species.	
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The	mrgprC	subfamily	has	one	protein-coding	member	in	the	rat	and	one	in	the	mouse,	in	addition	to	
13	pseudogenes	in	the	mouse.	The	mrgprD-G	subfamilies	comprise	only	one	member	each	in	mouse,	
rat	and	human.	The	mrgprH	subfamily	has	again	one	member	in	the	mouse	and	the	rat	but	it	is	not	
found	 in	 human.	 The	 rat	mrgprF	 gene	was	 actually	 first	 reported	 in	 1990	 and	 named	 rat	 thoracic	
aorta	(RTA)	gene.	The	related	mas1L	gene	was	reported	in	1991.	The	last	subfamily	is	called	mrgprX	
and	 it	 is	 primate-specific	 and	 comprises	 only	 4	 members	 mrgprX1-4	 while	 the	 other	 reported	
sequences	are	polymorphisms	of	these	4	members.	All	the	members	are	still	considered	orphan	by	
the	International	Union	of	Basic	and	Clinical	Pharmacology	(IUPHAR)19,20	It	was	also	possible	to	clone	
members	 of	 the	 mrgprX	 subfamily	 from	 other	 primates	 like	 crab-eating	 macaque	 (Macaca	
fascicularis)	and	rhesus	monkey.	This	enables	development	of	animal	models	for	this	primate-specific	
subfamily.22,23	
Subfamilies	A,	B,	C	and	H	are	rodent-specific,	subfamily	X	is	primate-specific	and	subfamilies	D-G	are	
conserved	in	rodents	and	primates	(see	table	2).	The	evolution	of	mrgpr	genes	indicate	that	mrgprD-
G	are	old	genes	but	since	no	mrgpr	member	was	found	outside	Tetrapoda,	it	is	tempting	to	conclude	
that	 this	 family	 of	 genes	 has	 emerged	 after	 the	 divergence	 of	 bony	 fish	 from	 the	 line	 leading	 to	
Tetrapoda.	 MrgprH	 is	 the	 oldest	 gene	 since	 it	 includes	 a	 frog	 and	 two	 chicken	 members.	
Interestingly,	 all	 genes	 for	 mrgpr	 other	 than	 mas,	 mas1L,	 and	 mrgprH	 are	 located	 on	 a	 single	
chromosome	 in	 human	 (chromosome	 11),	 rat	 (chromosome	 1),	 and	 mouse	 (chromosome	 7)	 as	
shown	in	figure	2.20	In	addition,	an	evolutionary	analysis	on	the	mrgpr	gene	subfamilies	in	human	and	
mouse	 was	 performed.	 A	 pairwise	 comparison	 of	 the	 members	 within	 each	 subfamiliy	 was	
conducted	and	the	Ka/Ks	ratios	were	calculated	(the	ratio	between	nonsynonymous	and	synonymous	
substitution	 rates).	 Interestingly,	 the	 results	 showed	a	 robust	positive	 selection	 in	 the	extracellular	
regions,	 whereas	 the	 intracellular	 loops	 as	 well	 as	 7	 transmembrane	 helices	 were	 under	 negative	
selection.	 Since	 the	 extracellular	 loops	 are	 responsible	 for	 ligand	 binding,	 this	 suggests	 that	 these	
receptors	could	couple	to	non-related	ligands.	This	was	especially	the	case	for	the	human	MRGPRX	
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subfamily,	 which	 showed	 an	 excess	 of	 radical	 amino	 acid	 replacements	 that	 usually	 influence	 the	
function	of	the	protein.21		
	
Figure	1:	Phylogeny	of	mas-related	seven	transmembrane	receptors.	A	phylogenetic	tree	of	all	38	mrgpr	members	from	the	
nine	mrgpr	subfamilies	(A–H,	X)	of	mice	(m),	rat	(r),	human	(h),	and	rhesus	monkey	(Rh).19	
	
Table	2:	The	different	subfamilies	of	mas-related	protein-coding	genes	and	their	number	in	mouse,	rat	and	
human	
Subfamily	 Number	of	genes	
Mouse	 Rat	 human	
mrgprA*	 18	 1	 n.a	
mrgprB**	 9	 7	 n.a	
mrgprC*	 1	 1	 n.a	
mrgprD	 1	 1	 1	
mrgprE	 1	 1	 1	
mrgprF	 1	 1	 1	
mrgprG	 1	 1	 1	
mrgprH	 1	 1	 n.a	
mrgprX	 n.a	 n.a	 4	
n.a:	not	available	
*:	several	pseudogenes	in	the	mouse	
**:	several	pseudogenes	in	both	rat	and	mouse	
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Figure	2:	Chromosomal	 (Chr.)	 localizations	of	mrgpr	genes	 in	human,	 rat,	and	mouse.	The	genes	are	 shown	as	arrows	 in	
their	direction	of	transcription.20	
Since	the	mouse	has	more	than	20	mrgprA	and	14	mrgprC	genes	and	pseudogenes	(rat	has	only	one	
from	each	subfamily),	the	big	expansion	of	the	mrgpr	family	in	mouse	has	also	been	investigated.	The	
suggested	 model	 was	 that	 mrgprA	 and	 mrgprC	 had	 a	 common	 ancestor	 gene	 whereas	 mrgprB	
originated	from	a	different	ancestor.	Of	note,	according	to	the	model	mrgprX	receptors	should	have	
had	 the	 same	 ancestor	 as	mrgprA	 and	mrgprC.	 The	 expansion	 in	mice	 took	 place	 after	 rat-mouse	
speciation	due	to	retrotransposon-mediated	crossover	events.	The	findings	suggest	that	the	diversity	
of	mrgpr	 in	 rodents	 could	be	 reduced	 to	a	 core	 set	of	4	different	genes	approximating	 the	 limited	
mrgpr	diversity	 in	 humans.24	Unfortunately,	 despite	 the	probable	 redundancy	 in	 rodents,	 the	 later	
investigations	 revealed	 that	 it	 is	 not	 accurate	 to	 oversimplify	 the	 diversity	 of	mrgpr	 in	 rodents	 as	
discussed	below.		
The	expression	of	different	MRGPR	subfamilies	and	receptors	was	a	major	point	of	interest	since	the	
very	 discovery	 of	 these	 receptors.	 The	 restricted	 expression	 in	 dorsal	 root	 ganglia	 (DRG)	 is	 an	
indication	of	 involvement	in	nociception.	 In	more	details,	two	main	populations	of	sensory	neurons	
of	 the	 DRG	 emerge	 in	 the	 adulthood.	 The	 first	 population	 is	 called	 peptidergic	 neurons.	 These	
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neurons	 are	 regulated	 by	 nerve	 growth	 factor	 (NGF)	 and	 its	 trk	A	 receptor.	 NGF	 enhances	 the	
expression	 of	 peptides	 like	 substance	 P	 and	 calcitonin	 gene-related	 peptide	 (CGRP).	 The	 second	
population	 is	 non-peptidergic	 neurons.	 These	 neurons	 are	 regulated	 by	 glial	 cell	 line-derived	
neurotropic	 factor	 (GDNF)	and	 its	ret	receptor.	These	neurons	do	not	contain	substance	P	or	CGRP	
but	they	express	P2X3	receptors.	Most	importantly,	the	non-peptidergic	neurons	bind	the	isolectin-
B4	 (IB4+).25,26	 Interestingly,	 IB4+	neurons	respond	preferentially	 to	non-noxious	 inputs,	which	are	a	
main	 characteristic	 of	 neuropathic	 pain	 as	well	 as	 an	 indication	 of	 the	 involvement	 in	 establishing	
chronic	 pain	 states.27,28	 This	 suggests	 that	 selectively	 targeting	 a	 biochemical	 molecule	 in	 IB4+	
neurons	may	be	an	approach	to	deal	with	neuropathic	pain.	Dong	et	al.	found	a	distinct	expression	
profile	 of	mouse	MRGPRA2-8	 receptor	 subtypes	 in	 different	 subpopulations	 of	 IB4+	 neurons	with	
some	overlapping	 in	 the	expression	at	 least	 at	birth.	Moreover,	 it	was	discovered	 that	 there	 is	 ca.	
15%	 overlapping	 between	 MRGPRA	 subtypes	 and	 MRGPRD	 receptor	 at	 birth.	 Nevertheless,	 in	
adulthood	 the	 expression	 will	 be	 segregated.17	 Most	 interestingly,	 MRGPRD+	 and	 MRGPRB4+	
neurons	 in	 adult	 mice	 innervate	 distinct	 peripheral	 targets,	 skin	 epidermis	 and	 the	 hairy	 skin,	
respectively.29,30	The	reason	behind	this	compartmentalized	expression	seems	to	be	the	runt	domain	
transcription	 factor	 Runx1.	 It	 turned	 out	 that	 MRGPRA/B/C	 expression	 persists	 only	 in	 Runx1	
negative,	whereas	the	MRGPRD	compartment	is	Runx1	positive	as	illustrated	in	figure	3.31		
	
Figure	 3:	 Schematics	 of	 two	MRGPR	 compartments.	 The	 “A/B/C”	 compartment	 expresses	MRGPRA3/A4,	MRGPRB4,	and	
MRGPRC11	in	a	partially	overlapping	manner,	and	the	“D”	compartment	expresses	MRGPRD.31	
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In	 an	 approach	 to	 overcome	 the	 apparent	 complexity	 and	 potential	 gene	 redundancy,	 Liu	 et	 al.	
generated	 deficient	 mice	 with	 a	 deleted	 845-kilo	 base	 region	 (instead	 of	 knocking	 out	 individual	
genes)	 in	chromosome	7,	which	comprises	30	mrgpr	genes	and	pseudogenes	as	 shown	 in	 figure	2.	
More	 precisely,	 this	 region	 comprises	 12	 intact	 open	 reading	 frames	 (mrgprA1-A4,	 A10,	 A12,	 A14,	
A16,	A19,	B4,	B5	and	C11).	 	 The	deficient	mice	did	not	 show	any	difference	 compared	 to	wt	mice	
regarding	acute	noxious	heat,	cold	mechanical	and	chemical	stimulation.	The	L5	spinal	nerve	ligation	
model	 of	 neuropathic	 pain	 and	 histamine-induced	 itch	 induced	 the	 same	 responses	 in	 wt	 and	
deficient	 mice.	 Interestingly,	 the	 deficient	 mice,	 in	 contrast	 to	 wt	 mice,	 showed	 a	 significantly	
reduced	 itch	 response	 to	 the	 pruritogenic	 anti-malaria	 drug	 chloroquine.	 Further	 investigations	 of	
the	 individual	 knocked	 out	 genes	 revealed	 that	 only	MRGPRA3	 responded	 to	 chloroquine	with	 an	
EC50	of	27	µM.	This	indicated	that	MRGPRA3+	neurons	could	be	histamine-independent	itch-specific	
neurons	 and	 revealed	 its	 potential	molecular	mechanism	 for	 the	 first	 time.32	Wilson	et	 al.	 tried	 to	
further	 investigate	 the	 itch	mechanism,	 in	which	 it	was	 found	 that	 chloroquine	 and	BAM8-22,	 the	
agonists	at	murine	MRGPRA3	and	MRGPRC11,	respectively,	depend	on	transient	receptor	potential	
A1	 (TRPA1)	 for	 their	 itch	 transduction.	 Although	 TRPA1	 is	 expressed	 in	 a	 subset	 of	 TRPV1-positive	
neurons,	it	was	suggested	that	TRPV1	is	not	required	for	BAM8-22	and	chloroquine-dependent	itch.	
In	 contrast,	 TRPV1	 is	 necessary	 for	 histamine-related	 itch.	 Hence,	 selective	 TRPA1,	 MRGPRA3	 or	
MRGPRC11	antagonists	could	inhibit	itch	transduction.33		
In	an	interesting	paper,	it	was	described	that	MRGPRA3+	neurons	in	DRG	could	be	labeled	and	it	was	
demonstrated	 that	 they	 exclusively	 innervate	 the	 epidermis	 of	 the	 skin	 and	 confirmed	 that	 only	
MRGPRA3+	 neurons	 respond	 to	 chloroquine.	 It	 was	 also	 demonstrated	 that	 MRGPRA3+	 neurons	
represent	a	compartment	within	the	pain-related	TRPV1+	neurons.	Most	strikingly,	it	was	shown	that	
capsaicin	would	 induce	only	pain	 in	wild-type	mice	but	the	same	dosage	of	capsaicin	would	 induce	
only	itch	if	the	TRPV1	was	knocked	out	from	all	neurons	except	the	MRGPRA3+	neurons	as	shown	in	
figure	4.	Thus,	it	was	proven	that	MRGPRA3+	neurons	are	itch-specific	neurons	and	the	relatedness	
between	pain,	itch	and	compartmentalization	of	MRGPR	receptors	was	elegantly	demonstrated.34	
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Figure	4:	Both	pruriceptive	(green	circles)	and	non-pruriceptive	(red	circles)	neurons	respond	to	capsaicin.	The	response	is	
pain	if	the	both	types	of	neurons	are	activated	and	itch	if	only	pruriceptive	neurons	are	activated,	modified	from.35	
	
Unfortunately,	the	expression	pattern	of	the	human	MRGPRX	receptors	has	not	been	investigated	in	
detail.	Only	Lembo	et	al.	investigated	the	mRNA	expression	of	mrgprX1	and	mrgprX4	receptors	in	the	
DRG	 and	 trigeminal	 ganglia.	 It	 has	 been	 found	 that	 only	 7	 %	 of	 mrgprX-positive	 cells	 expressed	
substance	 P	 or	 CGRP,	 whereas	 most	 of	 the	 mrgprX-positive-neurons	 bind	 IB4	 (76%)	 and	 many	
express	TRPV1	(56%)	indicating	that	mrgprX	receptors	are	associated	preferentially	with	the	IB4	class	
of	nociceptors.18	
In	 this	 thesis	 the	 main	 interest	 is	 the	 human	 MRGPRX	 subfamily.	 Hence,	 the	 ligands,	 signaling	
pathways	as	well	 as	physiologic	 functions	of	 the	members	of	 this	 family	will	 be	discussed	 in	detail	
(see	 below).	 Nevertheless,	 the	 knowledge	 about	 other	 human	 MRGPR	 subfamilies	 and	 rodent-
specific	 subfamilies	 could	provide	 insights	 into	 the	 functions	of	MRGPRX	 subfamily.	 Therefore,	 the	
current	knowledge	will	be	briefly	mentioned.	
The	 MRGPRD	 subfamily	 consists	 of	 only	 one	 member,	 which	 is	 conserved	 among	 rodents	 and	
humans.	Four	pairings	have	been	suggested	for	this	receptor,	the	first	with	ß-alanine	and	the	second	
with	alamandine	(Ala-angiotensin-1-7).36,37	Two	other	ligands	have	also	been	suggested	(GABA	and	ß-
aminoisobutyric	 acid).	 This	 member	 is	 both	 Gq-	 and	 Gi-coupled	 and	 suggested	 to	 have	 a	 high	
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constitutive	 activity.	 As	 mentioned	 above	 MRGPRD	 has	 its	 own	 compartment	 in	 DRG	 and	 the	
activation	of	MRGPRD+	neurons	 induced	 itch	and	pain.	MRGPRD	is	also	expressed	 in	the	heart	and	
was	shown	to	have	vasodilatory	effects,	which	makes	this	receptor	the	only	member	of	MRGPR	till	
now	that	is	not	only	phylogenetically	but	also	functionally	related	to	the	MAS	gene	receptor.19,	20	The	
human	MRGPRD	is	the	best	characterized	human	MRGPR	member	after	MAS	itself.		
MRGPRE/F/G	subfamilies	consist	of	only	one	member	each	and	do	not	have	any	reported	ligands	till	
now.	This	is	also	the	case	for	the	rodent-specific	MRGPRH	subfamily.	The	rat	MRGPRD	was	shown	to	
form	multi-heterodimers	with	MRGPRE	in	HEK293	cells.	MRGPRE	and	MRGPRF	seem	to	be	linked	as	
well	since	mrgprE	KO	mice	have	a	strong	reduction	in	the	expression	of	MRGPRF	receptors.20,	38		
	
The	MRGPR	receptors	in	the	rodents	have	been	studied	in	more	detail	and	many	ligands	have	been	
identified	till	now.	Bender	et	al.	reported	the	nucleobase	adenine	as	the	physiological	ligand	for	the	
only	member	of	the	rat	MRGPRA	subfamily	with	a	Ki	value	of	18	nM	in	binding	assays.39	The	murine	
MRGPRA9	and	A10	were	also	found	to	be	activated	by	adenine	in	the	nanomolar	range	but	testing	
adenine	at	the	human	MRGPRX	subfamily	members	did	not	show	any	signal.	In	addition,	a	hamster	
receptor	was	 found	 to	 be	 activated	by	 adenine.40,	41,	23	Dong	 et	 al.	 described	RF-amide	peptides	 as	
potential	 physiological	 neuropeptides	 for	 activating	 murine	 MRGPRA1	 and	 MRGPRA4	 receptors.	
MRGPRA1	was	activated	most	by	FLRFamide	peptide	with	an	EC50	of	20	nM,	whereas	MRGPRA4	was	
activated	 by	 NPAFamide	 with	 an	 EC50	 of	 60	 nM	 in	 calcium	 mobilization	 assay.	 Both	 receptors	
responded	similarly	 to	adrenocorticotropin	 (ACTH).17	The	search	 for	 ligands	confirmed	 that	distinct	
RF(Y)G	and/or	RF(Y)	amide-peptides	could	activate	MRGPRC11	as	well	as	MRGPRA1.	MRGPRC11	was	
found	 to	 be	 activated	 most	 potently	 by	 proopiomelanocortin	 (POMC)	 products	 γ1-	 and	 γ2-MSH	
(melanocyte	 stimulating	 hormone),	 dynorphine-14	 and	 BAM22	 (bovine	 adrenal	medulla)	with	 EC50	
values	in	the	low	nanomolar	range.42	The	rat	MRGPRC	receptor	was	also	activated	by	the	same	RF-
amide	peptides	and	it	turned	out	that	the	active	moiety	is	the	7-C-terminal	amino	acids	of	γ2-MSH.43	
The	 nature	 of	 these	 agonists	 led	 Lee	 et	 al.	 to	 propose	 that	 the	 native	 ligands	 to	 some	 MRGPR	
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receptors	are	mediators	of	mast	cell-sensory	nerve	interactions.	Therefore,	mMRGPRC11-expressing	
HEK	 cells	 were	 activated	 both	 by	 the	 supernatant	 of	 IgE-sensitized	 RBL-2H3	 mast	 cells	 and	 by	
coculture	of	both	cells	after	IgE-sensitization	and	therefore	gave	support	to	this	hypothesis.44	Hin	et	
al.	developed	recently	small	molecules	as	peptidomimetic	agonists	at	MRGPRC	receptor	 in	both	rat	
and	 mouse.	 They	 synthesized	 short	 Arg-Phe-NH2	 derivatives	 in	 which	 the	 arginine	 residue	 is	
substituted	by	an	arginine	mimetic.	 Interestingly,	there	were	species	differences	within	the	rodents	
since	 some	 active	 derivatives	 in	 the	 mouse	 were	 inactive	 in	 the	 rat	 and	 vice	 versa	 as	 shown	 for	
compound	 1	 and	 2	 in	 table	 2.45	 This	 means	 there	 are	 interspecies	 differences	 on	 the	 medicinal	
chemistry	 level	 in	addition	to	the	 lack	of	clear	orthologs	between	humans	and	rodents.	Hence,	 the	
extrapolation	of	the	data	from	rodents	to	the	humans	should	be	conducted	with	great	caution	when	
it	 comes	 to	 physiological	 functions	 and	 ligand	 affinities	 of	 MRGPR	 receptors.	 Table	 3	 shows	 the	
structures	of	the	agonists	at	the	rodent	receptors.	
Table	3:	The	structure	of	the	most	potent	agonistic	compounds	at	the	rodent	MRGPR	receptors	
Name	 Structure	 Receptor		 EC50	value	
Chloroquine	
	
	
	
mMRGPRA3	
	
	
27	µM32	
Adenine	
	
mMRGPRA9/A10	
rMRGPRA	
8/9.8	nM40,41	
2.9	nM39	
FLRFamide	 FLRFa	 mMRGPRA1	 20	nM17	
NPAFamide	 AGEGLNSQFWSLAAPQRFa	 mMRGPRA4	 60	nM17	
ACTH	 SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF	 mMRGPRA1/A4	 60/200	nM17	
γ2-MSH	 YVMGHFRWDRFG	 mMRGPRC11	
rMRGPRC	
11	nM42	
37	nM43	
Dynorphin-14	 IRPKLKWDNQKRYG	 mMRGPRC11	 22	nM42	
Compound	1	
	
mMRGPRC11	 794	nM45	
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Compound	2	
	
mMRGPRC11	
rMRGPRC	
1,260	nM45	
630	nM45	
Excursus:	Bovine	adrenal	medulla-22	and	opioid	system	
According	 to	 IUPHAR,	 the	 suggested	putative	 ligands	 for	MRGPRX1	 and	MRGPRX2,	 bovine	 adrenal	
medulla-22	 (BAM22)	 and	 cortistatin-14,	 respectively,	 are	 neuropeptides.	 Hence,	 it	 is	 important	 to	
address	 these	 ligands	 in	 some	 detail	 before	 delving	 into	 both	 receptors.	 Cortistatin-14	 will	 be	
discussed	 in	detail	 later	 (see	below).	 It	 is	 important	to	keep	 in	mind	that	BAM22	 is	a	neuropeptide	
and	 neuropeptides	 are	 derived	 from	 larger	 proteins	 known	 as	 proneuropeptides	 or	 prohormones.	
These	precursors	undergo	proteolytic	processing	to	generate	the	smaller	active	neuropeptides.46	The	
proteolytic	 processing	 occurs	 usually	 at	 dibasic	 residues	 that	 flank	 the	 N-	 and	 C-termini	 of	
neuropeptides	 within	 their	 precursors.	 The	 dibasic	 residues	 Lys-Arg	 (KR)	 most	 often	 flank	 the	
neuropeptides	but	 also	KK,	 RR	 and	RK	occur.	 	 Processing	 at	 nonbasic	 residues	occurs	occasionally.	
This	 means	 proteolysis	 and	 tissue-specific	 processing	 of	 the	 proneuropeptides	 depend	 on	 the	
proteases	available	in	a	specific	tissue	in	the	first	place.47	
Since	the	discovery	of	the	enkephalins	in	1975,	many	other	opioids	have	been	described.	BAM20	as	
well	 as	 BAM22	 were	 isolated	 from	 bovine	 adrenal	 medulla	 and	 were	 designated	 “big”	 Met-
enkephalins	 at	 first.	 It	 is	 now	 clear	 that	 the	 opioid	 peptides	 belong	 to	 three	 peptide	 families,	
proenkephalin	 (also	 proenkephalin	 A),	 prodynorphin	 (also	 proenkephalin	 B)	 and	
proopiomelanocortin	(POMC).	Proenkephalin	A	is	processed	to	4	copies	of	Met-enkephalin,	one	copy	
of	 Leu-enkephalin,	 one	 copy	 of	 the	 heptapeptide	 Met-enkephalin-Arg-Phe,	 one	 copy	 of	 the	
octapeptide	 Met-enkephalin-Arg-Gly-Leu,	 in	 addition	 to	 peptide	 E	 and	 its	 fragments	 as	 shown	 in	
figure	5.48,49	Peptide	E	is	a	25	amino	acid	(aa)	peptide	with	Met-enkephalin	at	its	N-terminus	and	Leu-
enkephalin	 at	 its	 C-terminus.	 Its	 fragments	 are	 BAM22,	 BAM20	 and	 BAM12.	 These	 neuropeptides	
have	 been	 shown	 to	 be	 released	 from	 adrenal	 medulla	 along	 with	 catecholamine.	 All	 of	 these	
Introduction	
14	
	
peptides	were	physiologically	more	active	 than	Met-enkephalin	on	the	contractility	of	canine	small	
intestine.	 BAM22	was	 able	 to	 activate	 all	 three	 opioid	 receptor	 subtypes.50	 Further	 investigations	
revealed	 that	of	Proenkephalin	processing	 in	chromaffin	cells	plays	a	 role	 in	 immunomodulation	 in	
addition	to	nociception.	Using	MALDI-TOF	mass	spectrometrical	analysis,	it	was	feasible	to	unravel	16	
novel	 cleavage	 sites	 and	 30	 cleavage	 products.	 The	 role	 of	 these	 peptides	 was	 not	 clear	 and	 the	
possibility	that	these	novel	entities	were	due	to	the	extraction	procedure	could	not	be	excluded.51,52	
Nevertheless,	this	study	shows	that	there	could	be	many	peptides	still	to	be	characterized.	It	was	also	
found	 that	 BAM22	 is	 significantly	 elevated	 in	 the	 plasma	 of	 rats	 in	 a	 model	 of	 induced	 acute	
cholestasis.	This	could	have	a	biological	relevance	since	in	liver	cholestasis	there	are	abnormalities	in	
immune	 function,	 adrenal	 steroidogenesis	 and	 glucose	 homeostasis.	 BAM22,	 as	 a	 potent	 opioid,	
could	well	be	involved	in	these	abnormalities	(including	itch).53	
	
Figure	 5:	A:	 Schematic	 representation	 of	 proenkephalin	 and	 the	 dibasic	 amino	 acids	 flanking	Met-enkephalin	 (M),	 Leu-
enkephalin	 (L),	 octapeptide	 Met-enkephalin-Arg-Gly-Leu	 (O),	 heptapeptide	 Met-enkephline-Arg-Phe	 (H).	
Proopiomelanocortin	(POMC)	and	its	active	smaller	neuropeptides	are	also	flanked	by	dibasic	amino	acids.	B:	The	primary	
sequence	of	preproenkephalin.	The	first	28	amino	acids	(in	 italics)	are	a	cleavable	signal	peptide.	The	dibasic	amino	acids	
are	in	red	in	case	of	Met-enkephalin,	green	in	case	of	Leu-enkephalin,	blue	in	case	of	the	octapeptide	Met-enkephalin-Arg-
Gly-Leu	and	last	seven	amino	acids	represent	the	heptapeptide	Met-enkephline-Arg-Phe.	Pepitde	E	(underlined	sequence)	
and	its	fragements	are	also	represented.	Figure	5	is	modified	from	ref.47.	
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1.3.1	MRGPRX1	receptor	
	
MRGPRX1	(accession	number:	NM147199)	 is	till	now	the	best	characterized	human	receptor	 in	the	
MRGPRX	subfamily.	Although	MRGPRX1	is	officially	an	orphan	receptor,	BAM22	has	been	described	
as	a	putative	agonist.	Interestingly,	the	classical	opioid	YGGFM	motif	in	BAM22	was	not	required	to	
activate	MRGPRX1.	Hence,	BAM8-22	was	a	potent	full	agonist	and	its	effect	was	not	antagonized	by	
naloxone.18	The	coupling	of	MRGPRX1	was	reported	to	be	via	Gq	in	all	relevant	publications,	but	some	
reported	 an	 additional	 Gi	 coupling	 as	 well.18,23	 Although	 the	 brain	 has	 the	 required	 machinery	 to	
process	BAM8-22,	it	is	not	clear	if	this	peptide	could	be	produced	in	the	vicinity	of	DRG.	Hence,	it	is	
not	clear	if	BAM8-22	could	be	an	endogenous	ligand	for	MRGPRX1.19	It	was	also	found	that	rMRGPRC	
and	mMRGPRC11	could	be	activated	by	BAM22.	Thus,	it	was	supposed	that	the	rodent	MRGPRC	and	
the	 human	 MRGPRX1	 are	 functional	 orthologs.	 In	 addition,	 it	 turned	 out	 that	 MRGPRC	 but	 not	
MRGPRX1	could	be	more	potently	activated	by	γ2-MSH,	a	POMC	cleavage	product	(see	figure	5	and	
table	2).	As	with	BAM22,	 the	active	moiety	of	 γ2-MSH	was	 found	 to	be	 in	 the	C-terminal	part.	 γ2-
MSH6-12	was	the	active	form	at	MRGPRC.42,43		
These	 interspecies	 differences	 should	 always	 be	 taken	 into	 account	 and	 this	 is	 especially	 the	 case	
when	it	comes	to	MRGPR	receptors.	Two	other	findings	demonstrate	this	point.	First,	Solinski	et	al.	
showed	 that	MRGPRX1	 receptor	 expressed	 in	HEK293,	 COS,	 F11	 and	ND-C	 cells	 does	 not	 undergo	
agonist	induced	endocytosis	upon	activation	via	BAM22.	In	contrary,	both	rMRGPRC	and	mMRGPRC	
underwent	endocytosis	upon	activation.	Since	endocytosis	could	have	important	pharmacodynamical	
ramifications	like	the	correlation	between	tolerance	and	opioid	receptor	endocytosis,	using	results	of	
animal	experiments	should	only	be	conducted	with	great	caution.54	Of	note,	Kunapuli	et	al.	reported	
contradictory	data	 about	MRGPRX1,	 in	which	 they	 showed	BAM8-22-induced	endocytosis	 in	U2OS	
cells.55	 This	 contradiction	 could	 be	 due	 to	 the	 U2OS	 cell	 line.	 Second,	 Liu	 et	 al.	 investigated	 the	
relationship	 between	 protease	 activated	 receptor	 2	 (PAR2)	 and	 mMRGPRC11,	 which	 are	 both	
expressed	 in	 the	 same	neurons	 in	 the	DRG.	PAR2	 is	 activated	by	 trypsin,	 tryptase	or	 the	 synthetic	
ligand	SLIGRL,	which	 is	derived	 from	 its	 tethered	 ligand	sequence.	Since	SLIGRL	 induces	histamine-
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independent	 itch,	 it	 was	 assumed	 that	 this	 effect	 is	 PAR2-dependent.	 However,	 PAR2-/-	 mice	 did	
scratch	more	significantly	than	wild-type	mice	after	SLIGRL-subcutaneous	administration.	This	proved	
that	 this	 peptide	 targeted	 other	 receptors	 than	 PAR2	 in	 order	 to	 induce	 itch.	 Upon	 further	
investigation,	it	was	found	that	SLIGRL	activated	exclusively	mMRGPRC11	with	an	EC50	of	10.1	µM.	In	
accordance,	 the	 previously	 mentioned	 mrgpr	 KO-mice32	 showed	 a	 reduced	 itch	 response	 to	 the	
peptide.	Most	 interestingly,	 the	human	corresponding	peptide	SLIGKV	was	not	able	 to	activate	 the	
functional	 ortholog	 MRGPRX1	 but	 MRGPRX2,	 revealing	 the	 complexity	 of	 the	 interspecies	
relationships	 between	 MRGPR	 members.56	 Despite	 these	 differences,	 it	 remains	 important	 to	 go	
through	the	known	 information	about	MRGPRC	receptor,	which	could	offer	 insights	 into	MRGPRX1	
and	 other	 human	 MRGPR	 members.	 It	 should	 be	 mentioned	 that	 the	 effect	 of	 BAM8-22	 on	
nociception	 was	 a	 matter	 of	 controversy	 with	 some	 publications	 attributing	 analgesic	 effects	 and	
other	algesic	effects	to	BAM8-22.	
The	effect	of	BAM22	on	c-fos-like	 immunoractivity	(an	 indication	of	nociceptive	 input	from	primary	
afferents)	 was	 investigated	 in	 the	 rat	 dorsal	 horn	 after	 thermal	 noxious	 stimulus.	 BAM22	 could	
inhibit	 the	 immunoreactivity	 in	 both	 opioid-dependent	 and	 opioid-independent	 manner.57	
Intrathecal	 (i.t)	 administration	 of	 BAM22	 potently	 and	 persistently	 increased	 the	 tail	 withdrawal	
latency.	 This	 effect	was	 only	 partially	 inhibited	 by	 naloxone.58	 The	 expression	of	 BAM22	 itself	was	
also	 investigated	 in	 an	 inflammation	 model	 using	 complete	 Freund’s	 adjuvant	 (CFA).	 BAM22	 was	
upregulated	 in	 the	spinal	cord	and	the	DRG	small	 to	medium	size	sensory	neurons.	 Inhibitory	anti-
BAM22	antibodies	reduced	the	mechanical	threshold	in	the	inflammation	model	but	not	in	the	naïve	
rats.59	 BAM8-22	 was	 not	 able	 to	 prevent	 morphine	 tolerance	 and	 hyperalgesia	 in	 rat	 when	
administered	with	morphine	on	a	daily	basis	but	it	could	significantly	reduce	morphine	tolerance	and	
hyperalgesia	when	administered	every	other	day	(intermittently).	These	findings	could	be	explained	
by	the	desensitization	of	rMRGPRC	receptor	after	daily	BAM8-22	administration.60	In	order	to	explain	
the	 analgesic	 effects	 of	 BAM8-22,	 it	 was	 suggested	 that	 BAM8-22	 can	modulate	 NMDA-mediated	
activation	of	 spinal	dorsal	horn	neurons.61	Guan	et	al.	exploited	 the	mouse	 line	deficient	 in	 the	12	
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mrgpr	 genes32	 (see	 also	 figure	 2)	 by	 comparing	 its	 response	 to	 formalin	 injection	 (nociceptor	
activation	as	well	as	tissue	 inflammation)	with	the	response	of	wt-mice.	KO-mice	showed	a	greater	
increase	in	c-fos-expressing	neurons,	which	means	a	more	pronounced	inflammatory	pain	response.	
Hence,	at	 least	one	of	 the	12	MRGPRs	seems	 to	be	 involved	 in	 limiting	 the	excitability	of	neurons.	
Upon	 i.t	 administration	of	 BAM8-22	 there	was	 a	 significant	 decrease	 in	 both	 thermal	 hyperalgesia	
and	mechanical	allodynia	 in	 the	wt-mice	whereas	 the	KO-mice	were	unaffected.62	The	same	group	
further	investigated	both	BAM8-22	and	the	selective	MRGPRC	agonist,	compound	2	(see	table	2),	and	
found	out	 that	MRGPRC	agonism	at	 spinal	but	not	peripheral	 sites	 contributed	 to	 the	 inhibition	of	
hyperalgesia	and	neuropathic	pain.63	These	data	suggest	that	agonists	rather	antagonists	are	relevant	
as	drugs	at	MRGPRC	and	its	human	ortholog	MRGPRX1.	
On	 the	 other	 hand,	Grazzini	 et	 al.	 found	 that	 the	 selective	 rMRGPRC	 agonist	 γ2-MSH6-12	 induced	
hyperalgesia	 and	 allodynia	 after	 intradermal	 injection	 and	 hyperalgesia	 after	 central	 application.43	
BAM22	 was	 also	 found	 to	 increase	 noxious	 heat-induced	 calcitonin	 gene-related	 peptide	 (CGRP)	
release	as	an	indication	of	activation	of	a	large	nociceptor	population.64	In	another	study,	γ2-MSH6-
12	 was	 also	 found	 to	 induce	 hyperalgesia	 and	 allodynia	 in	 the	 rat	 upon	 intradermal	 application.	
siRNA	 was	 designed	 to	 knock	 out	 the	 mrgprC	 gene	 both	 in	 vivo	 and	 in	 vitro.	 This	 knockout	 was	
adequate	 to	 completely	 terminate	 the	 responses	 to	 the	 agonist.65	 Heterologous	 expression	 of	
MRGPRX1	in	rat	neurons	showed	that	MRGPRX1	can	inhibit	M-type	potassium	channels,	which	could	
increase	the	excitability.66	In	order	to	investigate	downstream	signaling	of	MRGPRX,	the	receptor	was	
expressed	in	the	dorsal	root	ganglia-like	F11	cell	line.	BAM8-22	could	activate	MRGPRX1	resulting	in	
protein	kinase	C	(PKC)-dependent	sensitization	of	TRPV1	to	heat	and	protons.	MRGPRX1	could	also	
activate	 TRPV1	 in	 PKC-independent	manner,	 via	 diacylglycerol	 (DAG)	 and	 phosphatidylinositol-4,5-
bisphosphate	 (PIP2)	after	phospholipase	C	activation.67	The	 same	group	 investigated	 the	previously	
mentioned	hypothesis	that	the	biochemical	communication	between	mast	cells	and	sensory	neurons	
could	 provide	 insights	 into	 MRGPR	 receptor.44	 In	 their	 interesting	 study	 they	 demonstrated	 that	
MRGPRX1	 can	up-regulate	 chemokine	 receptor	 2	 (CCR2).	 BAM8-22	 could	 induce	 the	 expression	of	
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CCR2,	which	 has	 been	 linked	 to	 neuropathic	 pain,	 in	 both	HEK	 and	dorsal	 root	 ganglia	 cells.	 Since	
MRGPRX1	 is	also	expressed	 in	 the	 immune	system,	BAM8-22	was	 investigated	at	LAD-2	mast	cells.	
Interestingly,	 BAM8-22	 induced	 the	 release	 of	 the	 chemokine	 CCL2,	 the	 native	 agonist	 at	 CCR2	
receptor.	This	shows	that	BAM8-22	exerts	its	effect	on	the	immune	and	peripheral	nervous	system.68	
These	data	imply	that	MRGPRX1	antagonists	could	represent	a	novel	approach	to	tackle	neuropathic	
pain.	
It	 is	 difficult	 to	 reconcile	 all	 the	 previous	 data.	 The	 fact	 that	 MRGPR	 receptor	 induce	 itch	 via	
activation	of	the	neurons	and	simultaneously	inhibit	neuropathic	pain	could	not	be	easily	explained.	
It	is	also	noticeably	that	the	analgesic	and	algesic	effects	of	BAM22	and	BAM8-22	were	observed	in	
the	 same	 animal	 models.43,60,65,66	 These	 contradictions	 could	 be,	 at	 least	 partially,	 explained	 by	
different	 BAM8-22	 effects	 at	 the	 periphery	 vs.	 central	 terminals.	 Alternatively,	 BAM8-22	 could	
modulate	 cellular	 activities	 differently	 at	 cell	 bodies	 as	 compared	 to	 central	 termini.	 Differences	
could	also	occur	as	a	result	of	disparate	distribution	and	compartmentalization	of	MRGPR	receptors,	
different	singaling	machinery	(Gq	vs.	Gi)	and	unique	modulation	of	ion	channels.62	In	a	seminal	study	
on	 15	 healthy	 human	 volunteers,	 BAM8-22	 applied	 via	 cowhage	 spicules	 induced	 significant	 itch,	
which	was	occasionally	accompanied	by	hyperalgesia	but	no	wheal	or	neurogenic	flare	(histaminergic	
symptoms).	Thus,	the	only	 investigation	 in	humans	so	far	 indicates	that	BAM8-22	mediates	 itch	via	
MRGPRX1.69	
The	medicinal	chemistry	of	MRGPRX1	is	the	most	developed	among	the	MRGPRX	subfamily	members	
with	 potent	 agonistic	 and	 antagonistic	 compounds	 described.	 Wroblowski	 et	 al.	 discovered	 by	
calcium	 mobilization	 assay	 in	 a	 high	 throughput	 context	 a	 series	 of	 pyridazinones	 as	 active	
compounds	 at	 the	 MRGPRX1	 receptor.	 Modeling	 study	 of	 the	 receptor	 with	 the	 most	 active	
compound	(see	figure	7)	was	also	conducted	based	on	the	crystal	structure	of	bovine	rhodopsin.	The	
proposed	key	 interactions	were	with	 the	 following	amino	acids:	Tyr	99,	Tyr	106,	Glu	157,	Asp	177,	
Phe	232,	Phe	236	and	His	254.70	In	another	work	and	in	order	to	synthesize	agonists	for	MRGPRX1,	
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Malik	et	al.	adopted	a	solid-phase	approach	and	synthesized	a	class	of	small	molecules	belonging	to	
tetracyclic	 benzimidazoles,	 which	 demonstrated	 a	 high	 affinity	 for	 both	 MRGPRX1	 and	MRGPRX2	
receptors	 as	 shown	 in	 figure	 7.71	 It	 was	 also	 shown	 that	 chloroquine	 could	 activate	MRGPRX1	 in	
addition	to	mMRGPRA3	(see	above),	which	means	that	MRGPRX1	could	also	be	considered	as	related	
to	 both	mMRGPRA3	 and	mMRGPRC11.	 Nevertheless	 the	 affinity	 was	 10-fold	 lower	 at	 the	 human	
receptor	with	an	EC50	value	of	297	µM.32	Kunapuli	et	al.	developed	the	first	antagonists	at	MRGPRX1.	
The	 scaffold	was	 2,3-disubstituted	 azabicyclo-octanes.55	 Interestingly,	 this	 class	 of	 compounds	was	
found	 to	antagonize	MRGPRC	 receptors	as	well.63	The	most	active	 compound	 is	 shown	 in	 figure	7.		
Bayrakdarian	et	al.	developed	2,4-diaminopyrimidine	derivatives	as	potent	antagonists	after	finding	
an	 initial	 hit	with	 a	 quinazoline	 core.72	 	 Potent	 and	 selective	 positive	 allosteric	modulators	 (PAMs)	
have	been	recently	developed	for	the	MRGPRX1	receptor	based	on	2-(cyclopropanesulfonamido)-N-
(2-ethoxyphenyl)benzamide.	 These	 PAMs	 were	 human-specific	 with	 no	 activity	 at	 MRGPRC	
receptors.73	Figure	6	shows	the	most	potent	ligands	developed	so	far.	
There	are	still	two	important	unrelated	findings	about	MRGPRX1	receptor	in	the	literature.	The	first	
was	 the	 formation	 of	 heterodimers	 between	MRGPRX1	 and	 the	 delta	 opioid	 receptor	 when	 both	
receptors	are	overexpressed.	When	both	are	coactivated	by	BAM22,	MRGPRX1	dominates	over	delta	
opioid	receptor	and	inhibits	its	signal.	It	is	not	known	if	this	interaction	is	physiologically	relevant	but	
it	could	have	implications	for	pain	and	morphine	tolerance	if	proven	in	native	tissues.74	The	second	
finding	was	the	extensive	copy	number	variation	in	the	mrgprX1	gene.	Using	a	novel	PCR	technique	
to	determine	the	absolute	copy	number	of	a	gene,	it	was	found	that	some	individuals	could	have	up	
to	 6	 copies	 of	 mrgprX1.	 This	 could	 be	 an	 explanation	 for	 the	 great	 variation	 between	 individuals	
regarding	the	itch	sensation.38,75		
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Figure	6:	Structures	of	the	most	potent	ligands	developed	at	MRGPRX1	receptor	with	the	reported	potency	and	type	of	the	
assay	used	in	the	corresponding	publications.	
	
Excursus:	Cortistatin-14	
	
In	1996	a	new	mRNA	in	the	rat	brain	was	discovered,	corresponding	to	a	112	amino	acid	protein	with	
a	secretion-signal	sequence	and	two	cleavage	sites	for	mature	peptides.	The	protein	showed	in	its	C-
terminus	 a	 remarkable	 similarity	 to	 somatostatin.	 Further	 investigations	 found	 that	 this	 protein	 is	
expressed	 mainly	 in	 the	 cerebral	 cortex	 and	 hippocampus	 and	 more	 precisely	 in	 the	 GABAergic	
interneurons.	 The	 novel	 neuropeptide	 reduced	 dramatically	 the	 electrical	 activity	 of	 the	 cerebral	
cortex.	Taking	 this	 inhibitory	property	and	 the	marked	expression	 in	 the	cortex	 into	 consideration,	
the	protein	was	named	preprocortistatin	and	the	mature	neuropeptides	were	named	cortistatin-14	
(CST-14)	and	cortistatin-29	(CST-29).76	Tostivint	et	al.	have	published	in	the	same	year	the	CST	of	the	
frog	but	 they	 figured	out	 that	 it	 is	a	 second	variant	of	 somatostatin	 in	 the	 tetrapods	and	named	 it	
somatostatin-2.77	 In	 1997,	 the	 human	 peer	 of	 the	 rat	 preprocortistatin	 was	 cloned.	 The	 human	
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neuropeptides	were	named	CST-17	and	CST-29	and	showed	a	similar	expression	profile	in	the	brain	
as	in	the	rat.	CST	has	shown	an	impressive	affinity	to	all	5	somatostatin	(SST)	receptor	subtypes.	The	
IC50	 values	 in	 the	 cAMP	 assays	 as	 well	 as	 Ki	 values	 in	 the	 binding	 assays	 of	 CST	 at	 SST	 receptors	
showed	affinities	in	the	low	nanomolar	to	the	sub-nanomolar	range.	This	affinity	was	comparable	to	
that	 of	 SST	 itself.76-78	 This	 high	 affinity	 led	 to	 the	 assumption	 that	 CST	 and	 SST	 activate	 solely	 the	
same	receptors.	Nevertheless,	 some	observed	effect	of	CST	could	not	be	 induced	by	SST.	Mendez-
Diaz	 et	 al.	 found	 for	 example	 that	 CST	 could	 induce	 analgesia	 in	 rat	 but	 not	 SST.	
Intracerebroventricular	 administration	 of	 CST	 reduced	 pain	 perception	 using	 the	 Hot	 Plate	 test.79	
Such	findings	could	be	explained	by	the	binding	of	CST	to	its	own	receptor.	Several	years	later,	two	
targets	 have	 been	 identified	 to	 bind	 CST-14,	 namely	 the	MRGPRX2	 receptor	 and	 ghrelin	 receptor	
(also	known	as	GHS-R	or	growth	hormone	secretagogue	receptor).	CST-14	binds	to	these	receptors	
with	 less	potency	 than	to	SST	 receptors.	The	 IC50	and	KD	values	described	were	 two-digit	 figures	 in	
the	 nanomolar	 range.80,81	 The	 previous	 findings	 could	 explain	 that	 1)	 CST	 and	 SST	 are	 encoded	 by	
different	genes,	2)	CNS	neural	populations	expressing	 these	neuropeptides	do	not	 fully	overlap,	3)	
SST	 increased	 cortical	 excitability,	whereas	 this	 is	 depressed	by	CST,	 4)	 if	 coexpressed	 in	 the	 same	
neurons,	CST	and	SST	are	regulated	by	different	signals.82		
Table	4:	Names	and	sequences	of	the	3	neuropeptides,	whose	receptors	could	be	addressed	by	cortistatin-14.	
Name	 Sequence	 Modification	
Cortistatin-14	 PCKNFFWKTFSSCK	 Disulfide	bridge	between	2	-	13	
Somatostatin-14	 AGCKNFFWKTFTSC	 Disulfide	bridge	between	3	-	14	
Ghrelin	 GSSFLSPEHQRVQQRKESKKPPAKLQPR	 Ser-3	=	Ser(n-octanoyl)	
	
The	fact	that	CST	is	expressed	not	only	in	the	cerebral	cortex	but	in	other	peripheral	tissues	like	the	
immune	 system	 and	 gastrointestinal	 tract	 as	 well	 as	 its	 ability	 to	 bind	 to	 more	 than	 one	 7TMR,	
promoted	the	search	for	a	unique	physiological	role	of	this	neuropeptide.	CST	was	proposed	to	take	
the	 role	of	a	 connecting	 link	between	different	 tissues	 (brain-gut	 communication	 for	 instance)	and	
was	 investigated	more	 rigorously	 in	 the	 immunology	 and	 endocrinology	 (both	 physiologically	 and	
malignant	 pathologically)	 fields.	 It	 should	 be	 noted	 that	 the	 role	 of	 CST	 in	 the	 immune	 system	 is	
suggested	to	take	place	through	any	of	the	three	receptors,	whereas	its	endocrinological	importance	
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is	due	to	SST	and	ghrelin	receptors.83-87	Capuano	et	al.	have	demonstrated	that	CST	does	not	modify	
the	basal	 release	of	calcitonin	gene-related	peptide	 (CGRP),	a	main	neuropeptide	mediator	of	pain	
transmission,	but	it	significantly	reduces	CGRP	after	its	stimulation	with	different	secretagogues.	The	
inhibition	of	CGRP	release	could	have	been	shown	both	in	primay	cultures	of	rat	trigeminal	neurons	
and	rat	brainstem	explants.	This	could	be	of	 importance	for	chronic	pain,	migraine	or	post-herpetic	
neuralgia.89	In	a	murine	trinitrobenzene	sulfonic	acid	(TBNS)	induced	model	of	Crohn’s	disease	(CD),	
CST-29	 could	 significantly	 reverse	 the	manifestations	of	 CD.	 Interestingly,	 CST-29	 reversed	 the	 lost	
body	 weight	 and	 was	 found	 to	 inhibit	 the	 inflammatory	 cascade	 via	 inhibition	 of	 tumor	 necrosis	
factor	alpha	(TNF-α),	interleukin	1	beta	(IL-1ß),	interleukin-6	(IL-6)	and	NO	as	well	as	the	induction	of	
the	anti-inflammatory	interleukin-10	(IL-10).	These	effects	could	not	be	fully	 induced	by	SST.90	 	Due	
to	its	modulation	of	the	immune	response,	CST	was	further	investigated	in	various	murine	models	of	
endotoxemia.	 CST-29	 could	 attenuate	 the	 production	 of	 the	 inflammatory	 mediators	 of	 activated	
macrophages.91	 In	 a	 recent	 interesting	 study	 CST	 KO-mice	 were	 generated.	 The	 lack	 of	 CST	
significantly	exacerbated	pain	in	acetic	acid	induced	visceral	pain,	CFA-induced	chronic	inflammatory	
pain,	 paw	 incision-induced	allodynia	 and	 thermal	hyperalgesia	 as	well	 as	 arthritis-induced	bilateral	
allodynia	models.	CST	was	found	to	be	highly	expressed	in	dorsal	root	ganglia,	especially	in	the	small	
to	medium	diameter	neurons.	At	the	molecular	level,	it	was	demonstrated	that	the	kinases	ERK	and	
Akt	were	inhibited	by	CST	which	caused	decreases	in	substance	P,	CGRP	and	expression	of	TRPV1	in	
the	DRG.	CST	was	also	expressed	in	GABAergic	interneurons	and	in	the	spinal	cord.92		
The	aforementioned	publications,	especially	the	ones	based	on	in	vivo	models	in	the	rat	and	mouse,	
indicate	 an	 interesting	 potential	 of	 CST	 in	 the	 therapy	 of	 several	 diseases.	 Nevertheless,	 it	 should	
always	 be	 kept	 in	 mind	 that	 the	 differences	 between	 humans	 and	 rodents	 are	 very	 big.	 The	
extrapolation	of	such	data	on	CST	to	humans	should	be	carried	out	very	cautiously.		
1.3.2	MRGPRX2	receptor	
	
MRGPRX2,	(accession	number:	NM-054030),	is	the	second	member	of	MRGPRX	subfamily,	which	was	
discovered	 in	 2001	 and	 was	 thought	 to	 be	 exclusively	 expressed	 in	 the	 small	 diameter	 sensory	
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neurons	 of	 the	 DRG	 and	 play	 a	 role	 in	 nociception.17,18	 Like	 other	 human	 MRGPRX	 receptors,	
MRGPRX2	does	not	have	a	direct	ortholog	in	rodents	but	orthologs	have	been	found	in	macaque	and	
rhesus	monkeys.22,23	This	member	 is	 less	characterized	than	MRGPRX1	regarding	both	physiological	
functions	 and	 medicinal	 chemistry.	 Nontheless,	 it	 is	 far	 better	 understood	 than	 MRGPRX3	 and	
MRGPRX4.	 Although	 all	 MRGPRX	members	 are	 still	 officially	 orphans,	 the	 first	 putative	 ligand	 for	
MRGPRX2,	CST-14,	was	put	forward	by	Robas	et	al.	in	2003.	CST-14	showed	an	EC50	value	of	25	nM	in	
calcium	assay	in	HEK	cells,	whereas	SST-14	showed	an	EC50	of	780	nM.	In	addition,	it	was	found	that	
the	 receptor	 has	 a	 sole	 Gq	 coupling.19,81	 Kamohara	 et	 al.	 demonstrated	 that	 MRGPRX2	 can	 be	
activated	 by	 another	 physiological	 ligand,	 namely,	 proadrenomedullin	 N-terminal	 peptide.	 The	
powerful	hypotensive	proadrenomedullin	N-terminal	20	peptide	 (PAMP-20)	and	 its	 truncated	 form	
PAMP-9-20/PAMP-12	activated	MRGPRX2	in	calcium	assays	with	an	EC50	value	like	that	of	CST-14.	It	
has	also	been	shown	that	MRGPRX2	is	also	expressed	in	the	adrenal	chromaffin	cells	besides	DRG.	In	
that	 paper	 it	 was	 reported	 that	 MRGPRX2	 expressed	 in	 CHO	 cells	 is	 both	 Gq	 and	 Gi	 coupled.93	
Burstein	et	al.	 confirmed	MRGPRX2	dual	coupling	 to	Gq	and	Gi	both	 in	human	and	rhesus	using	an	
interesting	proliferation	assay.23	Akuzawa	et	al.	reported	that	MRGPRX2	could	be	activated	in	calcium	
assays	by	morphine	(EC50	value	4.5	µM),	dextrophan	(EC50	1.4	µM)	as	well	as	3-methoxy-morphanin	
(EC50	4.7	µM).	It	was	reported	that	MRGPRX2	is	desensitized	and	internalized	after	incubation	with	1	
µM	CST-14	 or	 100	 µM	morphine.94	 	 In	 a	 screening	 campaign	 it	was	 possible	 to	 identify	 TAN-67,	 a	
potent	δ	opioid	agonist,	as	an	agonist	at	MRGPRX2	receptor	with	an	EC50	value	of	ca.	1	µM	in	both	ß-
arrestin	 and	 calcium	 mobilization	 assays.95	 A	 recent	 paper	 described	 the	 natural	 product	
complanadine	A	as	a	selective	MRGPRX2	agonist	after	screening	it	at	165	7TMRs	(see	figure	7).	The	
EC50	 value	 was	 5.5	 µM	 in	 calcium	 assays.96	 The	 only	 novel	 synthetic	 agonists	 for	 MRGPRX2	 were	
proposed	 by	 Malik	 et	 al.	 (also	 for	 MRGPRX1	 as	 mentioned	 above).	 These	 agonists	 were	 not	
peptidergic	 but	 have	 a	 tetracylic	 benzimidazole	 scaffold	 as	 illustrated	 in	 figure	 7.71	 These	 data	
revealed	 that	MRGPRX2	 is	 the	only	member	of	 the	MRGPRX	 family	 (at	 least	 for	 now)	 to	be	 found	
outside	the	DRG	and	seems	to	be	rather	promiscuous	regarding	the	activating	ligands.	Van	Hagen	et	
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al.	 have	 found	 that	 monocytes,	 macrophages	 and	 dendritic	 cells	 produce	 CST	 and	 express	 SST2	
receptors	 but	 not	 mrgprX2,	 whereas	 thymus	 expresses	 SST1,	 2,	 3	 and	 mrgprX2	 receptors	 on	 the	
mRNA	 level.88	 In	 fact	 immunology	 turned	 out	 to	 be	 the	 field	 with	 the	 most	 extensive	 research	
concerning	MRGPRX2	functions	and	ligands.	The	only	cells	in	the	immune	system,	which	undoubtedly	
express	MRGPRX2	receptors	on	the	protein	level,	are	mast	cells.	
Mast	 cells	 express	 beta2	 adrenergic	 receptors,	 adenosine	 receptors,	 several	 chemokine	 receptors,	
GPR34,	 Histamine	 H4,	 several	 nucleotide	 receptors	 as	 well	 as	 MRGPRX1	 and	 MRGPRX2.	 The	
activation	 of	 some	 of	 these	 receptors	 leads	 to	 degranulation	 of	 the	 mast	 cells,	 which	 means	 a	
potential	 to	 treat	 diseases	 like	 asthma	 and	 urticaria.	 MRGPRX2	 is	 one	 of	 these	 potential	 target	
receptors.97	 Mast	 cells	 can	 release	 its	 inflammatory	 mediators	 via	 IgE-dependent	 and	 IgE-
independent	 pathway.	 The	 IgE-independent	 pathway	 involves	 the	 activation	 via	 basic	
secretagougues	 (substance	 P,	 mast	 cell-degranulating	 peptide,	 neuropeptide	 Y,	 compound	 48/80	
etc.).	Since	no	receptor	for	basic	secretagougues	was	found,	 it	was	suggested	that	these	mediators	
interact	 directly	with	 the	 G	 proteins.	 Tatemoto	 et	 al.	 have	 found	 that	 basic	 secretagougues	 could	
activate	MRGPRX2	(but	not	MRGPRX1)	receptor	with	EC50	values	between	10-4	and	10-7	M	in	calcium	
assays	using	HEK-293	cells.	Thus,	MRGPRX2	was	proposed	to	be	an	atypical	7TMR	with	various	weak	
endogenous	agonists.98		
It	 is	 also	 noteworthy	 to	mention	 that	 the	 LAD2	mast	 cell	 line	 is	 a	 suitable	 cell	 line	 to	 investigate	
natively	expressed	MRGPRX1	and	MRGPRX2.	Up	to	date	there	is	no	known	cell	 line	able	to	natively	
express	MRGPRX3	or	MRGPRX4	receptors.19	
Subramanian	 et	 al.	 have	 demonstrated	 that	 the	 C5a	 receptor	 antagonist	 PMX-53,	 a	 cyclic	
hexapeptide	based	on	the	terminal	amino	acid	sequence	of	C5a,	behaves	as	an	agonist	at	MRGPRX2	
receptor.	 PMX-53	 (see	 table	 5)	 could	 induce	 mast	 cell	 degranulation	 and	 a	 calcium	 signals	 via	
MRGPRX2	 receptor	 and	 this	 effect	 could	 not	 be	 detected	 in	 a	murine	 cell	 line	 due	 to	 the	 lack	 of	
MRGPRX2	receptors.	The	EC50	value	of	PMX-53	was	not	determined	in	this	paper.99	The	same	group	
found	 also	 that	 the	 C3a	 agonist,	 E7,	 could	 activate	MRGPRX2	 receptors	 in	 mast	 cells	 and	 induce	
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degranulation,	 thus	behaving	as	 a	dual	 agonist	 at	MRGPRX2	and	C3a	 receptors	 as	well.100	Another	
component	 of	 the	 immune	 system,	 which	 was	 reported	 to	 act	 via	 MRGPRX2	 receptors,	 is	 the	
antimicrobial	 peptide	 LL-37	 (see	 table	 5).	 LL-37	 was	 previously	 reported	 to	 induce	 chemokine	
production	and	mast	cell	degranulation	via	unknown	mechanisms.	In	this	study,	it	was	also	suggested	
that	MRGPRX2	 is	 one	of	 the	 few	7TMRs	 that	 are	 resistant	 to	phosphorylation,	 desensitization	 and	
internalization.101	 It	 is	 noteworthy	 to	mention	 that	 the	 resistance	of	MRGPRX2	 to	 phosphorylation	
means	 that	 no	 ß-arrestin	 recruitment	 can	 take	 place.	 This	 is	 apparently	 not	 true	 since	we,	 in	 our	
group,	 are	 able	 to	 conduct	 ß-arrestin	 assay	 using	 the	 MRGPRX2	 cell	 line	 with	 very	 clear	 positive	
results.	 In	 this	 publication,	 a	 cell-based	 radioactive	 phosphorylation	 assay	 was	 employed	 to	
investigate	 the	 phosphorylation.	 The	 text	 in	 this	 paper	 described	 a	 resistance	 to	 phosphorylation.	
Intriguingly,	 in	 the	 same	paper	a	 figure	 showed	a	CST-induced	phosphorylation.	Although	 the	CST-
induced	phosphorylation	was	less	pronounced	than	C3a-induced	phosphorylation,	it	does	not	mean	
that	 MRGPRX2	 is	 phosphorylation	 resistant	 since	 the	 degree	 of	 phosphorylation	 is	 7TMR-
dependent.102	 The	 resistance	 to	 desensitization	 and	 internalization	 is	 contrary	 to	 the	 findings	 of	
Akuzawa	et	al.94	The	same	discrepancy	has	also	been	reported	regarding	the	MRGPRX1	receptor	(see	
above).	The	resistance	to	desensitization	and	 internalization	would	make	sense	as	the	mrgpr	genes	
were	conceived	to	function	as	“nociceptive	sensors”.17,18,23	Hence,	they	are	expressed	in	a	permanent	
manner	in	the	cell	membrane	to	intercept	painful	stimuli.		
Other	cationic	antimicrobial	peptides,	human	ß-defensin	2	and	3	(hBD	2,	3),	were	found	to	activate	
MRGPRX2	 and	 cause	 mast	 cell	 degranulation.103	 To	 the	 best	 of	 our	 knowledge	 no	 antagonists	 at	
MRGPRX2	receptor	have	been	described	yet.	
In	a	recent	interesting	study,	MRGPRX2	receptor	expression	in	skin	mast	cells	of	patients	with	chronic	
urticaria	(CU)	was	compared	with	that	of	a	nonatopic	control.	The	study	showed	that	the	expression	
levels	of	mrgprX2	mRNA	in	skin	mast	cells	are	much	higher	than	in	lung-derived	mast	cells	and	that	
the	number	of	MRGPRX2+	mast	cells	was	significantly	greater	 in	skin	tissues	from	CU	patients	than	
the	 in	nonatopic	control.	Hence,	the	blockade	of	MRGPRX2	on	human	skin	mast	cells	might	offer	a	
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novel	 approach	 to	 the	 prevention	 and	 treatment	 of	 severe	 CU.104	 This	 study	 is	 the	 first	 one	 to	
investigate	MRGPRX2	expression	in	patients.	
Table	5	shows	the	peptidergic	agonists	whereas	figure	8	shows	all	non-peptidergic	agonists	described	
above.	 It	 is	clear	now	that	MRGPRX2	is	activated	by	many	ligands,	which	do	not	have	that	much	in	
common	at	 first	 glance.	 In	 order	 to	 elucidate	 this	 agonism,	Nothacker	 et	 al.	 have	 investigated	 the	
similarity	 between	 the	most	 potent	 agonists	 CST-14	 and	 PAMP-12.	 An	 active	 core	 consisting	 of	 2	
aromatic	 amino	 acids	 and	 a	 basic	 amino	 acid	 at	 the	 C-terminus	 arranged	 in	 a	 specifically	 spaced	
manner	seems	to	be	important	to	activate	MRGPRX2	(amino	acids	in	bold	in	table	5).105	It	is	also	clear	
from	 the	 later	 reported	 agonists	 that	 aromatic	 as	 well	 as	 positively	 charged	 amino	 acids	 are	
important	(see	table	5).	
Efforts	to	identify	a	peer	for	MRGPRX2	in	rodents	have	also	been	made.	Tatemoto	et	al.	investigated	
rat	 MRGPR	 receptors	 in	 mast	 cells	 and	 could	 detect	 the	 mRNA	 of	 mrgprB1,	 mrgprB2,	 mrgprB3,	
mrgprB6,	mrgprB8	and	mrgprB9.	Nevertheless,	only	MRGPRB3	was	reported	to	be	activated	by	basic	
secretagogue	in	a	reporter	gene	assay	and	calcium	assay.98	McNeil	et	al.	suggested	that	MRGPRB2	is	
the	 murine	 ortholog	 of	 MRGPRX2	 using	 pharmacological	 and	 expression	 data.	 MRGPRB2	 was	
activated	by	CST-14,	PAMP-9-20	as	well	 as	 compound	48/80	 (and	other	basic	 secretagougues)	and	
expressed	 exclusively	 in	 connective	 tissue	 mast	 cells	 (but	 not	 mucosal	 mast	 cells).	 Importantly,	
MRGPRB2	was	involved	only	in	IgE-independent	histamine	release.	This	led	to	investigation	of	drugs	
which	 show	allergic	adverse	 reactions	with	 low	 IgE-titre	and	have	structure	 relatedness	 to	cyclized	
compound	48/80	(more	potent	mast	cell	activator	than	compound	80/48).	At	first,	peptidergic	drugs	
like	 icatibant,	 cetrorelix	 and	 mastoparan	 were	 considered.	 Secondly,	 the	 motif	
tetrahydroisoquinoline	 (THIQ)	was	 searched	 for	 in	approved	drugs.	This	 led	 to	 the	 identification	of	
non-steroidal	neuromuscular	blocking	drugs	(nicotine	receptor	antagonists).	By	expanding	the	search	
to	dihydroquinolines,	 the	 fluoroquinoline	antibiotics	were	 identified.	 Interestingly,	 the	 investigated	
peptidergic	 drugs,	 fluoroquinolines	 and	 non-steroidal	 neuromuscular	 blocking	 drugs	 (except	
succinlycholine)	were	all	able	to	activate	both	MRGPRB2	receptor	(in	vivo	and	in	vitro)	and	MRGPRX2	
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receptor	 (in	 vitro).	 These	 findings	 led	 to	 the	 establishment	 of	 a	 mouse	 model	 to	 investigate	
MRGPRX2	receptor.	Nevertheless,	it	should	be	noted	that	CST-14	and	PAMP-9-20	were	very	weak	at	
MRGPRB2	with	EC50	values	of	21.3	and	12.4	µM,	respectively.106	These	values	seem	to	be	too	high	for	
physiological	neuropeptides.	
Table	5:	The	sequences	of	the	peptides	(except	compound	48/80)	reported	to	activate	MRGPRX2	receptor.	All	
EC50	values	were	obtained	using	calcium	assay		
Name	 Sequence		 EC50	value	
CST-14	 																																																				PCKNFFWKTFSSCK	 25	to	1,585	nM2381,116	
SST-14	 																																AGCKNFFWKTFTSC	 780	nM81	
PAMP-20	 ARLDVASE	FRKKWNKWALSR-amide	 251	nM93	
PAMP-9-20/PAMP-12	 																																								FRKKWNKWALSR-amide	 57.2	nM93	
Minimal	core	structure	 																																																	WxxFxxxK/R	 	
Substance	P	 RPKPQQFFGLM	 2,470	nM98	
Oxytocin	 CYIQNCPLG	 1,470	nM98	
Dynorphin	A	 YGGFLRRIRPKLKWDNQ	 1,850	nM98	
PMX-53	 Ace-Phe-[Orn-Pro-dCha-Trp-Arg]	 n.d99	
E7	 WWGKKYRASKLGLAR	 n.d100	
LL-37	 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	 n.d101	
hBD2	 GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP	 n.d103	
hBD3	 GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK	 n.d103	
n.d:	not	determined	
	
Figure	7:	The	structures	of	non-peptidergic	ligands	reported	to	activate	MRGPRX2	receptor.	
	
It	 is	 obvious	 that	 the	 signaling	 as	well	 as	 physiological	 and	 pathological	 roles	 of	 this	 receptor	 still	
need	to	be	further	investigated.	Hence,	more	drug-like	pharmacological	tools	would	be	of	high	value.	
In	 the	 case	 of	MRGPRX2,	 unlike	MRGPRX1,	 antagonists	 seem	 to	 have	more	 therapeutic	 potential	
than	 the	agonists.	 It	 should	be	mentioned	 that	 it	 is	unusual	 that	many	physiological	 agonists	have	
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been	described	for	one	receptor.	A	further	issue	is	that	the	most	potent	agonist	native	(CST-14)	has	
an	 EC50	 value	 in	 the	 lower	micromolar	 range,	which	 is	 rather	 unimpressive	 for	 a	 neuropeptide.	 In	
addition,	the	expression	of	CST	is	mainly	in	the	cortex,	whereas	that	of	MRGPRX2	is	in	the	DRG	and	
mast	cells,	makes	the	pairing	of	the	receptor	with	this	ligand	even	more	questionable.	
1.3.3	MRGPRX3	receptor	
	
MRGPRX3,	 (accession	number:	NM_054031.3),	 is	 the	third	member	of	MRGPRX	subfamily.	There	 is	
no	reported	 ligand	till	now.	Burstein	et	al.	used	a	proliferation	assay	to	predict	 the	coupling	of	 the	
receptor.	 It	was	found	that	MRGPRX3	is	only	Gq	coupled.23	Nevertheless,	a	direct	agonist	should	be	
used	to	verify	this	finding.	Kaisho	et	al.	overexpressed	MRGPRX3	receptor	in	rats,	in	which	MRGPRX3	
gene	was	put	under	 the	control	of	actin	promoter.	The	rats	showed	 liquification/degeneration	and	
swelling	 of	 the	 lens	 fiber	 cells.	 Focal	 skin	 desquamation	 was	 also	 observed	 in	 these	 rats.	 In	 both	
epidermis	 and	 lens,	 an	 increase	 in	 cell	 proliferation	was	 detected.107	 Another	 study	 detected	 SVA	
(SINE-VNTR-Alu)	elements	in	the	5’	untranslated	region	of	mrgprX3	gene.	SVA	elements	are	capable	
of	generating	individual	variation	in	gene	expression	at	loci	in	which	they	are	present	and	they	cause	
various	human	diseases	 like	 insertional	mutagens.108	 SVA	belong	 to	 the	 retroelements,	which	have	
been	 suggested	 to	 have	 caused	 the	 expansion	 of	 the	 mrgpr	 subfamilies	 in	 mice24	 (see	 above).	 A	
recent	 paper	 has	 shown	 the	 expression	 of	 mrgprX3	 on	 mRNA	 and	 protein	 level	 in	 the	 corneal	
endothelial	cells.	This	protein	was	suggested	as	a	molecular	marker	for	this	cell	type	since	it	was	not	
found	in	other	cell	types	in	the	eye.109	These	findings	suggest	a	physiological	role	of	MRGPRX3	in	the	
eye,	 in	 addition	 to	 nociception.	 A	 study	 in	 epigenetic	 changes	 (methylation)	 in	 newborns	 has	
revealed	that	mrgprX3	gene	undergoes	 increase	 in	methylation	with	age	and	with	periconceptional	
environment	 (micronutrient	 supplementation).	 Interestingly,	 these	 epigenetic	 changes	 were	
detected	only	 in	male	newborns,	 suggesting	a	potential	 sexual	dimorphism	 (genetic	differentiation	
between	men	and	women)	of	mrgprX3	gene	regulation.110	A	recent	genome-wide	association	study	
to	 analyze	 the	 genetic	 variants	 related	 to	hallux	 valgus	 found	 that	 a	 SNP	 in	 the	 5’	 flanking	 of	 the	
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mrgprX3	gene	has	a	protective	effect	in	women	but	is	associated	with	a	higher	risk	in	men.111	These	
differences	between	sexes	in	association	with	MRGPRX3	still	need	to	be	further	elucidated.	
1.3.4	MRGPRX4	receptor	
	
MRGPRX4	(accession	number:	NM_054032.3)	is	the	fourth	member	of	the	MRGPRX	subfamily.	There	
is	 no	 reported	 endogenous	 ligand	 till	 now	 but	 recently	 Kroeze	 et	 al.	 reported	 nateglinide,	 a	 KATP-
channel	 blocker	 (see	 figure	 8),	 as	 an	 agonist	with	 an	 EC50	 value	of	 9.1	µM	 in	 a	 ß-arrestin	 assay.112	
Burstein	et	 al.	 predicted	a	 sole	Gq	 coupling	of	 the	 receptor.23	Gylfe	et	 al.	 have	detected	MRGPRX4	
receptor	 in	 colorectal	 cancer	 tissue	 samples	 and	 identified	 this	 gene	 as	 a	 potential	 oncogene.113	
Recently	 two	 new	 proteomics	 data	 banks,	 humanproteomemap.org	 and	 proteomicsdb.org,	 were	
introduced.	 Both	 are	 based	 on	mass	 spectrometrical	 techniques.114,115	 According	 to	 the	 new	 data,	
MRGPRX4	 is	 expressed	 in	 CD8+	 T-lymphocytes.	 This	 could	 simplify	 the	 investigation	 of	 MRGPRX4	
since	T-lymphocytes	are	easier	to	culture	than	sensory	neurons.	In	addition,	this	could	reveal	a	new	
way	 of	 communication	 between	 neurons	 and	 the	 immune	 system	 via	 MRGPRX4	 receptors.	 Data	
107,113	indicate	that	MRGPRX3	and	MRGPRX4	could	play	a	role	as	oncogenes.	
	
Figure	 8:	 The	 chemical	 structure	 of	 Nateglinide,	 an	MRGPRX4	 agonist.	 The	 reported	 EC50	 value	 in	 ß-arrestin	 assay	 was	
9.1	µM.	
1.4	Aim	of	the	thesis	
	
The	aim	of	the	thesis	was	to	characterize	the	four	subtypes	of	human	MRGPRX	receptors.	The	first	
step	was	 to	 search	 for	 pharmacological	 tools,	 taking	 advantage	 of	 the	 diverse	 compound	 libraries	
available	in	the	pharmaceutical	chemistry	department.	Further	optimization	of	the	found	ligands	was	
intended	 to	 improve	 both	 potency	 and	 selectivity.	 Since	 agonistic	 synthetic	 ligands	 for	 both	
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MRGPRX1	and	MRGPRX2	have	already	been	discovered,	our	search	was	focused	on	antagonists	for	
these	two	subtypes.		
On	the	contrary,	MRGPRX3	and	MRGPRX4	had	no	published	pharmacological	 tools	available	at	 the	
beginning	of	 this	 thesis.	Hence,	 the	aim	was	 to	 find	agonistic	 tool	 compounds	and	 then	 search	 for	
antagonistic	ones.	The	initial	tools	were	intended	to	be	further	optimized	to	ideally	reach	the	highest	
feasible	affinity	and	selectivity.	
Having	 found	 tools,	 the	 goal	 was	 to	 employ	 them	 for	 a	 pharmacological	 characterization	 using	
several	 assays	 like	 ß-arrestin,	 cAMP,	 calcium	 mobilization	 assay	 in	 order	 to	 further	 elucidate	 the	
signal	transduction	of	these	poorly	understood	receptors.		
It	should	be	noted	that	MRGPRX4	was	of	central	interest	from	the	very	beginning.	Therefore,	thesis	
aimed	 at	 deepening	 the	 characterization	 of	 this	 particular	 receptor	 regarding	 its	 physiological	 and	
pathological	 role,	 searching	 for	 cell	 lines	 with	 native	 expression,	 in	 addition	 to	 the	 synthesis	 of	 a	
radioligand	as	a	valuable	pharmacological	tool.	
In	essence,	we	aspired	to	pave	a	new	way	to	investigate	the	MRGPRX	receptors.	This	could	open	new	
doors	 to	 elucidate	 these	 exclusive	 primate	 7TMRs	 and	 enable	 other	 research	 group	 to	 investigate	
them	in	a	variety	of	aspects.	
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2.	Results	and	Discussion	
2.1	MRGPRX1	receptor	
	
The	 medicinal	 chemistry	 of	 the	MRGPRX1	 receptor,	 with	 several	 moderately	 potent	 agonists	 and	
antagonists,	 is	 the	 most	 advanced	 one	 among	 the	 four	 members	 of	 the	 MRGPRX	 receptor	
subfamily.55,70,71,72	 Since	 the	 current	 understanding	 of	 the	 physiological	 role	 of	 this	 receptor54,67,69	
indicates	a	potential	role	of	antagonists	as	therapeutics	for	pain	and	itch,	it	was	decided	to	carry	out	
screening	for	antagonists.	
2.1.1	Screening	of	compound	libraries	in	search	for	MRGPRX1	antagonists	
	
In	 order	 to	 identify	 potential	 antagonists,	 the	 compound	 libraries	 1-8	were	 screened	 (see	 chapter	
4.10).	 The	 screening	was	 done	 using	 a	 ß-arrestin	 assay	 at	 10	 µM	 (n=1).	 A	 specific	 compound	was	
considered	as	a	hit	if	it	showed	more	than	50%	inhibition	of	the	signal	induced	by	the	agonist	BAM22	
at	its	EC80	concentration	(see	chapter	4.8.1).		
Prior	to	searching	for	antagonists	at	MRGPRX1	receptors,	 it	was	required	to	choose	an	agonist	and	
perform	a	concentration-response	curve.	The	ß-arrestin	cell	line	used	in	the	assay	was	commercially	
available	from	DiscoverX®.	BAM22	was	chosen	as	agonist	to	perform	the	assay	and	it	showed	an	EC50	
value	of	2.51	±	0.49	µM	as	shown	in	figure	9.	This	value	is	higher	than	the	reported	EC50	values	in	the	
nanomolar	range,18,116	which	are	reported	using	calcium	assays.	This	is	could	be	due	to	the	frequently	
observed	tendency	of	ß-arrestin	assays	to	give	higher	EC50	values	than	calcium	assays.117	This	finding	
is	also	an	indication	that	BAM22	is	probably	not	the	physiological	ligand	since	neuropeptides	tend	to	
have	much	lower	EC50	values	at	their	receptors.82,84		
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Figure	9:	The	mean	curve	of	three	 independent	experiments	of	BAM22	at	MRGPRX1	receptor	using	ß-arrestin	assay.	The	
determined	EC50	value	was	2.51	±	0.49	µM.	
	
A	cheap	alternative	to	BAM22	could	be	the	antimalaria	drug	chloroquine.32	Unfortunately,	it	was	not	
possible	 to	 conduct	 ß-arrestin	 assays	 using	 chloroquine	 as	 an	 agonist	 because	 no	 signal	 could	 be	
detected	upon	screening	at	100	µM	(data	not	shown).	The	described	EC50	value	of	297	µM	in	calcium	
assays	 is	extremely	high	and	could	explain	the	 lack	of	signal	 in	the	 less	sensitive	ß-arrestin	assay.	 It	
should	also	be	noted	that	BAM8-22	could	be	used	as	an	alternative	agonist	at	MRGPRX1	since	it	has	
no	opioid	activity	like	BAM22,	but	it	is	more	expensive.	
Having	ensured	the	suitability	of	the	assay	and	determined	the	EC50	value	of	BAM22,	it	was	possible	
to	initiate	screening	for	antagonists.	This	screening	was	done	at	the	beginning	of	2014,	and	since	the	
compound	 libraries	 would	 always	 be	 reviewed	 and	 expanded,	 the	 reported	 results	 concerning	
MRGPRX1	applies	to	the	status	of	compound	libraries	in	April	2014.	
The	 screening	of	 compound	 libraries	 3-7	 (see	 chapter	 4.10)	 resulted	 in	no	hit	 (data	not	 shown).	 It	
should	here	be	mentioned	that	the	glycoside	digitonin	from	the	compound	library	7	blocked	80%	of	
the	 signal	 at	 10	 µM	 but	 this	 result	 is	 probably	 an	 artifact	 due	 to	 the	 detergent	 properties	 of	 the	
compound.	
The	screening	of	compound	library	2	resulted	in	very	weak	hits.	The	compounds	were	so	weak	that	
no	full	curves	could	be	obtained,	but	it	might	be	interesting	for	future	investigations	to	keep	in	mind	
that	 xanthine	derivatives	 could	be	 antagonistic	 at	MRGPRX1.	 The	 structure	of	 the	hits	 is	 shown	 in	
figure	10.	
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Figure	10:	The	structures	of	the	weak	hits	at	MRGPRX1	receptor	from	the	compound	library	2.	Both	showed	an	inhibition	of	
48%	and	49%	at	10	µM	in	ß-arrestin	assay.	
	
The	 most	 potent	 hits	 were	 identified	 in	 the	 compound	 library	 1.	 The	 three	 hits	 were	 MIRA-1,	
cantharidin	and	ZM39923,	and	their	structures	are	shown	 in	table	6.	Taking	the	chemical	structure	
and	biological	activity	 into	account,	 it	seemed	that	there	could	be	 instability	 (cyclic	acid	anhydride)	
and	 non-specific	 activity	 (kinase	 inhibition)	 issues.	 Therefore,	 it	was	 decided	 to	 further	 investigate	
the	 compounds.	 The	 effect	 of	 cantharidin	 on	 cells	 was	 first	 investigated	 because	 it	 is	 a	 toxin.119	
Cantharidin	turned	out	to	be	too	toxic	since	the	cells	died	within	30	minutes	of	the	addition	of	the	
compound.	 Hence,	 this	 compound	 was	 considered	 inappropriate	 to	 be	 a	 pharmacological	 tool	 at	
least	in	ß-arrestin	assays	due	to	the	3	hours	incubation	time.	
Table	6:	The	detected	hits	(first	three	compounds)	with	their	previously	described	biological	activity.	
Name	 Structure	 Biological	Activity	
MIRA-1	
	
Restores	 wild-type	 function	 of	
mutant	 p53	 and	 promotes	
apoptosis	 in	 a	 mutant	 p53-
dependent	manner	with	 IC50	of	
10	µM118	
Cantharidin	
	
Toxin	 inhibitor	 of	 protein	
phosphatases	 1	 and	 2A	with	 Ki	
values	 of	 1.7	 and	 0.16	 µM,	
respectively119	
ZM39923	
	
Potent	 inhibitor	 of	 Janus	
tyrosine	kinase	3	(JAK3),	pIC50	is	
7.1120	
ZM449829	
	
Potent	 inhibitor	 of	 Janus	
tyrosine	kinase	3	(JAK3),	pIC50	is	
6.8120	
	
It	 is	 noteworthy	 that	 ZM39923	 would	 break	 down	 in	 neutral	 buffer	 (t1/2=36	 min,	 pH=7.4)	 to	
ZM449829120	 (see	 table	 5).	 Owing	 to	 the	 long	 incubation	 time	 in	 ß-arrestin	 assay,	 the	 detected	
inhibition	is	probably	due	mainly	to	ZM449829.	Since	this	compound	could	interact	with	amino	acids	
via	Michael	 addition,	 the	 inhibition	 could	 be	 irreversible.	 Therefore,	 ZM39923	 was	 also	 excluded.	
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MIRA-1	was	investigated	as	well.	The	determined	IC50	value	was	12.1	±	0.6	µM	as	shown	in	figure	11.	
So	 far,	 this	 seems	to	be	 the	most	promising	antagonist	 to	be	 found	at	MRGPRX1,	especially	 that	 it	
seems	to	be	relatively	selective	since	it	was	not	reported	as	a	hit	at	other	receptors.	Nonetheless,	it	is	
inferior	 to	 the	best	antagonists	mentioned	 in	 the	 literature.	MIRA-1	should	be	 further	 investigated	
since	 this	 compound	 is	 an	ester,	which	means	 it	will	 probably	be	degraded	upon	 contact	with	 the	
cells.	Since	this	compound	could	induce	apoptosis,	it	is	important	to	exclude	this	effect	(cell	death	or	
decrease	 in	 cell	 number)	 as	 a	 cause	of	 signal	 inhibition.	 This	 result	 should	be	 viewed	with	 caution	
because	the	inhibition	was	only	noticeable	at	a	high	concentration	of	10	µM	as	seen	in	figure	11.	
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Figure	11:	The	mean	curve	of	three	independent	experiments	of	MIRA-1	at	MRGPRX1	receptor	using	ß-arrestin	assay.	
	
It	 should	 be	 added	 that	 the	 compound	 library	 9	 was	 screened	 at	 10	 µM	 both	 as	 agonists	 and	
antagonists	but	no	hit	could	be	found	(data	not	shown).	
Since	MRGPRX1	and	MRGPRX2	could	both	be	activated	by	tetracyclic	benzimidazole	derivatives71,	it	
is	 also	 plausible	 that	 both	 could	 also	 be	 inhibited	 by	 benzimidazole	 derivatives.	 Hence,	 the	
synthesized	 compounds	 for	 the	 MRGPRX2	 project	 (till	 CB39)	 (see	 MRGPRX2,	 chapter	 2.2,	 for	 all	
compounds)	were	screened	at	MRGPRX1	 receptor	both	as	agonists	and	antagonists.	The	screening	
for	 antagonists	 led	 to	 very	weak	 inhibition	or	no	 inhibition	at	 all.	 The	best	 inhibitors	 are	 shown	 in	
table	7.	The	 inhibition	was	unfortunately	weak	 so	 that	no	curves	 could	be	determined.	 It	was	also	
difficult	to	deduce	SAR	for	this	receptor	from	these	data.		
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Table	7:	The	compounds	with	the	best	inhibition	results	at	MRGPRX1	receptor		
Code	 Structure	 IC50	±	SEM	(µM)	
	
Max.	Inhibition	at	
100	µM	(%)	
	
CB18	
	
>	100	µM	 48	
CB20	
	
>	100	µM	 39	
CB24	
	
>	100	µM	 42	
The	 results	 of	 screening	 for	 agonists	 are	 shown	 in	 table	 8.	 Only	 two	 hits	 have	 been	 found.	 CB16	
turned	out	to	be	a	partial	agonist.	The	normalized	curves	of	BAM22	and	CB16	are	given	in	figure	13.	
It	 could	be	 interesting	 to	 test	derivatives	of	CB16	with	a	 substituted	benzyl	 group	or	a	 longer	 side	
chain	 than	 methyl	 (see	 figure	 12).	 CB22	 was	 not	 active.	 Hence,	 phenethyl-	 instead	 of	 benzyl-
substitution	is	not	tolerated.	CB27	was	too	weak	an	agonist	to	carry	out	a	curve.	
Table	8:	The	compounds	with	the	best	activation	results	at	MRGPRX1	receptor		
Code	 Structure	 EC50	±	SEM	(µM)*	
	
Max.	Activation	at	
100	µM	(%)	
	
CB16	
	
18.1	±	0.3	 40	
CB27	
	
>	100	µM	
	
24		
*:	Results	are	mean	±	SEM	of	three	independent	ß-arrestin	experiments	
	
Figure	12:	Potential	agonists	at	MRGPRX1	receptor	derived	from	the	structure	of	CB16	
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Figure	13:	Normalized	dose-response	curves	of	BAM-22	and	CB16	at	MRGPRX1	receptor.	
	
2.1.2	Discussion	
	
It	was	possible	to	confirm	the	activity	of	BAM22	at	the	MRGPRX1	receptor	and	a	ß-arrestin	assay	was	
chosen	 for	 further	 investigations.	 In	 addition,	 a	 systematic	 search	 for	 antagonists	 using	 the	 then	
available	compound	 libraries	has	been	done.	The	results	 indicate	a	difficulty	 in	 identifying	a	potent	
antagonist	 at	 MRGPRX1	 receptor.	 This	 is	 a	 general	 problem	 with	 the	 MRGPRX	 receptor	
subfamily.121,122	 Nevertheless,	 it	 was	 possible	 to	 single	 out	 one	 candidate	 (MIRA-1)	 as	 a	 potential	
antagonist.	MIRA-1	 should	 be	 further	 investigated	 to	 verify	 its	 activity.	 Calcium	mobilization	 assay	
could	 in	 principle	 be	 performed	 since	 this	 receptor	 is	 Gq	 coupled.23	 Due	 to	 the	 fact	 that	 calcium	
mobilization	assays	are	real-time	assays	and	the	incubation	time	is	considerably	shorter,	it	could	be	
advantageous	 to	 investigate	MIRA-1	 using	 this	 kind	 of	 assay	 to	 avoid	 any	 toxicity	 due	 to	 the	 long	
incubation	 time.	 It	 should	 be	mentioned	 that	 initial	 calcium	 assay	 experiments	 in	 an	 attached-cell	
format	have	been	conducted	but	were	not	fruitful.	This	could	be	due	to	this	kind	of	assay	format.	It	is	
advisable	to	carry	out	the	suspension	cell	format.	In	this	context	it	is	important	to	refer	to	the	issue	
of	expression	systems.	All	 investigated	MRGPRX	receptors	in	this	thesis	were	overexpressed	in	CHO	
cells	and	calcium	assays	were	always	difficult	to	conduct,	and	when	conducted	successfully	the	signal	
was	 pretty	 low.	 This	 raised	 the	 question	 about	 the	 suitability	 of	 the	 CHO	 expression	 system	 for	
carrying	 out	 an	 effective	 calcium	 assay.	 This	 point	 still	 needs	 to	 be	 addressed	 and	 since	MRGPRX	
receptors	 are	 exclusive	 primate	 receptors	 and	 have	 restricted	 expression	 profiles,17,18	 other	
expression	systems	 like	astrocytoma	cells,	COS	7	or	HEK	293	cell,	could	be	tried	out.	The	nature	of	
Results	and	Discussion	
37	
	
the	7TMRs	in	ß-arrestin	assays	as	a	fusion	protein	could	interfere	with	the	G	protein	coupling	as	well.	
In	 addition,	 two	weakly	 potent	 xanthine	derivatives	 have	been	 found.	 This	 could	 be	 interesting	 to	
follow	since	many	such	derivatives	are	available	in	our	department	and	the	compound	library	2	is	in	
constant	 expansion.	 The	 MRGPRX2	 ligands	 provided	 another	 source	 of	 screening	 for	 MRGPRX1	
receptor.	 Having	 screened	 many	 derivatives,	 it	 was	 not	 possible	 to	 identify	 any	 interesting	
antagonist.	 Nonetheless,	 it	 was	 possible	 to	 find	 a	 weak	 partial	 agonist	 (CB16).	 Since	 MRGPRX2	
project	 would	 likely	 be	 further	 followed,	 it	 is	 recommended	 to	 screen	 the	 rest	 of	 the	 MRGPRX2	
ligands	at	MRGPRX1	receptor.	These	findings	indicate	that	more	efforts	should	be	done	to	find	new	
hits	at	MRGPRX1	receptor	like	expanding	the	screening	and/or	choosing	another	assay	to	confirm	the	
detected	hits.	However,	since	potent	ligands	for	MRGPRX1	receptor	have	already	been	described	in	
the	literature,	this	had	lower	priority	within	this	study	and	we	focused	more	on	the	other	MRGPRX	
receptor	subtypes.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Results	and	Discussion	
38	
	
	
	
Results	and	Discussion	
39	
	
2.2	MRGPRX2	receptor	
	
MRGPRX2	 receptor	 is	 the	 only	 member	 of	 MRGPRX	 subfamily	 that	 is	 reported	 to	 be	 expressed	
outside	 the	DRG.	 It	 is	expressed	 in	 the	mast	cells,	a	component	of	 the	 immune	system,	and	 in	 the	
adrenal	 chromaffin	 cells.93,98	 The	 described	 agonist	 at	 this	 receptor,	 cortistatin-14,	 could	 activate	
three	7TMRs	(somatostatin,	ghrelin	and	MRGPRX2)	as	mentioned	in	the	introduction.	Hence,	it	could	
be	interesting	to	develop	selective	and	potent	agonists	at	MRGPRX2	without	activating	the	other	two	
7TMRs.	 The	MAS-related	 gene	 receptors	 share	 characteristics	 like	 a	 big	 expansion	 in	 the	 rodents	
(especially	in	the	mouse)	and	the	ability	to	be	activated	by	very	heterogeneous	ligands	ranging	from	
the	small	adenine	to	large	peptides	like	BAM22.	In	addition,	it	is	difficult	to	define	orthologs	between	
species	 based	 on	 the	 sequence	 of	 these	 genes.17,23	 However,	 a	 recent	 study	 suggested	 that	 the	
mouse	MRGPRB2	 receptor	 is	 a	 functional	 and	 pharmacological	 ortholog	 of	 the	 human	MRGPRX2,	
which	could	have	important	implications	for	elucidating	the	function	of	the	human	receptor.106	
2.2.2	Screening	of	compound	libraries	in	search	for	MRGPRX2	antagonists	
	
Our	first	efforts	were	to	validate	the	finding	that	CST-14	is	able	to	activate	MRGPRX2	receptor	in	ß-
arrestin	assay.	The	used	cell	line	was	a	commercial	cell	line	from	DiscoverX®.	Figure	14	shows	a	clear	
activation	of	the	receptor	with	an	EC50	252	±	13	nM	value	of	and	a	maximal	S/N	of	18.		
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Figure	14:	The	mean	curve	of	three	independent	experiments	of	CST-14	at	MRGPRX2	receptor	using	ß-arrestin	assay.	The	
determined	EC50	value	was	252	±	13	nM.	
	
Results	and	Discussion	
40	
	
It	 is	 important	 to	 mention	 that	 S/N	 ratio	 throughout	 this	 study	 was	 calculated	 by	 dividing	 the	
maximal	signal	induced	via	a	compound	or	a	test	sample	by	the	basal	signal	induced	by	the	negative	
control,	which	is	usually	DMSO	or	buffer.	
After	establishing	the	assay,	a	search	for	antagonists	using	our	compound	libraries	has	been	initiated.	
The	antagonist	assay	was	performed	as	described	in	(see	chapter	4.8.1)	and	the	compound	libraries	
1-7	and	 the	 compound	 library	10	have	been	 screened.	 The	 screening	was	done	at	10	µM	using	ß-
arrestin	 assay	 (n=1).	 A	 specific	 compound	 was	 considered	 as	 a	 hit	 if	 it	 showed	 more	 than	 50%	
inhibition	of	the	signal	induced	by	CST-14	at	its	EC80	value	(1	µM).	
The	first	phase	(April	2013)	was	the	screening	of	compound	libraries	1	and	7.	Several	hits	have	been	
identified	in	the	initial	screening	but	upon	further	investigations	only	menadione	(structure	in	figure	
14)	 from	 the	 compound	 library	 7	 seemed	 to	demonstrate	 reproducible	 results.	 The	 IC50	 value	was	
determined	to	be	5.39	±	1.51	µM	as	shown	in	figure	15.		
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Figure	15:	The	mean	dose-response	curve	of	three	independent	ß-arrestin	experiments	using	menadione	as	agonist	at	
MRGPRX2	receptor.	The	determined	IC50	value	was	5.39	±	1.51	µM.	
	
Menadione	 (2-methyl-1,4-naphthoquinone)	 is	 a	 yellow	 powder	 but	 its	 stock	 solution	 in	 DMSO	 is	
colorless.	Due	to	these	results	it	would	be	interesting	to	test	other	1,4	naphthoquinone	derivatives	in	
order	 to	 investigate	 both	 toxicity	 and	 potency	 of	 these	 derivatives.124	 Menadione,	 also	 known	 as	
vitamin	 K3,	 a	 precursor	 of	 vitamins	 K1	 and	 K2,	 has	 been	 used	 as	 a	 therapeutic	 agent	 with	 several	
applications:	 for	hypothrombinemia,	as	an	anticancer	drug,	as	an	anti-inflammatory	agent	and	as	a	
component	of	multivitamin	drugs.	Vitamin	K3	presents	cytotoxicity	towards	several	types	of	cells	 in	
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the	human	body	by	inducing	oxidative	stress	through	redox-cycle,	generating	reactive	oxygen	species	
(ROS).	Oxidative	 stress	 in	high	 levels	produces	oxidative	damage	 in	 cell	 structures	 (lipids,	 proteins,	
RNA	and	DNA)	leading	to	apoptosis	or	necrosis	of	the	cells.	Because	of	this	property	menadione	has	
been	widely	used	with	cancer	chemotherapeutic	agents,	since	 it	 is	effective	 in	killing	tumor	cells.	 It	
has	also	been	demonstrated	that	it	kills	preferentially	fast	growing	cells.	Since	tumor	cells	have	this	
characteristic,	 its	toxicity	towards	normal	cells	is	much	lower.	Nowadays	menadione	is	only	used	as	
anticancer	 agent.	 Its	 applications	 on	 coagulation	 problems	 and	 vitamin	 deficiency	 are	 not	 advised	
because	 of	 its	 referred	 toxicity.125-131	 One	 advantage	 is	 that	 menadione	 could	 be	 commercially	
available	and	a	cheap	pharmacological	tool.	
The	second	phase	of	the	screening	for	antagonists	(June	2014)	encompassed	compound	libraries	2-6	
and	the	compound	library	10.	These	efforts	 led	to	the	identification	of	three	hits	with	reproducible	
results.	The	hit	from	the	compound	library	5	was	termed	H351,	the	one	from	the	compound	library	2	
was	called	SL318	and	the	last	hit	from	the	compound	library	3	was	termed	CB8.		Figure	15	shows	the	
results	of	the	ß-arrestin	experiments	conducted	using	these	hits	as	antagonists. The	determined	IC50	
values	were	as	 follows:	2.42	±	0.22	µM	for	CB8,	9.80	±	1.39	µM	for	SL318	and	9.21	±	2.28	µM	for	
H351.	These	hits	were	counter-screened	at	GPR55	and	GPR18	and	showed	no	activity	at	these	7TMRs	
(data	 not	 shown).	 The	 hits	 are	 from	 different	 scaffolds.	 SL381	 is	 a	 xanthine	 derivative;	 H351	 is	 a	
pyrimidine	 derivative,	whereas	 CB8	 is	 tricyclic	 benzimidazole	 derivative	 (see	 figure	 16).	 SL381	 and	
H351	 showed	 a	 complete	 inhibition	 at	 their	 highest	 concentration,	 but	 CB8	 showed	 only	 75%	
inhibition	 at	 its	 highest	 concentration.	 CB8	 showed	 the	 best	 IC50	 value	 and	 a	 similar	 scaffold	
(tetracyclic	benzimidazole)	has	already	been	reported	to	be	active	at	MRGPRX1	and	MRGPRX2	but	as	
an	agonist71	(see	also	figure	8).	
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Figure	16:	Chemical	structure	and	mean	dose-response	curve	of	the	three	detected	hits	at	MRGPRX2	receptor.	The	results	
are	mean	±	SEM	of	three	independent	ß-arrestin	experiments.	The	determined	IC50	values	for	H351,	SL381	and	CB8	were	
9.80	±	1.39,	9.21	±	2.28	and	2.42	±	0.22	µM,	respectively.	
	
It	was	decided	 to	 take	CB8	as	a	 lead	compound	 to	develop	more	potent	derivatives.	The	chemical	
synthesis	was	done	in	collaboration	with	Professor	Herdewijn	and	his	coworkers.	In	order	to	establish	
initial	 structure-activity	 relationships	 (SARs),	 a	 total	 of	 19	 compounds	were	 screened	 at	MRGPRX2	
receptor	to	determine	their	IC50	values	and	maximal	inhibitions	compared	with	the	parent	compound	
CB8.	The	results	are	presented	 in	table	9.	The	compounds	stock	solutions	CB10,	CB12,	CB13,	CB14,	
CB16,	CB17,	CB18,	CB19,	CB20,	CB24,	CB25,	CB26	and	CB28	were	soluble	at	high	concentration	(10	
mM),	 while	 1	 mM	 stock	 solutions	 of	 CB11,	 CB15,	 CB21,	 CB22,	 CB23	 and	 CB27	 in	 DMSO	 were	
prepared.	The	results	are	shown	in	table	9.		
Table	9:	Chemical	structure	and	activity	of	several	derivatives	of	the	parent	hit	CB8	at	MRGPRX2	receptor.		
Code	 Structure	 IC50	±	SEM	(µM)*	
	
Max.	Inhibition	at	10	
µM	(%)	
	
CB8	
(Parent	compound)	
	
2.42	±	0.22	
	
75		
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CB10	
	
3.23	±	0.36	
	
89		
	
CB11	
	
>10	
	
-5		
	
CB12	
	
14.7	±	1.3	
	
80		
	
CB13	
	
>100	
	
22		
	
CB14	
	
3.22	±	0.82	
	
	
86		
	
CB15	
	
>10	 -25		
	
CB16	
	
>100	 24		
	
CB17	
	
>100	 -2		
	
CB18	
	
>100	 37		
	
	
CB19	
	
11.6	±	3.7	
	
81		
	
CB20	
	
>100	 16		
	
CB21	
	
0.583	±	0.049	
	
	
62		
	
CB22	
	
>10	 19		
	
CB23	
	
1.40	±	0.88	 30		
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CB24	
	
>100	 26		
	
CB25	
	
>100	 43		
	
CB26	
	
>100	 35		
	
CB27	
	
>10	 14	±	16	
	
CB28	
	
>100	 2	±	11	
	
*:	Results	are	mean	±	SEM	of	three	independent	ß-arrestin	experiments	
Only	6	compounds	were	found	to	be	active	 in	which	CB21	showed	the	highest	antagonistic	activity	
with	an	 IC50	of	0.583	 ±	0.049	µM	but	 the	maximal	 inhibition	was	 reduced	 to	63%.	CB23	 showed	a	
limited	 maximal	 inhibition	 despite	 the	 good	 potency	 as	 shown	 in	 figure	 17.	 These	 initial	 results	
indicate	 that	 the	 left	 side	of	 the	molecule	 should	not	have	bulky	substituents,	while	methyl,	ethyl,	
propyl	or	isopropyl	seem	to	be	appropriate.	
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Figure	17:	Mean	dose-response	curve	of	three	independent	ß-arrestin	experiments	of	the	six	active	antagonists	at	
MRGPRX2	receptor.		
From	the	previous	results,	it	was	possible	to	suggest	preliminary	structure-activity	relationships	and	
make	some	suggestions	for	optimization	as	demonstrated	in	figure	18.	
	
	
Figure	18:	Initial	structure	activity	relationships	of	the	antagonists	at	MRGPRX2	and	some	structures	predicted	to	be	potent.	
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Another	 two	 sets	 of	 compounds	 were	 synthesized	 and	 tested.	 The	 results	 are	 summarized	 in	
table	10.		
Table	10:	The	results	of	the	first	and	second	series	of	the	antagonistic	compounds	at	MRGPRX2	receptor		
Code	 Structure	 IC50	±	SEM	(µM)*	
	
Max.	Inhibition	at	100	
µM	(%)	
CB29	
	
>100	 4	
CB30	
	
>100	 36	
CB31	
	
>100	 40	
CB32	
	
>100	 22	
CB33	
	
0.278	±	0.042	 98	
CB34	
	
0.214	±	0.032	
	
97	
	
CB35	
	
>10	 20		
CB36	
	
0.290	±	0.098	 97		
CB37	
	
0.512	±	0.107	 96		
CB38	
	
>10	 4		
CB39	
	
5.66	±	1.15	 68		
*:	Results	are	mean	±	SEM	of	three	independent	ß-arrestin	experiments	
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These	 results	 confirm	 the	 suggested	 initial	 SAR.	 CB33	 showed	 approximately	 9-fold	 increase	 in	
potency.	 CB34	 demonstrated	 11-fold	 increase	 in	 potency	 compared	 with	 CB8.	 Both	 compounds	
showed	 an	 almost	 total	 inhibition	 at	 10	 µM.	 The	 second	 shipment	 contained	 also	 two	 important	
compounds,	CB36	and	CB37,	which	showed	a	considerable	increase	in	potency.	
At	this	point	of	time	there	was	an	optimization	of	ß-arrestin	assay	protocol	was	introduced.	Hence,	in	
order	 to	have	a	better	 comparison	and	 to	make	a	better	 choice,	compounds	CB33	and	CB34	were	
tested	again	according	to	the	new	protocol.	The	results	showed	a	slight	difference	as	given	in	figure	
19	and	 figure	20.	CB33	 turned	out	 to	be	 the	most	potent	compound.	Therefore,	 it	was	decided	 to	
consider	the	right	side	of	the	molecule	finally	optimized	and	to	further	modify	the	benzene	residue	of	
CB33	in	order	to	get	more	potent	derivatives.	
	
Figure	19:	The	results	of	the	best	four	compounds	in	the	first	series	of	derivates.	
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Figure	 20:	 The	mean	 curve	of	 three	 independent	 ß-arrestin	 assays	 of	 the	 four	 best	 compounds	 in	 the	 first	 series	 of	 the	
antagonists	at	MRGPRX2	receptor.	
	
Further	series	of	derivatives	were	dedicated	to	modify	the	benzene	residue.	Series	3	was	tested	and	
the	 results	 are	 shown	 in	 table	 11.	 From	 the	 results	 it	 is	 clear	 that	 only	 CB44	 is	 of	 interest	 in	 this	
series.	More	 importantly,	CB44	 is	a	mixture	of	 two	region-isomers	with	a	ratio	of	1:1.	CB40	has	no	
modification	 of	 the	 benzene	 residue	 but	 shows	 a	 good	 affinity	 and	 interestingly,	 the	 bulky	 para-
methoxyphenyl	substitution	is	tolerated.	
Table	11:	The	results	of	the	third	series	of	antagonists	at	the	MRGPRX2	receptor		
Code	 Structure	 IC50	±	SEM	(µM)*	
	
Max.	Inhibition	at	
100	µM	(%)	
CB40	
Only	n=1	
	
0.548	 82	
CB41	
	
ca.	100	µM	 52	
CB42	
	
ca.	100	µM	 58	
CB43	
	
ca.	100	µM	 55	
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CB44	
	
1.05	±	0.11	 85	
*:	Results	are	mean	±	SEM	of	three	independent	ß-arrestin	experiments	
Although	 CB44	 is	 not	 a	 derivative	 of	 CB33,	 CB44	 could	 give	 an	 indication	 of	 the	 benefits	 of	
substitution	of	aryl	 ring	 since	CB44	contains	a	methylated	aryl	 residue	 in	comparison	 to	CB14.	The	
results	show	a	3-fold	increase	in	potency	of	CB44	compared	with	CB14,	which	is	a	good	indication	of	
the	possibility	of	developing	potent	antagonists	via	an	appropriate	substitution	of	the	aryl	residue.	
Two	 further	 sets	 of	 compounds	 were	 tested	 as	 shown	 in	 table	 12	 but	 these	 derivatives	 do	 not	
possess	 the	 required	 substitution	 pattern.	 Therefore,	 the	 majority	 of	 these	 compounds	 were	
inactive.		
Table	12:	Results	of	the	fourth	and	fifth	series	of	the	potential	antagonists	at	the	MRGPRX2	receptor		
Code	 Structure	 IC50	±	SEM	(µM)*	
	
Max.	Inhibition	at	
100	µM	(%)	
CB45	
	
ca.	100	µM	 48		
CB46	
	
>100	µM	 0	
CB47	
	
>100	µM	 18		
CB48	
	
>100	µM	 6		
CB49	
	
>100	µM	 14		
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CB50	
	
>100	µM	 13		
CB51	
	
>100	µM	 18		
CB52	
	
ca	100	µM	 4	
CB53	
	
>100	µM	 -33	
CB54	
	
ca	100	µM	 48	
CB55	
	
>	100	µM	 2	
CB56	
	
>100	µM	 -18	
CB57	
	
>100	µM	 -13	
CB58	
	
>100	µM	 -44	
CB59	
	
>100	µM	 -4	
CB60	
	
0.148	±	0.042	 99	
*:	Results	are	mean	±	SEM	of	three	independent	assays	
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The	only	interesting	compound	in	this	series	was	CB60.	Its	affinity	indicates	that	the	substitution	of	O	
by	S	 is	beneficial	 since	CB60	showed	ca.	22-fold	 increased	potency	compared	 to	CB14	as	well	 as	a	
complete	inhibition	of	the	MRGPRX2	receptor.		
The	 sixth	 and	 seventh	 set	 of	 compounds	 contained	 potent	 antagonists	 as	 shown	 in	 table	 13,	 in	
particular	 CB63	 and	 CB64,	which	 are	methylated	 derivatives	 of	 CB36	 and	 CB33,	 respectively.	 Both	
compounds	were	mixtures	of	 regio-isomers	and	not	a	single	compound.	CB63	with	an	 IC50	value	of	
6.38	 nM	 could	 be	 the	 basis	 for	 preparing	 a	 radioligand.	 Unfortunately,	 this	 high	 potency	 was	
accompanied	by	very	bad	solubility	of	the	compounds.	In	order	to	avoid	the	issue	of	regio-isomers,	
methylation	 of	 both	 positions	was	 conducted	 as	 demonstrated	 in	 CB66	 and	 CB67.	 The	 insolubility	
problem	 was,	 unfortunately,	 evident	 with	 CB66	 and	 even	 more	 with	 CB67.	 The	 low	 inhibitory	
potency	of	CB67	compared	to	closely	related	compounds	may	be	partially	due	to	 its	bad	solubility.	
The	compounds	with	an	 isopropyl-substitution	had	a	better	 solubility	 than	 their	propyl-substituted	
counterparts.	However,	 it	was	clear	 that	 the	double	methylated	compounds	are	not	 advantageous	
because	of	the	decreased	potency	as	well	as	low	solubility.	
Table	13:	The	results	of	the	sixth	and	seventh	series	of	the	antagonistic	compounds	at	MRGPRX2	receptor		
Code	 Structure	 IC50	±	SEM	
(µM)*	
	
Max.	
Inhibition	at	
10µM	(%)	
CB62	
	
>100	 4	
CB63	
	
0.00638	±	
0.00189	
100	
CB64	
	
0.0711	±	
0.0152	
98	
CB65	
	
>10		 2	
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CB66	
	
0.0877	±	
0.0368	
99	
CB67	
	
1.40	±	0.36**	 98	
*:	Results	are	mean	±	SEM	of	three	independent	ß-arrestin	experiments	
**:	Data	are	extrapolated	due	to	bad	solubility	of	this	compound	
	
A	last	series	of	compounds	was	investigated.	In	this	set	of	compounds,	halogens	were	tried	instead	of	
methyl	 group.	 CB70	 and	 CB71	 with	 fluorine	 substitution	 showed	 the	 highest	 potency.	 Fluoro	
derivatives	seem	to	be	more	suitable	than	chloro	ones.	Of	note,	 the	di-substitution	 is	better	 in	the	
case	of	fluoro	compounds	than	monosubstitution	as	shown	in	table	14.	
Table	14:	The	results	of	the	eighth	and	nineth	series	of	potential	antagonists	at	the	MRGPRX2	receptor		
Code	 Structure	 IC50	±	SEM	
(µM)*	
	
Max.	
Inhibition	at	
10	µM	(%)	
CB68	
	
0.477	±	0.087	 96		
CB69	
	
0.169	±	0.017	 98		
CB70	
	
0.0209	±	0.0054	 99		
CB71	
	
0.0926	±	0.0426	 99		
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CB72	
	
0.213	±	0.079	 94		
CB73	
	
>10	 15		
CB74	
	
1.26	±	0.31	 85		
*:	Results	are	mean	±	SEM	of	three	independent	ß-arrestin	experiments	
These	were	 all	 the	 compounds,	which	 have	 been	 tested	 so	 far	within	 this	 thesis	 as	 antagonists	 at	
MRGPRX2	receptor.	The	curves	of	the	best	three	synthesized	antagonists	are	presented	in	figure	21.	
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Figure	21:	The	mean	curve	of	three	independent	ß-arrestin	assays	of	the	most	potent	antagonists	at	MRGPRX2	receptor.	
The	IC50	values	of	CB63,	CB64	and	CB70	are	0.00638	±	0.00189,	0.0711	±	0.0152	and	0.0209	±	0.0054	µM,	respectively.	
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2.2.3	In	vitro	pharmacokinetic	data	of	selected	MRGPRX2	antagonists	
	
The	 ADME	 (absorption,	 distribution,	 metabolism	 and	 excretion)	 profile	 is	 important	 for	 in	 vivo	
studies.	Therefore,	some	of	the	best	antagonists	were	investigated	 in	vitro	by	Pharmacelsus	GmbH,	
Saarbrücken;	 a	 contract	 research	 organization	 specialized	 in	 such	 studies.	 Three	 compounds	were	
investigated,	 namely,	 CB63,	 CB64	 and	 CB66	 with	 the	 IC50	 values	 of	 0.00638	 ±	 0.00189,	
0.0711	±	0.0152	and	0.0877	±	0.0368	µM,	respectively.	A	summary	of	the	results	is	given	below	(see	
tables	15-18).		
Table	15:	Blood-brain	barrier	permeability	of	the	MRGPRX2	antagonists		
BBB	 CB63	 CB64	 CB66	
Structure	
	 	 	
Flux	rate	 66.2%	 64.5%	 4.1%	
BBB	(blood	brain	barrier):	in-vitro	test,		
Impermeable	compound,	flux	rate	<	50%,		
Highly	permeable	compound,	flux	rate	>50%		
The	test	was	done	at	5	µM	for	CB63,	CB64	and	at	10	µM	for	CB66	
	
The	results	show	that	CB63	and	CB64	are	likely	to	penetrate	into	the	brain,	while	CB66	is	not	able	to	
penetrate.	This	could	be	due	to	the	low	solubility	of	CB66.	
Table	16:	Plasma	protein	binding	of	the	MRGPRX2	receptor	antagonists	
PPB	 CB63	 CB64	 CB66	
mouse	 99.86%	 99.41%	 99.66%	
rat	 99.86%	 99.81%	 99.51%	
human	 99.72%	 99.86%	 99.65%	
PPB	(plasma	protein	binding):	The	test	was	done	at	1	µM	
	
The	 investigated	 compounds	 show	 a	 relatively	 high	 PPB	 in	 all	 investigated	 species.	 This	 is	 no	
limitation	for	further	development.	The	plasma	protein-bound	fraction	may	serve	as	a	depot	for	the	
drug.	
Table	17:	The	inhibitory	IC50	values	of	the	MRGPRX2	receptor	antagonists	at	different	cytochrome	enzymes	
CYP	Inhibition	(µM)	 CB63	 CB64	 CB66	
CYP1A2	 2.7	 <1	 5.2	
CYP2B6	 >>5	 >>5	 >>10	
CYP2C9	 >5	 >5	 >10	
CYP2C19	 >5	 >5	 >10	
CYP2D6	 >>5	 >>5	 >>10	
CYP3A4	 2.6	 <1	 <1	
CYP	(Cytochrom	P450).	Results	were	extrapolated	after	screening	at	10,	5	and	1	µM	
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The	cytochrome	enzymes	are	 involved	in	drug	metabolism.	Therefore,	 inhibiting	or	activating	these	
enzymes	 is	 an	 important	 source	 of	 drug-drug	 interactions.	 CB63	 shows	 a	 moderate	 inhibition	 of	
CYP3A4	 (the	most	 relevant	 enzyme),	 while	 CB64	 and	 CB66	 show	 a	 relevant	 inhibition.	 This	 could	
mean	a	potential	for	interaction	with	other	drugs.	
Table	18:	The	half-life	and	intrinsic	clearance	of	the	MRGPRX2	receptor	antagonists	
Microsomal	
Stability	Assay	
CB63	 CB64	 CB66	
t1/2	
(Min)	
CLint	
(µg/min/mg	protein)	
t1/2	
(Min)	
CLint	
(µg/min/mg	protein)	
t1/2	
(Min)	
CLint	
(µg/min/mg	protein)	
mouse	 6.5	 213.3	 5.3	 261.6	 7.4	 187.3	
rat	 11.9	 116.5	 9.2	 150.7	 10.7	 129.6	
human	 7.7	 180.0	 6.4	 216.6	 10.6	 130.8	
t1/2	(Half	Life),		CLint	(Intrinsic	Clearance)	
	
All	investigated	compounds	show	low	metabolic	stability	and	a	short	half-life.	This	would	be	a	major	
limitation	 in	 drug	 development.	 The	 next	 step	 will,	 therefore,	 be	 to	 develop	 metabolically	 more	
stable	 derivatives	 based	 on	 a	 close	 analysis	 of	 the	 metabolic	 pathways.	 The	 fluoro-substituted	
compounds,	CB70	and	CB71,	may	show	improved	properties	and	should,	therefore,	be	subsequently	
tested	for	ADME	properties.			
2.2.4	Mechanism	of	the	mode	of	antagonism	
The	 observation	 that	 the	 MRGPRX2	 agonist,	 CST-14,	 is	 a	 peptide	 consisting	 of	 14	 amino	 acids	
containing	 two	disulfide	bridges,	while	 the	antagonists	are	pretty	 small	molecules,	prompted	us	 to	
investigate	 the	 mode	 of	 action	 of	 the	 synthesized	 antagonists.	 The	 aim	 was	 to	 know	 if	 the	
antagonism	 is	 allosteric	 or	 orthosteric.	 To	 address	 this	 question,	 curves	 of	 CST-14	 with	 varying	
concentrations	 of	 the	 antagonist	 were	 plotted	 and	 compared	 with	 the	 CST-14	 curve	 without	 any	
antagonist.	 The	 comparison	 was	 in	 terms	 of	 any	 rightward	 shift	 (change	 of	 EC50	 value)	 and	 the	
depression	of	the	maximal	response.	During	these	experiments	 it	turned	out	that	CST-14	could	not	
be	used	at	concentrations	higher	than	100	µM	because	it	then	causes	a	decrease	in	signal	(data	not	
shown)	due	to	a	presumably	toxic	effect	on	cells.	As	mentioned	above,	all	of	the	best	antagonists	had	
shown	a	full	inhibition	of	the	agonist.	However,	this	is	not	necessarily	an	indication	of	an	orthosteric	
mechanism	of	action.132	The	first	experiments	using	CB8	did	not	show	clear	results	(data	not	shown).	
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After	synthesizing	CB63,	it	was	decided	to	repeat	the	experiment.	The	first	experiment	was	done	in	
the	presence	of	10	nM	of	CB63	and	the	results	showed	an	orthosteric	mode	of	action	since	there	was	
a	 clear	 rightward	 shift	 (from	 451	 nM	 to	 1570	 nM)	 and	 there	 was	 no	 depression	 of	 the	 maximal	
inhibition	as	shown	in	figure	22a.	A	further	experiment	with	more	than	one	concentration	(1,	10,	100	
and	1000	nM)	of	CD63	confirmed	the	rightward	shift	(EC50	values	of	0.930,	2.01,	3.04,	6.22	and	27.0	
µM	for	0,	1,	10,	100,	and	1000	nM	of	CD63,	respectively)	and	revealed	that	for	1,	10	and	100	nM	of	
the	antagonist	there	is	no	depression	of	the	maximal	response,	whereas	for	higher	concentrations	of	
1000	nM	a	full	curve	could	not	be	obtained	due	to	limitations	in	CST-14	concentrations	(see	above)	
as	demonstrated	in	figure	22b.		
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Figure	22:	Concentration-response	curves	of	CST-14	in	the	presence	of	the	antagonist	CD63,	a:	rightward	shift	of	the	CST-14	
curve	in	the	presence	of	10	nM	of	CB63,	b:	rightward	shift	of	CST-14	in	the	presence	of	several	concentrations	of	CD63.	The	
maximal	concentration	for	CST-14	was	100	µM	due	to	toxic	effects	on	the	cells	at	higher	concentrations.	
	
In	figure	21b	the	curve	of	CST-14	with	1000	nM	did	not	reach	a	plateau.	The	reason	for	not	reaching	a	
maximal	response	could	be	an	insurmountable	antagonist.	In	order	to	interpret	the	point	we	should	
keep	in	mind	that	the	ß-arrestin	system	is	a	high	expression	system	(high	sensitivity)	with	a	receptor	
reserve.	 In	 such	 systems	 the	 depression	 of	 the	maximal	 response	 for	 insurmountable	 antagonists	
(irreversible	 or	 allosteric)	 occurs	 only	 at	 higher	 concentrations	 of	 the	 antagonists	 after	 an	 initial	
“pure”	 rightward	 shift	 for	 the	 lower	 concentrations.132	 Another	 possibility	 for	 not	 reaching	 the	
maximal	 response	 is	 that	despite	 the	competitive	nature	of	antagonism,	a	maximal	 response	could	
not	 be	 reached	due	 to	 the	 inability	 to	 increase	CST-14	 concentration	 (more	 than	 100	µM)	 so	 that	
CST-14	 could	 displace	 CD63.	 In	 order	 to	 interpret	 these	 data	 a	 Gaddum/Schild	 EC50	 shift	 was	
conducted	 to	 determine	 the	 Schild	 slope,	 which	 should	 be	 ca.	 1	 for	 competitive	 antagonism	 and	
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other	 than	one	 for	 cooperative	 antagonism.133	 The	determined	 Schild	 slope	 for	 the	 curve	 in	 figure	
21a	was	1.08,	which	is	a	clear	indication	of	the	orthosteric	nature	of	the	antagonism.	Another	usual	
characteristic	(but	not	always)	of	allosteric	modulation	can	be	the	shallow	SAR,134,135	which	was	not	
the	 case	 for	 the	 tricyclic	 benzimidazole	 derivatives	 as	 shown	 above.	 Our	 findings	 indicate	 an	
orthosteric	mode	of	action	for	these	antagonists,	with	respect	to	the	peptide	agonist	CST-14,	which	
has	 to	 be	 further	 confirmed	 by	 structural	 studies	 e.g.	 X-ray	 crystallography	 or	 mutagenesis	
experiments.		
2.2.5	Investigation	of	some	reported	agonists	
	
Antagonists	were	 the	main	 focus	of	 this	 study.	However,	 several	 interesting	agonists	have	 recently	
been	described	in	the	literature	as	reported	in	the	introduction.	Some	of	these	agonists	were	drugs	
like	 morphine,94	 antibiotics	 like	 ciprofloxacin,	 peptidergic	 drugs	 like	 icatibant,	 cetrorelix	 and	 non-
steroidal	neuromuscular	blocking	drugs	like	suxamethonium.106	Therefore,	we	tested	the	compounds	
that	were	available	 in	our	 laboratory,	namely,	morphine	and	ciprofloxacin.	Both	were	confirmed	as	
agonists	at	the	MRGPRX2	receptor.	Ciprofloxacin	has	a	very	limited	solubility	and	we	could	not	obtain	
a	full	curve.	The	S/N	ratio	was	3	(i.e.	partial	agonism)	and	the	absolute	increase	of	the	signal	was	very	
limited.	Morphine,	on	the	other	hand,	showed	a	very	robust	increase	in	signal	and	an	impressive	S/N	
ratio	of	18	(similar	to	that	of	CST-14,	i.e.	a	full	agonist).	The	EC50	value	for	morphine	was	25.9	±	1.3	
µM	as	shown	in	figure	23.		
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Figure	 23:	 The	 normalized	 mean	 of	 three	 curves	 of	 ciprofloxacin	 and	 morphine	 as	 agonists	 at	 the	MRGPRX2	 receptor.	
Morphine	 demonstrated	 an	 EC50	 value	 of	 25.9	 ±	 1.3	 µM.	 Results	 are	 mean	 ±	 SEM	 of	 three	 independent	 ß-arrestin	
experiments.	
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2.2.6	MRGPRB2	receptor	
	
Further	 attempts	 in	 investigating	 the	 MRGPRX2	 receptor	 were	 based	 on	 the	 seminal	 findings	 of	
McNeil	 et	 al.106	 in	 which	 they	 suggested	 the	 mouse	 MRGPRB2	 (accession	 number:	 NM_175531)	
receptor	 as	 a	 functional	 ortholog	 of	 the	 human	 MRGPRX2.	 Our	 aim	 was	 to	 investigate	 if	 our	
synthesized	 antagonists	 at	 the	 human	 receptor	 are	 active	 at	 the	 murine	 counterpart	 and	 to	
determine	their	potential	affinity.	Should	there	be	considerable	potency	of	our	antagonist,	this	would	
enable	us	using	mouse	models	to	take	MRGPRX2	research	a	step	further	in	pre-clinical	studies.	
The	cDNA	of	mrgprB2	was	provided	by	OriGene	Technologies	Inc.,	USA.	The	cDNA	was	sequenced	by	
GATC	 Biotech	 AG	 in	 Konstanz,	 Germany,	 in	 order	 to	 check	 for	 any	mutations.	 All	 sequences	were	
aligned	with	the	reference	sequence	and	no	mutation	was	found.	The	amplification	of	the	genes	and	
the	insertion	into	the	four	ß-arrestin	vectors	were	done	as	described	in	chapter	4.3.4.	The	Pyrobest™	
DNA-Polymerase	 from	TAKARA	BIO	 Inc.	was	applied	to	amplify	 the	genes.	A	sequence	analysis	was	
also	 performed	 after	 amplification	 and	 insertion	 into	 the	 vector	 to	 ensure	 that	 no	mutation	 took	
place	during	the	amplification,	and	the	results	were	all	positive.	The	lipofectamine	transfection	was	
done	as	described	in	chapter	4.5.1.	
The	first	step	is	usually	the	validation	of	the	agonist	and	the	suitability	of	the	assay.	To	address	this,	
CST-14	 was	 used	 as	 the	 standard	 agonist.	 Unfortunately,	 it	 was	 not	 possible	 to	 detect	 any	 signal	
when	 using	 CST-14	 up	 to	 100	 µM	 concentration.	 The	 transfection	 was	 repeated	 but	 the	 results	
remained	negative	for	all	generated	MRGPRB2	constructs	in	the	four	ß-arrestin	vectors.	Hence,	it	 is	
for	 now	not	 possible	 to	 investigate	 any	 antagonistic	 activity	 of	 our	 novel	MRGPRX2	 ligands	 at	 the	
mouse	receptor.	 It	 should	be	mentioned	that	 in	 reference	106	CST-14	showed	an	EC50	value	of	21.3	
µM,	which	 is	unusually	high	 for	a	neuropeptide.	Nevertheless,	 it	would	still	be	possible	 to	perform	
calcium	mobilization	assays	to	circumvent	the	often	less	sensitive	ß-arrestin	assay.	
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2.2.7	Discussion	
	
The	MRGPRX2	receptor	is	a	member	of	the	MRGPRX	subfamily.	It	is	noteworthy	that,	in	addition	to	
many	synthetic	drugs	(morphine,	ciprofloxacin	etc.),	several	physiological	agonists	(CST-14,	PAMP,	ß-
defensin,	basic	secretagogue	and	LL-37)	have	been	described	as	agonists	for	this	receptor.81,93,101,103	It	
is	noticeable	that	these	peptides	are	structurally	not	very	related	and	the	EC50	values	are	relatively	
high	compared	to	classical	peptide	receptors	(see	figure	8	and	table	5).	This	ability	of	MRGPRX2	to	be	
activated	by	several	agonists	distinguishes	this	receptor	from	many	7TMRs	and	this	could	be	relevant	
for	 the	physiological	 function	of	 this	 receptor	 if	 these	peptides	actually	 function	as	 agonists	under	
(patho)physiological	 conditions.	 One	 interesting	 explanation	 is	 a	 kind	 of	 similarity	 of	 MRGPR	
receptors	 to	 olfactory	 and	 taste	 receptors	 which	 are	 able	 to	 detect	 an	 extraordinary	 range	 of	
substances	 from	 the	 environment.	 By	 the	 same	 token,	 pain	 and	 itch	 demonstrate	 an	 outstanding	
versatility	and	their	receptors	could	be	“tuned”	to	respond	in	varying	degrees	to	different	stimuli.38	In	
this	thesis	we	found	that	this	 idea	applies	to	antagonists	as	well	 (interestingly,	no	antagonists	have	
been	described	in	the	literature	so	far).	Several	antagonists	have	been	identified	during	our	screening	
efforts	in	contrary	to	other	investigated	MRGPRX	receptors.	
Menadione,	 from	the	drug	 library,	was	the	 first	detected	antagonist	with	an	 IC50	value	of	5.39	µM.	
This	could	be	an	interesting	and	inexpensive	pharmacological	tool.	The	ability	to	modify	the	molecule	
could	also	be	an	option	to	increase	the	potency	of	this	antagonist.	In	order	to	verify	and	substantiate	
the	 findings	 and	 reduce	 the	 toxicity	 of	 menadione	 on	 the	 cells	 during	 ß-arrestin	 assays,	 calcium	
mobilization	assays	could	be	performed.	Two	other	antagonists,	H351	and	SL318	(see	figure	15),	have	
been	 identified	 in	the	compound	 libraries	5	and	2,	respectively.	Both	of	them	belong	to	a	different	
chemical	scaffold	but	showed	IC50	values	of	approximately	10	µM.	
The	most	potent	antagonist	was	detected	in	the	compound	library	3	and	was	termed	CB8.	The	IC50	
value	was	2.42	µM	and	it	possessed	a	tricyclic	benzimidazole	scaffold.	From	this	parent	compound	a	
total	 of	 65	 compounds	 have	 been	 synthesized	 in	 the	 group	 of	 prof.	 Herdewijn,	 Leuven	 (Belgium).	
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Solid	 structure-activity	 relationships	have	been	established	and	 the	 current	 state	 is	 summarized	 in	
figure	24.		
	
	
Figure	24:	The	established	structure-activity	 relationships	at	 the	MRGPRX2	 receptor	after	 synthesizing	a	 large	number	of	
antagonists.	
	
The	 best	 antagonist	 so	 far,	 CB63,	 has	 an	 IC50	 value	 of	 6.38	 nM.	 This	 potency	 could	 be	 suitable	 to	
develop	a	 radioligand,	which	would	be	a	powerful	pharmacological	 tool	 for	 further	studies.	Hence,	
developing	 a	 radioligand	 could	 be	 a	 plausible	 next	 step	 in	 investigating	 the	 MRGPRX2	 receptor.	
However,	this	should	take	place	after	further	investigation	of	SARs;	especially	in	positions	7	and	8	of	
the	benzimidazole	ring	because	this	could	lead	to	even	more	potent	antagonists.	Hence,	the	first	step	
in	 the	 chemical	 synthesis	 is	 to	 find	an	approach	 to	get	 rid	of	 the	 regio-isomer	problem	and	 to	get	
single	 compounds.	 The	 nature	 of	 antagonism	 was	 also	 investigated	 and	 turned	 out	 to	 be	 an	
orthosteric	 inhibition	 with	 regard	 to	 the	 peptide	 agonist	 CST-14.	 The	 fact	 that	 the	 CST-14	
concentration	could	not	be	increased	over	100	µM	was	a	barrier	during	our	efforts	to	investigate	the	
mode	of	antagonism.	This	indicates	the	importance	of	developing	potent	agonists	as	well	since	other	
described	agonists	like	morphine	or	ciprofloxacin	are	much	weaker.	The	newly	developed	MRGPRX2	
antagonists	 were	 also	 screened	 at	MRGPRX1	 and	 turned	 out	 to	 be	 selective	 against	MRGPRX1.	 A	
further	 investigation	of	 the	selectivity	of	 the	new	antagonists	against	MRGPRX4	receptor	would	be	
informative	 as	 well.	 Moreover,	 it	 would	 also	 be	 of	 interest	 to	 investigate	 the	 selectivity	 at	
somatostatin	and	ghrelin	receptors	since	both	could	be	activated	by	CST-14.		
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	Having	 established	 SARs	 for	 antagonists	 and	 developed	 potent	 ones,	 our	 aim	 was	 then	 directed	
towards	 expanding	 the	 investigation	 to	 a	 pre-clinical	 stage	 through	 a	mouse	model.	 This	 could	 be	
based	on	the	recent	finding	that	the	mouse	MRGPRB2	receptor	could	be	the	functional	ortholog	of	
the	 human	MRGPRX2	 receptor.	 As	 a	 first	 step,	 ADME	 profiles	 of	 the	 best	 three	 antagonists	 were	
generated	in	vitro.	The	obtained	results	make	clear	the	difficulties	throughout	stages	of	developing	a	
drug.	 The	 analyzed	 antagonists,	 CB63,	 CB64	 and	 CB66	 were	 all	 very	 potent	 in	 a	 cell-based	 assay.	
However,	the	pharmacokinetic	data	shows	a	very	high	plasma	protein	binding	(>99%),	in	addition	to	
a	very	short	half-life	of	less	than	8	minutes	for	all	investigated	antagonists.	This	would	have	negative	
implications	for	the	bioavailability	of	these	antagonists.	The	CYP-inhibition	is	also	pronounced,	which	
may	 lead	 to	drug-drug	 interactions.131	 The	CNS	accessibility	 seems	 to	be	 acceptable	 (for	 CB63	and	
CB64)	but	 the	expression	profile	of	MRGPRX2	 in	mast	 cells	 and	DRG	neurons	does	not	 necessarily	
require	BBB	penetration	depending	on	the	indication	pursued.	This	leads	us	to	further	requirements	
for	 the	 next	 series	 of	 antagonists.	 These	 requirements,	 besides	 getting	 rid	 of	 regio-isomers,	 are	
improved	water	solubility	since	this	seems	to	be	a	big	problem	upon	substituting	position	7	and	8,	in	
addition	to	reducing	the	clearance	and	abolishing	CYP	inhibition.		
Lastly,	 the	activity	of	our	novel	antagonists	at	human	receptors	were	 intended	to	be	also	tested	at	
the	mouse	MRGPRB2	receptor.	This	could,	unfortunately,	not	be	done	despite	a	successful	cloning	of	
the	respective	ß-arrestin	cell	 line.	The	hurdle	was	the	 inactivity	of	the	agonist	CST-14	at	the	mouse	
receptor	 in	 the	 ß-arrestin	 assay.	 This	 could	 be	 explained	 by	 the	 rather	 unimpressive	 EC50	 value	 of	
CST-14,	which	was	reported	in	a	calcium	assay.106	Therefore,	the	less	sensitive	ß-arrestin	assay	would	
not	enable	satisfying	concentration-response	curves	to	be	plotted.	Addressing	this	issue	could	be	via	
generating	another	MRGPRB2	cell	 line	and	re-testing	CST-14	at	 this	cell	 line.	The	results	of	calcium	
mobilization	assays	in	CHO	cells	are	usually	not	that	satisfying.	This	could	be	due	to	lower	levels	of	Gq	
protein.	Hence,	it	could	be	more	useful	to	express	the	mouse	MRGPRB2	receptor	in	a	HEK293	or	an	
astrocytes	cell	line.	
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2.3	MRGPRX3	receptor	
	
This	member	 of	 the	MRGPRX	 subfamily	 appears	 to	 be	 the	most	 enigmatic	 one.	 The	 expression	 is	
thought	 to	 be	 restricted	 to	 sensory	 neurons	 in	 the	DRG	but	 a	 new	 study	 suggested	 a	 role	 for	 the	
receptor	in	corneal	endothelial	cells.109	Since	there	is	no	described	tool	for	this	receptor,	our	aim	was	
to	find	the	first	agonist.		
2.3.1	Cloning	of	MRGPRX3	ß-arrestin	cell	line	
	
This	cell	line	was	cloned	since	DiscoverX®	does	not	offer	this	cell	line.	The	reason	behind	this	has	not	
been	disclosed.	 The	 cDNA	of	mrgprX3	was	provided	by	OriGene	Technologies	 Inc.,	USA.	 The	cDNA	
was	sequenced	by	GATC	Biotech	AG	in	Konstanz,	Germany,	 in	order	to	check	for	any	mutations.	All	
sequences	were	aligned	with	the	reference	sequence	and	no	mutation	was	found.	The	amplification	
of	 the	 genes	 and	 the	 insertion	 into	 the	 four	 ß-arrestin	 vectors	was	 done	 as	 described	 below	 (see	
chapter	 4.3.4).	 The	 Pyrobest™	 DNA-Polymerase	 from	 TAKARA	 BIO	 Inc.	 was	 applied	 to	 amplify	 the	
genes.	A	sequence	analysis	was	also	performed	after	amplification	and	 insertion	 into	 the	vector	 to	
ensure	that	no	mutation	took	place	during	the	amplification,	and	the	results	were	all	positive.	
The	lipofectamine	transfection	was	done	as	described	in	chapter	4.5.1.	To	confirm	the	expression	of	
the	cDNA	on	the	protein	level	and	to	compare	the	expression	level,	immunofluorescent	experiments	
were	done	as	described	 in	chapter	4.6,	using	the	antibody	against	the	Prolink	segment.	The	results	
showed	 clearly	 a	 higher	 expression	 using	 the	 ARMS1	 and	 ARMS2	 plasmids,	 while	 ProLink1	 and	
ProLink2	showed	a	less	pronounced	expression.	Hence,	the	MRGPRX3-ARMS2	cell	 line	was	used	for	
pharmacological	investigations	because	it	showed	the	highest	expression	as	shown	in	figure	25.	
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Figure	 25:	 The	 expression	 of	 MRGPRX3	 receptor	 in	 four	 different	 vectors	 ProLink1,	 ProLink2,	 ARMS1	 and	 ARMS2.	 The	
expression	of	the	receptor	is	located	in	the	cell	membrane	(green	fluorescence)	and	DAPI	was	used	to	investigate	the	cell	
nuclei.	MRGPRX3-ARMS2	construct	demonstrated	the	highest	expression.	
	
2.3.2	Screening	of	compound	libraries	in	search	for	agonists	
	
In	order	to	search	for	an	agonist	a	screening	of	several	compound	 libraries	has	been	conducted.	 In	
this	 search	 and	due	 to	 the	need	 for	 an	 agonist	 as	 indispensible	 tool	 for	 further	 investigations,	 the	
screening	 was	 done	 at	 10	 µM	 and	 an	 S/N	 ratio	 of	 as	 low	 as	 1.3	 was	 considered	 as	 a	 hit.	 The	
compound	 libraries	 1-5	 and	 7-10	were	 screened	 (see	 chapter	 4.10).	 The	 results	 of	 the	 compound	
libraries	2	and	4-10	were	all	negative	without	any	hit	 (data	not	shown).	Nevertheless,	 screening	of	
the	compound	libraries	1	and	3	revealed	one	hit	in	compound	library	1	with	an	S/N	ratio	of	1.6	(BMS	
191011:	a	potent	potassium	channel	opener123)	and	two	in	compound	library	3	with	an	S/N	ratio	of	
1.5	 and	 1.3	 (IDs:	 6265708	 and	 6258069,	 respectively)	 as	 shown	 in	 figure	 26.	 The	 screening	 was	
repeated	three	times	and	could	be	reproduced.	 	 Interestingly,	the	hits	from	the	compound	library	3	
share	 a	 benzimidazole	 scaffold	 like	 the	 other	 CB	 ligands	 for	 the	MRGPRX2	 receptor.	 All	 three	 hits	
were	also	oxadiazole	derivatives,	nevertheless	 these	are	two	different	 isomers.	 In	order	 to	confirm	
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the	 identity	of	these	hits,	an	LC-MS	measurement	was	conducted.	The	results	did	not	demonstrate	
the	 expected	 mass	 because	 there	 was	 a	 degradation	 of	 all	 three	 compounds.	 An	 LC-MS	 was	
conducted	using	 the	mother	plates,	 the	 results	 showed	no	 signs	of	 degradation	 (data	not	 shown).	
The	 compounds	 in	 the	 mother	 plates	 demonstrated	 no	 activity	 at	 all,	 which	 means	 that	 the	
degradation	products	in	the	daughter	plates	would	have	been	causing	the	signals.	
	
Figure	26:	The	chemical	structures	of	the	detected	hits	with	potential	MRGPRX3-agonistic	activity	and	the	predicted	active	
degradation	products.	
	
In	order	to	make	sure	that	the	increase	in	signal	is	concentration-dependent	a	curve	was	plotted.	As	
shown	in	figure	27	there	was	an	increase	of	signal	for	all	three	compounds.	The	absolute	increase	is	
not	that	high	compared	with	that	of	commercially	available	MRGPRX	receptor	cell	lines	but	this	could	
be	due	to	the	fact	that	commercial	cell	lines	of	MRGPRX1,	2	and	4	are	monoclonal	and	the	MRGPRX3	
cell	 line	 is	 a	 pooled	 one.	 These	 initial	 results	 tempted	 us	 to	 trace	 potential	 active	 degradation	
products.	
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Figure	 27:	 The	 three	 curves	 of	 the	 detected	 hits	 at	 MRGPRX3	 receptor.	 All	 the	 experiments	 were	 done	 once	 (n=1)	 in	
duplicates.	
	
In	order	to	do	this,	we	analyzed	the	LC-MS	measurements	of	the	active	solutions.	Unfortunately,	for	
BMS-191011	the	remaining	stock	solution	was	too	little	to	be	analyzed.	Hence,	it	was	not	possible	to	
have	an	informed	guess.	We	also	tried	to	heat	BMS-191011	to	100°C	for	30	minutes	but	that	did	not	
show	any	 increase	 in	activity	 (data	not	 shown).	The	measurements	of	 the	compounds	with	 the	 ID:	
6265708	and	6258069	showed	a	molecular	weight	of	200.2	and	256.29,	respectively.	This	led	to	the	
assumption	that	the	oxadiazole	ring	was	degraded	and	yielded	cyano	derivatives	as	shown	in	figure	
26.	 The	 proposed	 degradation	 products	 have	 molecular	 weights	 that	 are	 in	 harmony	 with	 the	
detected	 molecular	 weights	 but	 they	 were	 not	 commercially	 available	 according	 to	 a	 search	 in	
Scifinder.	 Yet	 a	 similar	 compound	 (figure	26)	was	 found	and	ordered	 from	Princeton	BioMolecular	
Research	 and	 designated	 Prin01.	 This	 compound	was	 screened	 three	 times	 but	 did	 not	 show	 any	
activity	 (data	 not	 shown).	 The	 assumed	 degradation	 product	 of	 the	 compound	 6265708	 was	
designated	BI03,	which	was	synthesized	by	Younis	Baqi.	BI03	was	also	tested	at	MRGPRX3	and	results	
were	unfortunately	disappointing.	The	first	step	to	search	for	the	problem	was	to	compare	the	LC-MS	
measurement	of	BI03	and	the	6265708	solutions.	Both	showed	the	same	spectrum	(data	not	shown).	
This	led	to	the	assumption	that	the	cells	could	have	lost	the	receptor.	New	cell	aliquots	were	thawed;	
one	in	ARMS1	and	the	other	in	ARMS2	plasmid,	for	the	sake	of	new	screening.	BI03,	Prin01	as	well	as	
previously	active	stock	solutions	were	screened	but	none	of	them	demonstrated	activity.		
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2.3.3	Discussion	
	
In	summary,	 the	cDNA	of	mrgprX3	was	successfully	cloned	 in	the	four	ß-arrestin	plasmids	and	four	
corresponding	cell	lines	have	been	generated.	The	expression	of	the	receptor	were	investigated	using	
an	antibody	against	 the	ProLink	 segment	and	 the	cell	 line	of	MRGPRX3	 in	 the	ARMS2	plasmid	was	
chosen	for	pharmacological	assays	due	to	the	high	expression	of	the	receptor	in	the	cell	membrane.	
The	 compound	 libraries	 1-5	 and	7-10	were	 screened	 in	 search	 for	 an	 agonist	 at	 this	 receptor.	 The	
search	was	done	according	to	the	status	of	the	compound	 libraries	 in	September	2014.	The	search	
led	 to	 no	 clear	 identification	 of	 a	 hit.	 Three	 compounds	 were	 found	 to	 be	 active	 but	 they	 were	
degraded	compounds.	The	active	moiety	remains	elusive	for	now.	Interestingly,	two	of	the	assumed	
hits	 showed	 a	 benzimidazole	 structure.	 The	 difficulty	 in	 finding	 an	 agonist	 for	MRGPRX3	 receptor	
could	be	due	to	several	reasons.	
The	 first	 reason	 could	 be	 the	 unsuitability	 of	 the	 ß-arrestin	 assay.	 This	 is	 difficult	 to	 explain	 but	 it	
could	 be	 the	 reason	 why	 DiscoverX®	 does	 not	 offer	 this	 cell	 line.	 The	 other	 reason	 could	 be	 the	
inability	to	have	a	stable	expression	in	the	cell	membrane,	which	has	already	been	described121	or	a	
rapid	 decrease	 in	 the	 expression	 of	 the	 receptor	 in	 the	 cell	membrane.	 In	 addition	 to	 the	 general	
difficulty	in	finding	a	ligand	for	the	MRGPRX	subfamily,	which	is	reflected	in	the	paucity	of	described	
ligands	 so	 far.	 To	 address	 these	 issues	 it	 is	 plausible	 to	 switch	 the	 screening	 assay	 to	 a	 calcium	
mobilization	assay	because	MRGPRX3	is	Gq	coupled	and	by	using	FACS	techniques	it	could	be	possible	
to	 pick	 a	 monoclone	 (e.g.	 m-Cherry	 approach)	 and	 have	 a	 potentially	 more	 reliable	 system.	 The	
screening	of	the	compound	libraries	should	be	repeated	using	higher	concentration	(e.g.	30	or	even	
100	µM)	because	 it	 is	 important	 to	have	even	a	weak	 initial	 tool	and	 then	 there	could	be	ways	 to	
improve	 the	 potency.	 The	 ligands	 at	MRGPRX2	 should	 be	 tested	 at	MRGPRX3	 as	 agonists	 as	well.	
Lastly,	 it	 should	be	kept	 in	mind	 that	 the	glioblastoma	cell	 line	 LN229	has	 shown	an	expression	of	
mrgprX3	on	the	mRNA	level.	Taking	into	account	that	the	LN229	cell	line	has	shown	very	encouraging	
results	regarding	calcium	assays	for	the	MRGPRX4	receptor	(more	details	see	chapter	4.8.3),	it	is	very	
useful	to	try	to	detect	MRGPRX3	receptor	in	this	cell	line	on	the	protein	level	using	either	an	antibody	
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or	 (should	 there	 be	 no	 acceptable	 antibody)	 subjecting	 a	 membrane	 preparation	 sample	 to	
proteomics	 mass	 spectrometry.	 If	 the	 expression	 could	 be	 confirmed,	 the	 LN229	 would	 be	 very	
helpful	in	investigating	this	receptor	via	calcium	mobilization	assay.	
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2.4	MRGPRX4	receptor	
	
MRGPRX4	 is	 a	 poorly	 investigated	 receptor.	No	 pharmacological	 tools	 had	 been	 described	 for	 this	
7TMR	at	the	beginning	of	this	thesis	and	the	physiological	role,	apart	from	apparent	involvement	in	
nociception,	 has	 not	 been	 elucidated.17,18	 MRGPRX4	 was	 reported	 to	 be	 Gq	 coupled	 via	 a	 novel	
proliferation	assay	called	Receptor	Selection	and	Amplification	Technology	(R-SAT™).23	Recently,	the	
antidiabetic	drug	nateglinide,	a	KATP-channel	blocker,	was	suggested	to	function	as	an	agonist	at	this	
receptor.112	
2.4.1	MRGPRX4	receptor:	the	human	adenine	receptor?	
		
The	first	step	in	investigating	the	MRGPRX4	receptor	was	an	approach	to	find	relatedness	within	the	
expanded	mas-related	 gene	 receptors	 in	 rodents.	Although	 there	 are	no	direct	 orthologs	between	
human	MRGPRX	subfamily	and	the	rodents’	receptors19,20,	the	relatedness	(sequence	identity)	could	
give	 an	 indication	 to	 a	potential	 shared	 ligand.	 From	 the	deorphanized	 rodents’	MAS-related	gene	
receptors,	MRGPRA9/A10	(accession	number:	NM_001288801,	JN662396)	and	rat	MRGPRA	(also	rat	
MRGPRX3,	 accession	 number:	 NM_145787)	 and	 the	 Chinese	 hamster	 adenine	 receptor	 (accession	
number:	 KC202822.1)	 showed	 the	 highest	 sequence	 identity	 of	 66%.	 Rat	 MRGPRA	 and	 mouse	
MRGPRA9/10	 receptors	 demonstrated	 sequence	 identity	 of	 64%,	 63%	 and	 65%,	 respectively,	 as	
shown	 in	 table	19.	 	All	 those	 receptors	 are	 activated	by	 adenine	 in	 low	nanomolar	 concentrations	
(see	table	2).		
Table	19:	Sequence	identity	of	the	nucleotides	of	the	cDNA	of	the	corresponing	genes	using	Clustal	Omega	tool	
Nucleotide	
sequence	identity	
Rat	MRGPRA	
(rAde)	
Mouse	MRGPRA9	
(mAde2)	
Mouse	MRGPRA10	
(mAde1)	
Hamster	cAde	
(cAde)	
Human	MRGPRX4	 64%	 63%	 65%	 66%	
	
Adenine	has	been	already	shown	to	have	interesting	physiological	effects.	Yoshimi	et	al.	reported	an	
increase	 in	 the	 number	 of	 Purkinje	 cells	 in	 rat	 primary	 cerebellar	 cultures	 after	 exposure	 to	 high	
concentrations	of	adenine	(1-2	mM)	but	this	effect	was	not	noticed	for	astrocytes.	The	mechanism	of	
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this	 neurotrophic	 effect	 remained	 elusive.136	 The	 oldest	 observation	 was,	 nevertheless,	 that	 1-
methyladenine	acts	as	a	maturation-inducing	hormone	in	starfish	oocytes.137	The	effect	of	adenine	in	
the	dorsal	horn	was	found	to	be	pronociceptive	since	the	spinal	administration	of	adenine	in	the	rat	
increased	 the	 excitability	 of	 C-fibres	 in	 a	 concentration	 dependent	manner.	 The	mechanism	 could	
also	not	be	 readily	 correlated	 to	mas-related	genes	 since	 these	 receptors	are	not	expressed	 in	 the	
dorsal	 horn	but	 only	 in	 the	DRG.138	Adenine	was	 also	 found	 to	 induce	 an	 inhibitory	 effect	 on	Na+-
ATPase	activity	through	a	Gi	protein-coupled	receptor	inhibition	of	the	adenylyl	cyclase/PKA	signaling	
pathway.139	Moreover,	it	was	found	through	binding	studies	that	radioactive	adenine	could	bind	with	
varying	affinities	at	different	rat	tissues	(brain,	cerebrum,	cerebellum,	spinal	cord,	kidney,	testis	and	
heart)	and	native	cell	 lines	 (human	astrocytoma	1321N1	and	murine	NG	108-15	cell	 lines).140,141	All	
the	previous	data	prompted	us	to	 investigate	MRGPRX4	as	a	potential	human	adenine	receptor.	 In	
fact	this	was	our	first	deorphanization	attempt.	
In	order	to	test	this	deorphanization	hypothesis,	adenine	was	tested	as	an	agonist	at	MRGPRX4	using	
the	ß-arrestin	assay.	The	ß-arrestin	cell	 line	was	a	commercial	one	 from	DiscoverX®.	The	 results	of	
the	testing	showed	no	increase	in	signal	even	when	the	concentration	of	adenine	was	as	high	as	500	
µM.	This	 is	 a	 clear	 indication	 that	adenine	 could	not	activate	MRGPRX4	 receptor	at	 least	 in	 the	ß-
arrestin	pathway.	Since	MRGPRX4	 is	also	Gq	coupled,	calcium	mobilization	assay	was	also	tried	but	
the	results	were	negative	as	well	as	shown	in	figure	28.	
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Figure	28:	Concentration-response	curves	of	adenine	at	MRGPRX4	receptor	using	ß-arrestin	assay	(left)	and	calcium	
mobilization	assay	(right).	Both	singaling	pathways	did	not	show	any	response	to	adenine.	
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In	 order	 to	 further	 our	 investigations,	 binding	 assays	 have	 been	 conducted	 to	 detect	 a	 possible	
binding	 of	 [3H]adenine	 to	 the	 receptor.	 This	 could	 be	 the	 case	 if	 adenine	 is	 an	 antagonist	 or	 a	
modulator	of	MRGPRX4	receptor.	Six	separate	binding	experiments	have	been	done	but	 there	was	
no	significant	binding	of	adenine	to	the	MRGPRX4	receptor	(data	not	shown).	All	these	results	were	
enough	to	conclude	that	MRGPRX4	is	not	the	human	adenine	receptor.	
2.4.2	Screening	of	compound	libraries	in	search	for	agonists:	a	challenging	
search	
	
Having	proven	that	adenine	is	not	a	ligand	for	MRGPRX4	receptor,	it	was	necessary	to	find	a	tool	for	
investigating	this	receptor.	Screening	of	the	then	(August	2012)	available	compound	libraries	in	our	
institute	was	 initiated.	 The	 high	 expression	 of	 the	 receptor	 on	 the	 cell	membrane	was	 confirmed	
using	an	antibody	against	the	ProLink	tag	of	the	receptor	(data	not	shown).	The	compound	libraries	1	
and	3-6	were	screened	(see	chapter	4.10).	Although	the	screening	has	been	done	twice	at	10	and	at	
100	µM,	it	was	not	possible	to	find	any	agonist	for	this	receptor.		
2.4.3	The	second	deorphanization	approach:	cerebrospinal	fluid	
	
Since	 the	 screening	 of	 the	 available	 compound	 libraries	 and	 the	 adenine-based	 deorphanization	
approach	 were	 not	 fruitful,	 it	 was	 necessary	 to	 find	 a	 new	 approach.	 The	 most	 interesting	
characteristic	of	the	mas-related	genes	is	their	restricted	expression	in	the	DRG.17,18	One	way	would	
be	 the	 screening	 of	 different	 tissue	 extracts	 of	 the	 DRGs	 (reverse	 pharmacology	 approach).	 The	
active	fractions	could	then	be	further	fractioned,	purified	and	analyzed	(e.g.	peptide	fraction	etc.)	till	
an	 active	metabolite	 is	 found.	 	 Such	an	approach	has	been	 carried	out	 successfully	 and	 led	 to	 the	
deorphanization	of	several	7TMRs	and	to	the	identification	of	important	endogenous	neuropeptides.	
Opioid	receptor-like	1	(ORL1)	was	deorphanized	via	rat	brain	extracts	and	nociceptin	was	identified	
as	 a	 ligand.142,143	 The	 peptides	 orexin	 A	 and	 B	were	 identified	 and	 paired	 to	 their	 receptors	 in	 an	
organ	 extraction	 approach	 and	 RNA-subtraction	 approach	 simultaneously	 by	 two	 different	
groups.144,145	This	was	followed	by	the	discovery	of	prolactin-releasing	peptide	and	apelin	for	GPR10	
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and	APJ	 receptors,	 respectively.146,147	 Interestingly,	 ghrelin	was	 identified	 in	 a	 stomach	extract	 and	
found	to	be	an	endogenous	ligand	at	its	7TMR,	which	is	mainly	expressed	in	the	brain.148	In	order	to	
realize	 such	 an	 approach	 for	 MRGPRX4	 receptor,	 human	 or	 monkey	 DRGs	 should	 be	 available	 in	
relatively	big	amount	since	the	native	ligand	is	usually	found	in	a	very	low	concentration.	This	was	a	
main	 hurdle	 for	 this	 approach.	 Another	 way	was	 to	 investigate	 the	 cerebrospinal	 fluid	 (CSF).	 This	
could	be	plausible	because	the	DRGs	are	surrounded	by	CSF.	In	addition,	CSF	has	been	approached	to	
determine	biologically	 active	proteins	 in	pathological	 conditions.149	 The	CSF-based	approach	would	
work	 provided	 that	 the	 native	 ligand	 is	 able	 to	 leak	 from	 the	 DRG	 tissue	 to	 CSF	 in	 a	 reasonable	
amount	 to	 be	 detected.	 If	 so,	 this	 approach	 could	 be	 advantageous	 because	 it	 reduces	 the	
complexity	of	a	tissue	extract	and	circumvents	the	difficulties	of	obtaining	human	DRG	tissues.	
Professor	Urlich	Wüllner	from	the	Neurology	Department	in	the	University	Clinic	in	Bonn	provided	us	
kindly	with	6	 samples	of	CSF.	One	sample	had	been	 taken	directly	and	split	 into	 two	samples.	The	
first	 sample	 was	 treated	 with	 a	 protease	 inhibitor	 (identity	 not	 disclosed)	 and	 the	 other	 was	 left	
untreated	and	both	were	 then	 frozen.	These	samples	were	 tested	on	MRGPRX4	and	a	weak	signal	
was	observed	(data	not	shown).	Since	the	concentration	of	a	potential	ligand	in	the	CSF	is	lower	than	
within	 the	DRG	tissue,	 it	was	decided	to	concentrate	 the	CSF	by	 the	 factor	of	10	via	 lyophilization.		
The	 concentrated	 CSF	 solutions	 were	 then	 tested	 in	 ß-arrestin	 assays.	 The	 results	 are	 shown	 in	
figure	29.	
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Figure	 29:	 The	 mean	 curves	 of	 three	 independent	 ß-arrestin	 assays	 of	 six	 CSF	 samples.	 The	 induced	 signals	 differed	
considerably	between	the	several	samples.	
	
It	should	first	be	mentioned	that	the	CSF	concentration	was	given	as	volume/volume	in	each	well	of	
the	96-well	plate.	 Interestingly,	 there	was	a	 considerable	difference	 in	 the	 induced	signal	between	
the	 samples	 of	 different	 origins.	 While	 some	 samples	 like	 sample	 6	 could	 induce	 a	 robust	 and	
reproducible	 signal,	 sample	 3	 could	 not	 cause	 any	 increase	 in	 signal.	 It	 is	 not	 possible	 to	make	 a	
confident	 conclusion	 out	 of	 these	 data	 but	 it	 is	 tempting	 to	 suggest	 that	 there	 is	 an	 agonist	 of	
MRGPRX4	 in	 the	CSF	 and	 this	 ligand	 is	 present	 at	 varying	 concentrations	 in	 the	different	 samples.	
Taken	 into	 consideration	 that	MRGPRX	 receptors	 are	 proposed	 to	 play	 a	 role	 as	 pain	 detectors23,	
these	 varying	 results	 could	 reflect	 a	 nociceptive	 input	 in	 the	 different	 samples.	 It	 could	 also	 be	
noticed	that	the	addition	of	protease	inhibitor	did	not	have	any	inhibitory	effect	on	the	signal.	This	
could	mean	 that	 the	agonist	 is	not	a	peptide	or	 that	 it	 is	a	 relatively	 small,	 stable	peptide	with	no	
cleavage	site	for	a	potential	protease.		
A	 second	 set	 of	 samples	 was	 sent	 from	 Prof.	 Wüllner,	 but	 the	 volumes	 were	 too	 small	 to	 be	
individually	investigated.	Therefore,	it	was	decided	to	pool	them.	This	combined	CSF	sample	showed	
a	signal	with	an	S/N	ratio	of	2	(data	not	shown).	
As	a	kind	of	control	CSF	was	tested	at	GPR55	in	the	same	test	system.	GPR55	is	expressed	mainly	in	
the	 brain	 and	 can	 be	 activated	 by	 cannabinoids	 and	 lipids	 such	 as	 lysophophatidylinositol.150	 CSF	
activated	GPR55,	which	is	not	unexpected	taken	into	consideration	its	expression	in	the	brain	and	the	
Results	and	Discussion	
74	
	
availability	of	a	potential	agonist	in	CSF.	In	order	to	investigate	whether	the	signal	is	just	an	artifact	or	
receptor-dependent,	 it	 was	 decided	 to	 compare	 the	 order	 of	 efficiency	 of	 the	 signal	 via	 the	
signal/noise	 (S/N)	 ratios	produced	by	 the	CSF	 from	different	 samples.	 The	 ratios	did	not	 show	 the	
same	order	of	efficiency	as	shown	in	figure	30.	
	
Figure	30:	S/N	ratios	of	CSF	from	different	samples	at	MRGPRX4	and	GPR55	receptors.	S1	w/o:	sample	1	without	protease	
inhibitor,	S1	w:	sample	1	with	protease	inhibitor.	
	
The	next	step	was	to	investigate	if	the	CSF	could	also	induce	a	signal	in	the	G	protein	pathways.	The	
coupling	 according	 to	 Burstein	 et	 al.23	 should	 be	 Gq	 only,	 while	 according	 to	 the	 prediction	 tool	
(http://athina.biol.uoa.gr/bioinformatics/PRED-COUPLE2/)	 MRGPRX4	 should	 be	 Gq	 and/or	 Gi-
coupled.	 	 Therefore,	 screening	of	 the	CSF	 samples	 via	 cAMP	and	 calcium	mobilization	assays	were	
done.	Table	19	 shows	 the	 results	of	 the	 calcium	mobilization	assay.	ATP	at	100	µM	was	used	as	a	
positive	control	in	CHO	cells	because	it	can	activate	one	or	more	of	P2Y	receptors.	
Table	20:	The	results	of	screening	of	CSF	samples	using	calcium	mobilization	assay	and	the	ratio	to	ATP	signal.	
Test	sample	or	compound	 Fluorescence	 Ratio	(CSF/ATP)	
ATP	(100	µM)	 11	 1	
S1	w/o	 40	 3.6	
S1	w	 62	 5.6	
S2	 81	 7.3	
S3	 86	 5.6	
S4	 62	 7.8	
S5	 89	 8	
S6	 63	 5.7	
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The	results	show	a	different	pattern	compared	to	the	ß-arrestin	results.	All	samples	induced	a	strong	
calcium	signal.	Sample	3,	for	instance,	exhibited	a	robust	increase	in	calcium	signal	but	no	ß-arrestin	
signal.	These	results	could	be	explained	by	the	endogenous	expression	of	different	7TMRs	in	the	CHO	
cells,	which	have	 a	Gq	 coupling	 and	 could	be	 activated	by	CSF.	 In	 contrary,	 ß-arrestin	 assay	would	
ideally	give	a	signal	in	the	case	of	activating	the	7TMR	of	interest	only.		
The	screening	of	CSF	using	the	cAMP	assay	after	stimulation	of	cAMP	production	with	forskolin	(10	
µM)	did	not	show	any	signal	(data	not	shown).	It	should	also	be	mentioned	that	heating	the	CSF	to	
90	°C	 for	5	minutes	did	not	 change	 the	 signal	 in	 the	ß-arrestin	assay,	which	means	 that	 the	active	
entity	is	stable	under	these	condition.	
These	 findings	seemed	to	be	encouraging	to	continue	the	search	 for	a	 receptor	agonist	 in	 the	CSF.	
Since	 the	 search	 should	 be	 based	 on	 an	 assumption	 of	 the	 nature	 of	 the	 agonist	 in	 order	 to	
determine	further	steps,	our	assumption	was	that	the	agonist	could	be	a	peptide.	Although	MRGPR	
receptors	 could	be	activated	by	a	variety	of	agonists	of	different	nature	 that	do	not	have	much	 in	
common	 (adenine,	 ß-alanine,	 CST-14,	 BAM-22,	 several	 RF-peptides)122,	 the	 reported	 agonist	 at	
human	receptors	are	all	peptides.	Therefore,	it	was	decided	to	digest	the	peptides	using	a	protease	
and	 see	 if	 the	 signal	 would	 disappear.	 Trypsin	 is	 a	 serine	 protease,	 which	 cleaves	 predominantly	
proteins	 at	 the	 carboxyl	 side	 (or	 "C-terminal	 side")	 of	 the	 amino	 acids	 lysine	 and	 arginine	 except	
when	either	is	bound	to	a	C-terminal	proline.151	Trypsin	was	chosen	as	a	protease	because	of	its	wide	
specificity	and	availability.	CSF	samples	were	 incubated	with	trypsin	for	30	minutes	at	37	°C	before	
screening.	 There	 was	 a	 decrease	 in	 the	 signal	 of	 CSF	 but	 given	 that	 trypsin	 is	 used	 for	 cell	
detachment,	 it	 was	 not	 clear	 if	 the	 decrease	 in	 signal	 is	 due	 to	 a	 harmful	 effects	 of	 trypsin	 (e.g.	
cleaving	of	 the	 receptor)	or	due	 to	degradation	of	an	active	peptide	 ligand.	The	decrease	 in	 signal	
was	dependent	on	the	concentration	of	trypsin	as	shown	in	figure	31.	
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Figure	31:	The	decrease	in	ß-arrestin	signal	is	dependent	on	the	concentration	of	trypsin.	It	should	be	noted	that	at	higher	
concentration	the	basal	signal	was	reduced. 
	
The	next	plausible	step	was	to	fractionate	CSF	into	two	fractions	using	a	3	kDa	cutoff	Amicon®	Ultra,	
one	fraction	is	more	than	3	kDa	and	the	other	is	less	than	3	kDa.		Since	both	BAM22	and	CST-14	have	
a	molecular	weight	of	less	than	3	kDa,	it	was	expected	that	only	the	less	than	3	kDa	fraction	will	show	
an	activity.	Table	21	shows	the	results	of	CSF	of	two	samples	after	fractionation.	
Table	21:	The	results	of	testing	the	two	fractions	of	CSF	at	MRGPRX4	receptor	
Detected	fluorescence	 mean	±	SEM	 S/N	ratio	
PBS	 93368	 109760	 106912	 103347	±	5056	 1	
Sample	M.D.	<	3	kDa	 159752	 181056	 193768	 178192	±	9923	 1.72	
Sample	M.D.	>	3	kDa	 110680	 94744	 92440	 99288	±	5734	 0.96	
Sample	U.P.	<	3	kDa	 185712	 141464	 167160	 164778	±	12828	 1.59	
Sample	U.P.	>	3	kDa	 92248	 93936	 93104	 93096	±	488	 0.90	
	
As	expected	the	signal	was	now	only	obtained	from	the	fraction	of	less	than	3	kDa.	From	now	on	the	
further	testing	will	only	be	done	with	this	fraction.	Interestingly,	screenings	at	GPR55,	MRGPRX2	and	
GPR35	showed	that	the	less	than	3	kDa	fraction	did	not	have	any	agonistic	activity	(data	not	shown).	
Thus,	 it	 is	 clear	now	 that	 the	active	entity	 in	CSF	 is	pretty	 stable	 at	high	 temperature	and	 it	 has	 a	
molecular	weight	of	 less	 than	3	 kDa,	 but	 the	nature	of	 this	 entity	 is	 still	 elusive.	 Therefore,	 it	was	
decided	to	add	a	suitable	protease	inhibitor	to	trypsin	after	digesting	CSF	so	that	trypsin	would	not	
have	any	proteolytic	effect	on	the	cells.	
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2.4.4	Soybean	trypsin	inhibitor	
	
The	soybean	peptidase	inhibitor	(STI)	can	be	divided	into	two	types.	The	most	common	type	(used	in	
this	 work)	 is	 the	 Kunitz	 trypsin	 inhibitor	 (STI,	Mr	 of	 about	 20	 kDa,	 two	 disulfide	 bridges	 between	
amino	acids	39-86	and	amino	acids	136-145),	which	belongs	to	the	clan	IC	and	to	the	family	I3	in	the	
MEROPS	database.152,153	The	inhibitors	from	this	family	are	tight-binding,	reversible	inhibitors	with	ß-
trefoil	 structure.	 The	 members	 of	 this	 family	 show	 inhibition	 of	 serine,	 cysteine	 and	 aspartic	
proteases.154	STI	can	be	hydrolyzed	by	trypsin,	 the	cleavage	site	being	situated	between	Arg63	and	
Ile64	and	the	interaction	is	a	one-to-one	stoichiometry.	This	leads	to	a	conversion	of	the	single	chain	
inhibitor	 to	 two	 chains	 held	 by	 a	 single	 disulfide	 bond	 between	 residues	 number	 39	 and	 86.	 The	
complex	of	 STI	with	 trypsin	has	neither	 tryptic	nor	 inhibitory	activity;	 the	cleaved	 inhibitor	has	 full	
inhibitory	activity.155,156	
The	 active	 (<3	 kDa)	 fraction	 was	 assumed	 to	 cause	 the	 signal	 via	 a	 peptide.	 To	 check	 this	 out,	
incubation	with	trypsin	and	then	STI	each	for	30	minutes	was	done.	For	this	experiment	not	only	PBS	
should	be	considered	as	a	negative	control	but	also	trypsin/STI	and	STI	alone.	The	results	could	not	
be	 interpreted	 because	 the	 signal	 of	 CSF	 after	 treatment	with	 trypsin/STI	was	 considerably	 higher	
than	 for	 CSF	 alone.	 These	 results	 were	 reproducible	 and	 Trypsin/STI	 or	 STI	 alone	 induced	
approximately	the	same	signal	as	shown	in	figure	32.	In	this	case,	the	CSF-induced	signal	could	not	be	
detected	because	STI	 induced	a	more	robust	signal	with	a	higher	S/N	ratio.	This	 fact	represented	a	
barrier	for	further	 investigations	of	CSF	and	shifted	the	search	towards	STI	and	 interleukin	1-ß	(see	
next	two	chapters).	
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Figure	32:	the	detected	signal	in	ß-arrestin	assay	
	
These	 findings	 indicate	 that	 STI	 is	 inducing	 the	 robust	 signal	 at	 MRGPRX4	 receptor.	 This	 was	
unexpected	 but	 due	 to	 the	 high	 reproducibility	 of	 the	 results	 it	 was	 decided	 to	 screen	 STI	 at	 the	
human	MRGPRX2	receptor.		
	
Table	22:	The	effect	of	STI	on	the	signal	of	CST-14	at	MRGPRX2	receptor	
Detected	fluorescence	 mean	±	SEM	 S/N	ratio	
PBS	 1830176	 1692568	 1750048	 1757597	±	39902	 1	
CST-14	(10	µM)	 18900952	 17086272	 18715528	 18234250	±	576479	 10	
CST-14,	Try,	STI	 2320800	 2187640	 2336384	 2281608	±	47198	 1.2	
STI	 1975152	 2012016	 1843080	 1943416	±	51284	 1.1	
	
Conducting	 a	 two-tailed	 t	 test,	 the	 difference	 in	 signal	 between	 PBS	 and	 STI	 was	 statistically	
significant	 (p	 value	of	0.045),	 the	difference	between	PBS	and	 the	CST-14	plus	 trypsin	and	STI	was	
also	 statistically	 significant	 (p	 value	 of	 0.0011).	 Despite	 this	 statistical	 significance,	 the	 increase	 in	
signal	is	minimal	compared	to	the	signal	induced	by	CST-14	at	MRGPRX2	receptor.	It	was	concluded	
that	trypsin	could	cleave	CST-14	and	that	STI	can	be	added	to	inhibit	the	harmful	effect	of	trypsin	on	
the	 cells.	 These	 results	 show	 also	 that	 STI	 does	 not	 have	 an	 agonistic	 effect	 on	MRGPRX2.	 Taking	
these	 findings	 into	 account,	 STI	was	 investigated	 as	 a	 potential	 agonist	 at	MRGPRX4	 receptor.	 STI	
induced	 a	 robust	 signal	 as	 demonstrated	 in	 figure	 33.	 However,	 a	 plateau	 could	 not	 be	 reached	
within	the	range	of	tested	concentrations.	
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Figure	33:	The	mean	curves	of	three	independent	ß-arrestin	assays	with	the	soybean	trypsin	inhibitor	(STI)	at	MRGPRX4		
	
Upon	further	investigating	the	active	fraction	using	a	3	kDa	cutoff	Amicon®	Ultra,	it	was	shown	that	
the	 active	 fraction	 is,	 unlike	 CSF,	 >	 3	 kDa	 (data	 not	 shown).	 This	 led	 to	 the	 testing	 of	 an	 STI	
preparation	with	 high	 purity	 and	 the	 result	was	 identical	 (data	 not	 shown).	 These	 results	 indicate	
that	 STI	 is	 causing	 the	 signal	 and	 not	 a	 small	 peptide.	 Since	 STI	 is	 a	 plant	 protein	 and	 MRGPRX	
receptors	are	human	7TMRs,	a	search	for	similarity	between	STI	and	human	proteins	revealed	that	
such	a	similarity	was	based	on	the	ß-trefoil	structure	as	a	common	denominator.	
ß-Trefoil	 structures	 have	 relevance	 in	 human	 proteins	 and	 some	 proteins	 with	 high	 functional	
versatility	share	this	structure.	The	proteins	with	this	conserved	ß-trefoil	structure	interact	selectively	
with	 their	 different	 targets	 due	 to	 the	 low	 sequence	 homology	 among	 them.	 These	 targets	 are	
divided	 into	the	following	six	groups	according	to	their	biological	activity	 (first,	hydrolase	 inhibitors	
like	peptidase	inhibitors;	second,	interleukins	belonging	to	IL-1	family;	third,	fibroblast	growth	factors	
(FGFs);	fourth,	lectins	and	carbohydrate-binding	modules;	fifth,	fascin,	an	actin	cross-linking	protein;	
sixth,	multi-domain	 DNA-binding	 protein	 LAG-1,	 which	 acts	 as	 repressor	 or	 activator	 in	 the	 Notch	
signaling	pathway).157	 	From	these	six	groups	only	the	interleukin-1	family	seemed	to	be	interesting	
due	 to	 its	 role	 in	 pain	 and	 its	 expression	 in	 DRG	 (see	 chapter	 2.4.5).	 This	 led	 to	 a	 third	
deorphanization	attempt	(see	chapter	2.4.5).	Lastly,	it	should	be	stressed	that	the	increase	in	signal	
by	 STI	 did	not	 reach	 a	plateau	even	 in	 a	 concentration	up	 to	 200	µM.	 This	 looked	 like	 an	 artifact.	
Therefore,	STI	was	investigated	at	100	µM	using	GPR55	and	GPR35	cell	lines.	Both	receptors	showed	
a	 considerable	 increase	 in	 signal.	 Testing	 STI	 at	MRGPRX1	 receptor	 resulted	 in	 approximately	 the	
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same	 increase	 as	 in	 the	MRGPRX4	 cell	 line	 (data	 not	 shown).	 These	 observations	were	 enough	 to	
consider	STI	an	artifact	and	stop	investigating	it	further.			
2.4.5	Interleukin-1ß	and	its	N-terminal	cleavage	products:	The	third	
deorphanization	approach	and	an	elusive	entity	
	
The	Interleukin	1	(IL-1)	subtypes,	IL-1α	and	IL-1ß,	differ	markedly	in	the	primary	structures	but	both	
have	the	3D	ß-trefoil	structure.	Two	distinct	IL-1ß	receptor	binding	proteins	(IL-1	RI	and	IL-1	RII),	plus	
a	 non-binding	 signaling	 accessory	 protein	 have	 been	 identified.158,159	 Until	 recently,	 IL-1	 RI	 was	
considered	a	signal	 transducing	 receptor,	while	 IL-1	RII	was	believed	 to	be	a	dummy	receptor.	 It	 is	
now	known	that	 IL-1	signaling	 is	not	generated	by	the	 IL-1	RI	molecule,	but	by	an	 IL-1	RI	accessory	
protein	 that	 only	 interacts	 with	 IL-1	 RI.160,161	 The	 IL-1ß	 is	 a	 potent	 pleiotropic	 proinflammatory	
cytokine,	whose	concentration	in	the	CSF	is	commonly	monitored	in	neurological	disorders	including	
neuropathic	 pain	 and	 complex	 regional	 pain	 syndrome.162	 In	 the	 CNS,	 endogenous	 IL-1ß	 levels	
increase	 in	 neuropathic	 pain	 and	 cause	 release	 of	 excitatory	 glutamate	 in	 the	 dorsal	 horn	 via	
sphingomyelinase	 and	 Src-kinase	pathways.163,164	A	neuropathic	 pain-induced	 increase	 in	 IL-1ß	was	
also	 found	 in	 the	DRG	and	 trigeminal	 ganglia,	both	 in	 the	neurons	as	well	 as	 in	glial	 cells	 (satellite	
cells).165,166	In	addition	to	the	various	indirect	activation	mechanisms,	IL-1ß	was	suggested	to	act	as	a	
direct	 sensitizer	 of	 nociceptors	 via	 augmenting	 sodium	 currents.167	 This	 imminent	 role	 of	 IL-1ß	 in	
neuropathic	pain	led	us	to	investigating	it	as	a	potential	MRGPRX4	ligand.	
Initially,	 mouse	 IL-1α	 and	 rat	 IL-1ß	 (acquired	 through	 Biomedizin	 Forum	 of	 the	 Uni	 Bonn)	 were	
screened	 at	 concentrations	 from	 100	 nM	 till	 5	 nM	 but	 did	 not	 show	 any	 activity	 at	 MRGPRX4	
receptor	(data	not	shown).	Due	to	the	low	sequence	identity	of	murine	IL-1α	and	rat	IL-1ß	with	their	
corresponding	 human	 counterparts,	 screening	 of	 human	 IL-1ß	 seemed	 necessary.	 IL-1ß	 was	
purchased	as	a	5	µg	aliquot	from	InvitrogenTM	(manufactured	by	Sino	Biological	 Inc.).	 IL-1ß	 induced	
concentration-dependently	a	robust	signal	in	the	ß-arrestin	assay	with	an	EC50	value	of	739	±	180	nM	
as	demonstrated	in	figure	34.	
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Figure	 34:	 The	 mean	 curve	 of	 four	 independent	 ß-arrestin	 assays	 of	 interleukin-1ß	 (IL-1ß)	 at	 MRGPRX4	 receptor.	 The	
determined	EC50	value	was	739	±	180	nM	
	
This	 interesting	result	encouraged	us	 to	subsequently	 test	a	more	pure	 IL-1ß	preparation	since	 the	
one	purchased	from	InvitrogenTM	was	only	of	85%	purity.	5	µg	from	R&D	systems	were	ordered	but	
surprisingly	 no	 agonism	 could	 be	 detected,	 but	 rather	 a	 small	 decrease	 in	 the	 basal	 activity.	 For	
confirmation	another	95%	pure	5	µg	from	InvitrogenTM	were	tested	and	once	again	no	agonism	could	
be	 detected	 but	 only	 a	 decrease	 in	 the	 signal	 (data	 not	 shown).	 These	 findings	 led	 us	 to	 the	
assumption	 that	 the	 15%	 impurity	 was	 causing	 the	 increase	 in	 signal.	 The	 impurities	 were	
investigated	 using	 SDS-PAGE	 gel	 und	 were	 found	 to	 have	 a	mass	 of	 less	 than	 3	 kDa.	 Hence,	 two	
fractions	 (more	 and	 less	 than	 3	 kDa)	 of	 the	 IL-1ß	 solution	 were	 separated	 and	 tested.	 The	 result	
showed	that	only	the	less	than	3	kDa	fraction	was	active	as	shown	in	figure	35.	
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Figure	35:	 Fractionation	of	 IL-1ß	preparation	 led	 to	 the	 conclusion	 that	only	 the	 fraction	of	 less	 than	3	kDa	 is	 the	active	
fraction	in	ß-arrestin	assays	at	MRGPRX4.	This	experiment	was	done	only	once	due	to	the	expensive	material.	
	
In	order	to	make	sense	of	our	findings,	a	mass	spectrometrical	approach	was	necessary	for	analyzing	
the	 active	 IL-1ß	 fraction.	 PD	 Dr.	 Anke	 Schiedel	 sent	 IL-1ß	 as	 well	 as	 a	 CSF	 sample	 to	 Freiburg	 for	
analysis.	 Both	 samples	 were	 first	 digested	 with	 trypsin	 and	 then	 subjected	 to	 MALDI-TOF	 and	
electrospray	ionization	mass	spectrometry.	The	results	confirmed	the	existence	of	IL-1ß,	in	addition	
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to	other	proteins,	in	both	CSF	and	the	active	fraction	of	IL-1ß.	The	peptides,	which	could	be	detected,	
are	listed	in	table	23	and	table	24.	
Table	23:	The	sequences	of	IL-1ß	fragment	peptides,	their	intensities	and	their	masses,	which	were	found	in	the	
fraction	of	 less	 than	3	 kDa	of	 CSF	 after	 digestion	with	 trypsin.	 The	 individual	 peptides	 are	 given	 in	 different	
colors	and	their	location	within	the	mature	IL-1ß	is	shown	in	the	last	row	of	the	table.	
CSF	 Sequence	 intensity	 mass	
	 SLNCTLR	 80217	 862	
SLVMSGPYELK	 192730	 1222	
DDKPTLQLESVDPK	 144380	 1583	
APVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKD
DKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFLGGTKGGQDITDFTMQFV
SS	
	
Table	24:	The	sequences	of	IL-1ß	fragment	peptides,	their	intensities	and	their	masses,	which	were	found	in	the	
fraction	of	 less	than	3	kDa	of	 IL-1ß	after	digestion	with	trypsin.	The	 individual	peptides	are	given	 in	different	
colors	and	their	location	within	the	mature	IL-1ß	is	shown	in	the	last	row	of	the	table.	
IL-1ß	 Sequence	 intensity	 mass	
	 SLNCTLRDSQQK	 9749	 1448	
SLVMSGPYELK	 782570	 1222	
NLYLSCVLK	 798420	 1108	
NLYLSCVLKDDKPTLQLESVDPK	 7085400	 2674	
ALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLK	 140660	 3971	
DDKPTLQLESVDPK	 447050	 1583	
APVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKD
DKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFLGGTKGGQDITDFTMQFV
SS	
	
In	order	to	analyze	the	sequences,	it	should	be	borne	in	mind	that	the	sequences	were	detected	after	
digestion	with	trypsin	(i.e.	cleavage	after	basic	amino	acids	R	and	K)	and	that	the	detection	limit	was	
≥7	amino	acids.	The	results	suggest	that	the	N-terminal	sequence	could	be	responsible	for	the	signal	
and	the	detection	limit	of	7	amino	acids	means	that	the	first	4	amino	acids	at	the	N-terminus	would	
not	have	been	detected	and	it	means	also	that	a	maximum	of	6	amino	acids	after	each	R	or	K	would	
also	not	have	been	detected.	The	overlapping	of	detected	peptides	was	on	the	N-terminal	side	and	in	
the	middle	of	the	mature	IL-1ß.		Since	the	N-termini	of	proteins	are	often	reported	to	have	important	
functions168,169,	 the	 fate	 of	 IL-1ß	 could	 provide	 an	 insight	 into	 identifying	 structures	with	 potential	
activity.	Our	 search	 found	 that	while	 the	 activation	 of	 IL-1ß	 from	pro-IL-1ß	 takes	 place	 via	 several	
enzymes	like	caspase-1,	trypsin	and	matrix	metalloproteinase	9	(MMP-9)	the	degradation	of	mature	
IL-1ß	is	not	well	characterized.	Nonetheless,	 it	was	demonstrated	that	MMP-2,	MMP-3	and	MMP-9	
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can	 degrade	 IL-1ß	 but	 only	 MMP-3	 could	 effectively	 and	 completely	 degrade	 IL-1ß.	 The	 primary	
cleavage	site	of	IL-1ß	was,	nevertheless,	only	determined	for	MMP-2	and	turned	out	to	be	between	
Glu25-Leu26	170,171	 The	 sequence	 below	 is	 for	 IL-1ß	 and	 the	 sequence	 in	 red	 is	 the	 smaller	 cleavage	
product	of	MMP-2.	It	consists	of	25	amino	acids	with	a	molecular	weight	of	2780.	
APVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKD
DKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFLGGTKGGQDITDFTMQFV
SS		
	
Since	the	last	sequencing	was	done	using	trypsin	degradation,	the	sequences	obtained	were	ending	
either	in	arginine	or	lysine.	This	corresponds	not	to	the	original	sequences	in	the	IL-1ß	preparation.	In	
order	 to	 get	 a	 better	 knowledge	 of	 these	 sequences,	 the	 tryptic	 degradation	 should	 not	 be	
performed.	In	order	to	do	this,	a	new	sample	of	IL-1ß	was	dissolved	in	water,	and	then	fractionated	
into	more	and	less	3	kDa	fractions	via	Amicon®	Ultra.	Both	fractions	were	investigated	by	Dr.	Marc	
Sylvester	(Prof.	Gieselmann	group).	The	fraction	of	more	than	3	kDa	could	not	be	analyzed	properly	
without	tryptic	digestion	due	to	the	high	molecular	weight.	The	results	of	the	fraction	of	less	than	3	
kDa	 showed	 pronounced	 sequences	 from	 IL-1ß,	 especially	 of	 the	 N-	 and	 C-terminus	 as	 shown	 in	
table	25.	
Table	 25:	 The	 sequences	 of	 IL-1ß	 fragment	 peptides,	 their	 confidence	 levels	 and	 their	 masses,	 which	 were	
found	in	the	fraction	of	less	than	3	kDa	of	IL-1ß	without	trypsin	digestion.	The	individual	peptides	are	given	in	
different	colors	and	their	location	within	the	mature	IL-1ß	is	shown	in	the	last	row	of	the	table.		
IL-1ß	 Sequence	 Confidence	level	 mass	
	 APVRSLNCTLRD	 high	 1433	
PVRSLNCTLRD	 high	 1273	
APVRSLNCTLRDSQQKSLVMSG	 high	 2390	
GQDITDFTMQFVSS	 high	 1575	
TKGGQDITDFTMQFVSS	 high	 1862	
APVRSLNCTLRDSQQKSLVMS	 high	 2333	
LESVDPKNYP	 medium	 1161	
APVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKD
DKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFLGGTKGGQDITDFTMQFV
SS	
		
These	 results	 further	 supported	 the	 potential	 that	 an	 N-terminal	 fragment	 of	 IL-1ß	 could	 be	 the	
elusive	 physiological	 agonist	 of	MRGPRX4	 receptor.	 Similarly,	 two	 CSF	 samples	 were	 taken	 to	 Dr.	
Sylvester	for	analysis.	One	sample	revealed	several	peptides	from	70	different	proteins	as	expected	
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from	the	physiological	liquid	but,	unfortunately,	no	trace	of	IL-1ß	fragments	could	be	detected.	This	
could	 be	 due	 to	 the	 very	 low	 amount	 of	 this	 fragment	 as	well	 as	 the	 lack	 of	 tryptic	 degradation,	
which	 enables	 the	 statistical	 threshold	 to	 be	 lowered.	 The	 second	 sample,	 unexpectedly,	 did	 not	
demonstrate	anything	other	than	the	fibrinogen	alpha	chain.		
A	custom	synthesis	of	the	25	amino	acid	peptide,	the	cleavage	fragment	of	IL-1ß	induced	by	MMP-2,	
was	ordered	from	Proteogenix	Inc.	Upon	testing	in	ß-arrestin	assay	no	agonistic	activity	at	MRGPRX4	
of	this	peptide	could	be	detected	even	in	concentrations	up	to	100	µM.	The	screening	of	the	same	
peptide	 at	 MRGPRX1	 and	 MRGPRX2	 did	 not	 show	 any	 activity	 either	 (neither	 agonism	 nor	
antagonism).	 A	 second	 custom	 peptide	 was	 ordered	 according	 to	 the	 sequencing	 results	 of	
untrypsinated	 IL-1ß.	 This	 sequence	 (APVRSLNCTLRD)	was	N-terminal	 as	well	 as	 shown	 in	 table	 24.	
The	second	peptide	was	also	inactive	at	MRGPRX4	and	other	MRGPRX	receptors	as	well.	
These	 negative	 results	 led	 to	 the	 search	 for	 other	 degradosome	 products	 as	 potential	 ligands	 for	
MRGPRX4	 receptor.	 MMP-3	 seemed	 to	 be	 the	 most	 suitable	 protease	 candidate	 owing	 to	 the	
observation	 that	 MMP-3	 can	 degrade	 IL-1ß	 completely	 into	 small	 fragments.170	 In	 the	 first	
experiment	both	MMP-3	and	 IL-1ß	were	 from	 InvitrogenTM	and	had	85%	purity.	 In	 this	experiment	
5	µg	of	IL-1ß	were	dissolved	in	water	and	then	fractionated	as	usual	into	a	fraction	of	less	than	3	kDa	
and	another	of	more	than	3	kDa.	The	inactive	fraction	(more	than	3	kDa)	was	incubated	with	MMP-3	
for	2	h	at	37	°C	in	a	final	volume	of	500	µl.	As	a	control,	5	µg	MMP-3	from	the	same	lot	was	dissolved	
in	 500	µl	 (30	µl	 PBS	 and	 470	µl	water)	 and	 incubated	 for	 2	 h	 at	 37	 °C.	 Both	 the	 digested	 inactive	
fraction	and	the	control	MMP-3	were	fractioned	via	an	Amicon®	Ultra.	The	fraction	of	less	than	3	kDa	
was	 lyophilized	 and	 then	dissolved	 in	 30	µl	 PBS	 and	 tested	 in	ß-arrestin	 assays.	 The	digestion	was	
immediately	stopped	after	2	h	through	freezing	of	the	sample	in	liquid	N2.	Since	it	was	not	possible	to	
determine	 the	 concentration	 of	 the	 resultant	 digestion	 products,	 the	 concentration	 in	 ß-arrestin	
assays	 will	 be	 given	 as	 µl	 of	 test	 solution	 in	 100	 µl	 (the	 total	 volume	 of	 one	 well)	 as	 shown	 in	
figure	36.		
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Figure	36:	The	resultant	curves	of	one	ß-arrestin	assay	after	 incubation	of	 the	 inactive	 fraction	of	 IL-1ß	with	MMP-3	and	
subsequent	fractionation	into	more	and	less	than	3	kDa	fractions.	The	curve	of	MMP-3	alone	was	also	plotted	as	a	control.		
	
The	previous	 results	may	 suggest	 that	 the	 inactive	 fraction	of	 IL-1ß	was	digested	by	MMP-3	 to	 an	
active	species	at	MRGPRX4	receptor.	The	experiment	was	repeated	twice,	once	with	the	same,	less	
pure	 IL-1ß	(InvitrogenTM)	and	another	time	with	highly	pure	 IL-1ß	(R&D	systems).	 In	both	cases	the	
same	MMP-3	(Sigma	Aldrich)	was	used.	In	one	experiment,	the	less	pure	IL-1ß	was	treated	in	exactly	
the	 same	 way	 as	 in	 the	 previous	 experiment	 with	 the	 exception	 of	 incubating	 for	 4	 h.	 In	 this	
experiment	the	digested	fraction	of	>3	kDa	was	again	tested.	The	results	are	given	in	figure	37A.	In	a	
second	experiment,	the	highly	pure	proteins	were	used.	In	this	case,	4	µg	of	the	IL-1ß	was	incubated	
with	5	µg	of	MMP-3	(total	volume	of	500	µl).	After	the	incubation,	the	solution	was	fractionated	and	
both	 fractions	>3	kDa	and	<3	kDa	were	 lyophilized,	dissolved	 in	30	µl	PBS	and	 tested	 in	ß-arrestin	
assays	as	shown	in	figure	37B.	
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Figure	37:	The	resultant	curves	of	two	ß-arrestin	assays	after	 incubation	of	the	inactive	fraction	of	IL-1ß	with	MMP-3	and	
subsequent	fractionation	into	more	and	less	than	3	kDa	fractions.	The	experiment	A	was	done	using	a	less	pure	IL-1ß	(85%),	
whereas	experiment	B	was	done	using	a	pure	IL-1ß	(95%).	
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In	principle,	the	results	consolidate	the	findings	of	the	first	experiment.	These	digestion	experiments	
have	 limitations	 (see	 chapter	 2.4.6)	 but	 they	 indicate	 the	 ability	 of	 MMP-3	 to	 produce	 an	 active	
moiety	 at	 MRGPRX4	 receptor.	 Unfortunately,	 efforts	 to	 identify	 and	 isolate	 this	 potential	 agonist	
remained	elusive.	Despite	that	fact	that	5	µg	of	the	highly	pure	IL-1ß	were	digested	with	5	µg	MMP-3	
and	the	fraction	of	less	than	3	kDa	was	sent	to	Dr.	Sylvester	for	analysis,	the	data	he	provided	did	not	
show	any	trace	of	MMP-3	or	IL-1ß	in	this	fraction.	This	result	could	not	be	easily	explained.	Hereafter,	
it	was	not	possible	to	continue	our	search	for	an	active	peptide	because	of	the	bound	risk;	in	addition	
a	breakthrough	had	meanwhile	taken	place	during	parallel	screening	efforts	for	agonists	(see	chapter	
2.4.7).	
2.4.6	Discussion	I	
	
The	 investigation	 of	 MRGPRX4	 began	 with	 a	 hypothesis,	 based	 on	 sequence	 identity,	 that	 this	
receptor	could	be	the	human	receptor	for	the	nucleobase	adenine.	Screening	adenine	in	functional	
assays	(ß-arrestin	and	calcium	mobilization	assay)	did	not	show	any	activity	 in	spite	of	the	fact	that	
very	 high	 concentrations	were	 employed.	 Capitalizing	 on	 the	 availability	 of	 [3H]adenine	 in	 our	 lab	
competition	binding	studies	have	also	been	attempted	to	investigate	any	binding	of	adenine	(role	as	
a	modulator	 or	 an	 antagonist).	 These	 also	 have	 proven	 that	 adenine	 does	 not	 bind	 to	MRGPRX4.	
These	 data	 are	 sufficient	 to	 refute	 the	 hypothesis	 of	 MRGPRX4	 as	 the	 human	 adenine	 receptor.	
Adenine	has	previously	been	 investigated	at	other	MRGPRX	subfamily	members	and	has	shown	no	
activity	(data	from	Bernt	Alsdorf).	The	search	for	a	potential	human	adenine	receptor	has	not	been	
fruitful	yet.	
The	following	efforts	were	to	find	an	agonist	for	MRGPRX4	via	screening	several	compound	libraries.	
Unfortunately,	no	agonist	could	be	identified	in	this	search,	which	left	the	possibility	for	identifying	a	
ligand	 for	MRGPRX4	very	dim.	The	 inability	 to	 find	an	agonist	 through	screening	of	 small	molecule	
libraries	might	have	been	due	to	the	possibility	of	a	native	peptidergic	agonist	requiring	interaction	
of	 several	 amino	 acids	 in	 an	 extended	 area	 of	 the	 binding	 pocket	 of	 the	 receptor	 for	 inducing	 a	
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conformational	change.	Therefore,	a	small	molecule	could	not	easily	 imitate	a	sizable	peptide.	This	
assumption	 is	 substantiated	 by	 BAM22	 and	 CST-14	 being	 the	 cognate	 ligands	 at	 the	 related	
MRGPRX1	 and	 MRGPRX2,	 respectively.	 In	 order	 to	 break	 this	 impasse,	 a	 second	 deorphanization	
approach	was	put	to	test.	Taking	advantage	of	the	restricted	expression	pattern	of	MRGPRX4	in	the	
DRG	and	the	fact	that	DRGs	are	surrounded	by	CSF,	a	search	for	an	assumed	peptide	in	the	CSF	was	
initiated.	Such	an	approach	is	an	imitation	of	earlier	successful	efforts,	which	led	to	the	identification	
of	 several	 neuropeptides	 (orphanin	 FQ	 at	 Opioid	 receptor-like	1142,143,	 orexin	 A	 and	 B	 at	 orexin	
receptors144,	prolactin-releasing	peptide	and	ghrelin	at	their	receptors).146,148	Our	simplified	approach	
was	based	on	analyzing	a	physiological	fluid	and	not	an	organ	extract,	especially	because	in	the	case	
of	MRGPRX4	human	tissues	would	be	required.	CSF	was	concentrated	10-fold	via	lyophilization	and	
tested	in	ß-arrestin	assays.	It	was	possible	for	the	first	time	to	induce	a	robust	signal,	which	seemed	
to	 be	 sample-dependent.	 These	 interindividual	 differences	 could	 be	 due	 to	 different	 levels	 of	 the	
agonist	in	CSF	samples	corresponding	to	the	nociceptive	input.	Further	fractionation	of	the	samples	
revealed	that	the	active	moiety	is	 less	than	3	kDa	in	molecular	weight.	Further	efforts	to	digest	the	
peptides	using	trypsin	led	to	cell	toxicity	and	death	of	the	cells.	In	an	attempt	to	avoid	cell	toxicity,	a	
soybean	 trypsin	 inhibitor	 (STI)	 was	 added	 that	 caused	 an	 unspecific	 increase	 in	 signal,	 which	
confounded	the	signal	induced	by	CSF.	In	principle,	this	approach	is	an	interesting	one	but	the	search	
did	 not	 show	 a	 clear	 results	 and	 no	 peptide	 has	 been	 found	 so	 far.	 The	 search	 for	 neuropeptides	
combines,	as	from	the	above	mentioned	publications,	a	tissue	extract	and	then	extensive	analytical	
work	to	separate	and	fractionate	this	extract.	Such	an	approach	requires	a	hypothesis	of	the	nature	
of	 the	 ligand	 (peptide,	 fatty	 acid	etc.)	 in	order	 to	use	 the	 suitable	extraction	 solvent	 and	 then	 the	
application	 of	 several	 chromatographic	 methods	 (RP-HPLC,	 size	 exclusion	 chromatography,	 ion	
exchange	and	desalting	methods)	followed	by	LC-MS/MS	detection	(NMR	could	also	be	beneficial	for	
clarifying	the	structure).	The	yield	is	usually	very	limited;	for	instance	16	µg	of	ghrelin	were	extracted	
from	 40	 g	 of	 rat	 stomach	 tissue	 and	merely	 200	 pmol	 of	 orphanin	 FQ	were	 isolated	 of	 4.5	 kg	 of	
porcine	hypothalamus.143,148	This	means	that	a	relatively	very	large	amount	of	CSF,	much	more	than	
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we	had	at	hand	would	be	required	to	apply	the	same	procedure,	since	the	concentration	in	CSF	could	
be	considered	a	dilution	of	the	actual	concentration	in	the	DRG.	
The	 search	 for	 an	 agonist	 took	a	new	 turn	by	 investigating	 IL-1ß.	Upon	 investigating	 this	 cytokine,	
more	than	one	important	player	in	neuropathic	pain	came	into	play,	namely,	the	cross-talk	between	
cytokines,	opioid	and	MRGPRX	 receptors,	 in	addition	 to	 the	 role	of	proteases,	especially	MMPs,	 in	
neuropathic	pain	and	in	modifying	chemokine	signaling.	Our	results	after	investigating	IL-1ß	showed	
that	the	observed	activity	of	an	IL-1ß	preparation	at	MRGPRX4	did	not	result	from	the	mature	IL-1ß	
but	 from	an	entity,	which	 is	 less	 than	3	kDa	and	may	be	an	 impurity	or	another	constituent	of	 the	
tested	 solution.	 This	 impurity	 could	 be	 due	 to	 proteolysis	 of	 IL-1ß	 during	 extraction	or	 it	 could	 be	
from	 the	host	 in	which	 IL-1ß	 is	 produced	 (E.Coli	 in	 this	 case).	 The	degradome	of	 IL-1ß	 is	 not	well-
understood	 but	 it	 seems	 that	 MMP-2,	 MMP-3	 and	 MMP-9	 play	 a	 role	 in	 it.	 Since	 MMP-3	 was	
suggested	 to	 be	 the	 most	 effective	 degrader	 of	 IL-1ß,	 the	 degradome	 of	 IL-1ß	 was	 tested	 at	
MRGPRX4.	The	results	seem	to	 indicate	an	activation	of	MRGPRX4	via	 the	degradome	but	no	clear	
sequence	has	been	found.	Our	search	and	hypothsis	could	have	a	sound	theoretical	grounding;	the	
up-regulation	of	IL-1ß	and	its	role	in	neuropathic	pain	has	already	been	discussed.	The	role	of	MMPs	
in	 neuropathic	 pain,	 inflammation,	 immunity	 and	 cancer	 has	 been	 reviewed	 and	 their	 complex	
relationships	with	cytokines	have	been	established.172-174	The	role	of	MMP-9	in	activating	the	central	
and	peripheral	glia	has	been	described.175	In	neuropathic	DRG,	MMP-9	has	been	up-regulated	in	the	
early	phase	and	was	involved	in	the	activation	of	 IL-1ß,	whereas	MMP-2	showed	an	increase	in	the	
late	phase	(from	day	7)	of	neuropathic	pain	and	was	 implicated	in	the	maintenance	of	neuropathic	
pain	 and	 astroglial	 activation.176	 In	 rat	models	 of	 paclitaxel-induced	 neuropathy,	MMP-3	 has	 been	
demonstrated	 to	 be	 up-regulated.177	 Moreover,	 a	 cross-talk	 between	 MRGPRX1	 and	 chemokine	
receptor	 2	 has	 been	 described.	 BAM8-22,	 the	 selective	 MRGPRX1	 agonist,	 could	 up-regulate	
chemokine	receptor	2	expression,	which	has	been	linked	to	neuropathic	pain,	in	both	HEK	and	a	rat	
dorsal	root	ganglia	cell	line.	BAM8-22	was	investigated	at	LAD-2	mast	cells	and	it	could,	interestingly,	
induce	 the	 release	 of	 the	 chemokine	 CCL2,	 the	 native	 agonist	 at	 chemokine	 receptor	2.	 68	 Acute	
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morphine	administration	(a	potent	µ	receptor	agonist	and	a	weak	MRGPRX2	receptor	agonist)	could	
activate	 glial	 cells	 in	 the	 DRG	 and	 cause	 an	 up-regulation	 of	 MMP-9,	 which	 causes	 an	 enhanced	
release	 of	 IL-1ß	 and	 result	 in	 an	 analgesic	 effect.178,179	Moreover,	 the	 role	 of	MMPs	 in	 proteolytic	
processes	 of	 chemokines	 has	 been	 studied	 extensively.	MMP-2	 seems	 to	 play	 the	most	 important	
role	in	trimming	the	N-termini	of	chemokines	and	thus	regulating	their	activities.	This	could	lead	to	
inactivation	 and	 transforming	 agonists	 into	 antagonists	 (CCL2,	 CCL4,	 CCL7,	 CCL8,	 CCL11,	 etc)	 or	 to	
activating	other	chemoattractants	 (CCL16	and	CCL23).180-182	 In	 fact,	 it	 is	now	established	that	all	54	
human	chemokines	are	modified	regarding	to	their	biological	activity	via	MMP	members.183	In	order	
to	 highlight	 the	 pervasiveness	 of	 proteolytic	 processing	 in	 general,	 the	 origin	 of	 the	 N-terminal	
modification	 in	 the	 human	 proteome	 has	 been	 studied	 computationally	 on	 a	 global	 scale	 and	 the	
findings	indicate	that	approximately	24,000	N-termini	in	the	human	proteome	differ	from	canonical	
encoded	or	methionine	processed	N-termini.184	The	N-terminomics	and	C-terminomics	(degradomics	
in	general)	have	been	reviewed	and	special	mass	spectrometrical	techniques	have	been	developed	to	
study	them.185,186	A	recent	publication	showed	that	not	only	MMPs	but	also	cathepsins	could	modify	
chemokines.187	 In	 another	 important	 paper,	 a	 new	 concept	 of	 protease	 activated	 7TMR	 was	 put	
forward,	 in	which	 a	 protease	 cleaves	 the	 N-terminus	 of	 a	 7TMR	 and	 thus	 induces	 conformational	
changes	that	causes	downstream	signaling	without	any	tethered	or	diffusible	ligand.	It	was	suggested	
that	cathepsin	S	could	cleave	the	N-terminus	and	activate	mouse	MRGPRC11	receptor	with	an	EC50	
value	of	 140	nM.	 It	was	 also	 reported	 that	 cathepsin	 S	 could	 activate	MRGPRX2	and	papain	 could	
activate	MRGPRX1	but	no	EC50	values	were	given.188	All	the	interesting	previous	findings	investigated	
the	proteolytic	process	and	the	resultant	truncated	protein	but	any	potential	activity	of	the	cleaved	
fragments	 was	 not	 followed.	 Our	 initial	 results	 indicate	 that	 a	 fragment	 of	 IL-1ß	 (degradation	 vs.	
proteolytic	processing)	could	be	the	native	ligand	of	MRGPRX4,	which	could	be	the	first	example	of	a	
degradation	product	as	a	means	of	cross-talk	between	IL-1ß	(and	its	toll-like	receptor)	and	MRGPRX4	
(7TMR)	via	a	protease	(MMP-3).	Nontheless	some	caveats	should	be	mentioned.	The	digestion	of	IL-
1ß	with	MMP-3	was	 based	 on	 the	 experiments	 in	 references	 170,171,	 in	which	 identical	 amounts	 of	
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MMP-3	 and	 IL-1ß	 were	 incubated.	 These	 high	 concentrations	 of	 proteases	 represent	 extreme	
conditions,	 which	 are	 usually	 not	 met	 physiologically.183	 A	 further	 limitation	 was	 the	 lack	 of	
conducting	SDS-PAGE	gels	 in	order	to	confirm	the	extent	of	 IL-1ß	digestion	as	a	function	of	time	or	
MMP-3	concentration.	In	the	digestion	experiments	the	resultant	curves	did	not	reach	a	plateau	(see	
figure	35	and	figure	36).	This	could	indicate	an	artifact	if	the	plateau	is	still	not	reached	even	at	very	
high	 concentrations	 (see	 figure	 32).	 In	 the	 case	 of	 degraded	 IL-1ß	 the	 concentration	 remains	 low	
even	if	there	were	no	loss	during	the	filtration	via	Amicon®	Ultra	and	the	plateau	could	possibly	be	
reached	 if	higher	concentrations	were	 tested.	 In	more	details,	 the	concentration	of	 IL-1ß	 in	syovial	
fluid	is	reported	to	be	100	pg/ml189	and	in	the	CSF	to	be	50	pg/ml190	but	we	should	keep	in	mind	that	
the	concentration	at	inflammatory	sites	is	probably	considerably	higher.	Moreover,	IL-1ß	has	a	very	
high	 potency	 at	 its	 receptors	 in	 the	 lower	 nanomolar	 range	 and	 not	 in	 the	 picomolar	 range.	
According	to	literature	the	KD	value	is	in	the	range	between	1-3	nM.191,192	It	is	plausible	to	expect	such	
a	 value	 for	 a	 cleavage	 product	 at	 MRGPRX4	 receptor	 as	 well.	 Our	 experiments	 do	 not	 allow	 the	
calculation	of	a	molar	concentration	because	no	estimate	of	the	amount	of	the	active	moiety	could	
easily	be	made.	Another	aspect	is	often	the	lower	sensitivity	of	the	ß-arrestin	assay	due	to	the	lacking	
of	 the	phenomenon	of	a	“receptor	reserve”.	 It	should	be	mentioned	that	an	 IL-1ß	preparation	was	
further	tested	in	calcium	assays	and	in	a	native	cell	line	expressing	MRGPRX4.	The	result	was	always	
positive,	 which	 indicates	 the	 existence	 of	 a	 real	 agonist	 and	 not	 an	 artifact.	 The	 search	 for	 a	
peptidergic	 ligand	 is	 tedious	 and	 frustrating	 but	 the	 finding	 that	 nateglinide,	 a	 phenylalanine	
derivative,	 is	 an	 agonist	 at	MRGPRX4	 is	 an	 indication	 that	 this	 receptor	might	 be	 activated	 by	 an	
endogenous	peptide.	Nateglinide	shows	some	similarity	to	the	tripeptide	GFL.	GFL	should	be	a	not-
investigated	 endogenous	 peptide	 resulting	 form	 the	 substraction	 of	 BAM22	 from	 peptide	 E	 (see	
figure	5).	
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	In	conclusion,	the	hypothesis	of	the	degradome	of	IL-1ß	containing	an	agonist	at	MRGPRX4	could	not	
yet	be	proven	and	the	active	entity	remains	elusive.	
2.4.7	Screening	further	compound	libraries:	a	breakthrough	
	
Due	 to	 the	 lacking	 success	 with	 the	 hypothesis-driven	 deorphanization	 approaches,	 further	
compound	 libraries	 (not	 available	 at	 the	 first	 screening	 in	 2012)	 were	 screened;	 these	 were	
compound	 library	 2,	 7,	 8,	 10	 and	 11	 (see	 chapter	 4.10).	 All	 screenings	 were	 performed	 at	 a	 final	
concentration	of	 10	µM	unless	 the	 solubility	 of	 the	 compound	did	not	 allow	 the	 screening	 at	 that	
concentration.	
In	the	compound	library	11	lithocholic	acid	induced	a	signal	but	that	was	probably	an	artifact	since	no	
plateau	 could	 be	 reached	 even	 up	 to	 a	 concentration	 of	 100	 µM	 (data	 not	 shown).	 The	 lipophilic	
nature	 of	 this	 agonist	 could	 be	 responsible	 for	 inducing	 this	 non-specific	 signal.	 In	 the	 natural	
compounds	 library,	 Δ9-tetrahydrocanabinol	 (Δ9-THC)	 was	 active	 at	 MRGPRX4.	 The	 calculated	 EC50	
value	was	9.63	±	0.72	µM	as	demonstrated	in	figure	38.	Since	the	increase	in	signal	is	very	steep	as	
seen	in	figure	38,	and	Δ9-THC	is	previoustly	reported	to	activate	canabinoid	receptors	and	GPR55	in	
addition	to	several	 ion	channels193-195,	the	signal	was	deemed	unspecific.	 In	the	compound	library	8	
one	hit	could	be	identified,	Gü-1924,	which	induced	an	S/N	ratio	of	2	at	100	µM	but	it	was	too	weak	
to	plot	a	complete	concentration-response	curve	(data	not	shown).	
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Figure	38:	The	mean	curve	of	three	independent	ß-arrestin	assays	of	Δ9-THC	at	MRGPRX4.		
	
The	real	breakthrough	was	the	 identification	of	the	phosphoric	acid	ester	derivative	MSX-3	as	a	hit	
while	screening	the	compound	library	2.	
2.4.8	MSX-3	and	its	related	compounds	as	agonists	at	MRGPRX4	
	
MSX-3	induced	a	robust	and	reproducible	signal	upon	screening	at	MRGPRX4.	MSX-3	is	a	prodrug	of	
MSX-2,	a	potent	and	selective	A2A	adenosine	receptor	antagonist.	This	is	compound	is	vulnerable	to	
light-induced	 E/Z-	 isomerization.196,197	 Due	 to	 this	 instability,	 a	 new	 stock	 solution	 of	 MSX-3	 was	
prepared	 and	 a	 concentration-response	 curve	 was	 plotted	 as	 demonstrated	 in	 figure	 39.	 The	
determined	EC50	 value	was	175	±	28	nM.	This	 represented	a	breakthrough	as	 a	 first	 agonist	 and	a	
relatively	potent	one	as	well.	
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Figure	39:	The	mean	curve	of	three	independent	ß-arrestin	assays	of	MSX-3	at	MRGPRX4	receptor.	The	EC50	value	was	175	±	
28	nM.	
	
MSX-3	was	counter-screened	at	MRGPRX1,	MRGPRX2,	GPR18,	GPR55	and	GPR143	that	are	expressed	
in	the	same	CHO	ß-arrestin	system	and	there	was	no	activity	at	all	these	targets.	In	addition,	MSX-3	
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did	 not	 show	 any	 inhibition	 of	 human	 NTPDase	 1,	 NTPDase	 2,	 NTPDase	 3,	 NTPDase	 8.	 Thus,	
selectivity	was	ensured.	
Interestingly,	 MSX-3	 is	 prodrug	 of	 an	 A2A	 adenosine	 receptor	 antagonist	 and	 at	 MRGPRX4	 it	 is	 a	
potent	agonist.	This	led	us	to	investigating	the	actual	drug	MSX-2	and	other	related	compounds	like	
MSX-4,	 another	 prodrug	 of	 MSX-2	 coupled	 to	 valine,	 and	 Istradefylline,	 which	 shares	 the	 8-
styrylxanthine	 structure	with	MSX-2198,	 as	 well	 as	 preladenant	 as	 shown	 in	 figure	 40.	 All	 of	 these	
compounds	were	not	active	at	all.	Therefore,	MSX-3	represents	an	active	entity	at	MRGPRX4	and	the	
phosphate	 is	 essential	 for	 the	 agonistic	 activity	 and	 cannot	 be	 replaced	 e.g.	 by	 valine.	 In	 order	 to	
further	our	SAR	understanding,	related	8-ethinylxanthine	derivatives	like	NT	021071,	NT	021033,	NT	
02109,	NT	020052199	(figure	40)	were	screened	and	all	were	inactive.	The	NT	compounds	show	some	
differences	 to	 MSX-3.	 They	 possess	 a	 triple	 bond	 in	 their	 linker	 and	 they	 have	 a	 di-methoxy	
subsituent;	 only	 NT	 021071	 has	 a	 phosphorylated	 substitution	 at	 N3	 of	 its	 xanthine	 moiety.	 The	
inactivity	 could	 be	 due	 to	 the	 additional	 methoxy	 group	 or	 the	 triple	 bond.	 JH	 14021	 was	 an	
interesting	compound	since	its	only	difference	to	MSX-3	is	the	triple	bond	in	its	linker.	Thus,	it	has	no	
light	sensitivity	problem.	This	compound	was	considerably	less	potent	than	MSX-3	with	an	EC50	value	
of	more	 than	 10	 µM,	 and	 its	 efficacy	 was	 also	 lower	 than	 that	 of	MSX-3.	 This	 demonstrated	 the	
importance	of	the	double	bond	being	superior	to	the	triple	bond.	The	decrease	 in	activity	could	be	
explained	by	 the	 rigidity	of	 the	 triple	bond	 in	comparison	 to	 the	double	bond,	which	can	 form	 cis-	
and	trans-isomers	and	fit	better	 into	the	binding	pocket	of	the	receptor.	Hence,	so	far	the	agonism	
requires	a	phosphate	group	and	a	linker	with	a	double	bond.	In	addition,	two	methoxy	groups	at	the	
phenyl	ring	seem	to	be	intolerable.	
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Figure	40:	Structures	and	potencies	of	MSX-3-related	compounds	at	MRGPRX4	in	ß-arrestin	assay	
	
MSX-155	 is	 another	 important	 compound	 in	 the	 quest	 to	 understand	 the	 SARs	 of	 this	 scaffold.200	
MSX-155	is	a	phosphate	prodrug	of	DPCPX,	a	potent	and	selective	A1	adenosine	receptor	antagonist.	
This	compound	has	a	xanthine	core	and	a	phosphate	group	but	has	no	propargyl	but,	propyl	group	at	
N1,	no	methyl	at	the	N7	position	and	linked	aromatic	group	but	only	a	direct	cyclopentyl	substitution	
at	C8	of	the	xanthine	core.	At	first	glance	this	compound	is	considerably	different.	However,	 it	was	
potent	at	the	MRGPRX4	receptor	with	an	EC50	value	of	351	±	83	nM	as	shown	in	figure	41.	It	seems	
that	 the	 linker	 could	 be	 spared	 altogether.	 This	 is	 especially	 important	 since	 the	 double	 bond	 is	
vulnerable	to	light-induced	E/Z-isomerization.	It	should	be	mentioned	that	despite	the	importance	of	
these	novel	ligands,	it	was	difficult	to	obtain	reproducible	results	the	whole	time.	This	concerns	both	
the	potency	and	the	efficacy	of	these	compounds.	This	hampered	using	these	ligands	for	antagonist	
screening.	 This	 hard	 reproducibility	 could	 be	 attributed	 to	 the	 enzymatic	 instability	 of	 these	
phosphoric	acid	esters,	which	can	be	cleaved	by	phosphatases	expressed	on	the	cell	membrane.	
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Figure	41:	The	mean	curve	of	three	 independent	ß-arrestin	assays	of	MSX-155	at	MRGPRX4	receptor.	The	EC50	value	was	
351	±	83	nM.	
	
Since	the	ß-arrestin	assay	requires	a	relatively	 long	 incubation	time	(90	min),	substantial	hydrolysis	
may	 take	 place.	 Therefore,	 it	was	 decided	 to	 inhibit	 ecto-5ʹ-nucleotidase	 and	 to	 compare	 the	 S/N	
ratio	 and	 the	 EC50	 value.	 In	 order	 to	 do	 that	 the	 assay	 should	 be	 slightly	 modified.	 Therefore,	
Optimem	medium	was	discarded,	immediately	before	pipetting	the	agonists,	and	substituted	by	PBS	
containing	the	stable	ADP	analog,	AMP-CP201,	at	a	final	concentration	of	40	µM.	The	results	showed	
an	increase	in	S/N	ratios	both	for	MSX-3	(from	1.3	to	1.7)	and	MSX-155	(from	1.3	to	1.5)	and	the	EC50	
values	were	improved	(for	MSX-3	up	to	67	nM	and	for	MSX-155	up	to	266	nM)	but	there	were	still	
variations	in	the	determined	EC50	values,	which	could	be	due	to	other	phosphatases.		
These	results	indicate	the	importance	of	developing	more	stable	compounds	as	agonists	at	MRGPRX4	
receptor.	 Phosphonates	 instead	 of	 phosphates	 seemed	 to	 be	 the	most	 reasonable	 solution.	 Yet	 it	
was	 not	 easy	 to	 synthesize	 suitable	 derivatives.	 The	 first	 synthesized	 phosphonate,	 JH	 14102,	
demonstrated	 encouraging	 results	with	 an	 EC50	 value	 of	 17.4	 ±	 5.6	 nM	and	 an	 S/N	 ratio	 of	 2.2	 as	
shown	in	figure	42,	which	makes	it	one	of	the	most	potent	agonist	so	far.	JH	14102	is	a	phosphonate	
analog	of	MSX-3	but	without	the	methyl	group	at	the	N7	position.	A	direct	phosphonate	analog	has	
not	yet	been	synthesized,	but	is	in	preparation.	
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Figure	 42:	 The	 mean	 curve	 of	 three	 independent	 ß-arrestin	 assays	 of	 JH	 14102	 at	 MRGPRX4.	 The	 EC50	 value	 was	
17.4	±	5.6	nM	
	
2.4.9	Determination	of	the	G-protein	coupling	of	MRGPRX4	receptor	
	
The	G	protein	coupling	of	MRGPRX4	was	predicted	to	be	a	sole	Gq	coupling	via	a	proliferation	assay23	
but	 since	no	 agonist	 had	been	described	previously,	 our	 next	 step	was	 to	 determine	 this	 coupling	
using	our	novel	pharmacological	tools.		
It	was	not	possible	to	conduct	calcium	mobilization	assay	using	the	ß-arrestin	cell	line	in	the	attached	
cells	format	but	it	was	only	possible	as	a	suspension,	which	is	more	tedious	and	needs	10	times	more	
cells	to	be	seeded.	Nevertheless,	 it	was	possible	to	confirm	MSX-3	as	a	potent	agonist	with	an	EC50	
value	of	47.8	±	12.5	nM	as	shown	in	figure	43.	It	was	also	possible	to	demonstrate	that	JH	14021	is	
considerably	less	potent	with	an	EC50	value	of	ca.	10	µM,	which	is	in	harmony	with	the	SAR	obtained	
from	ß-arrestin	assays.	Therefore,	 the	Gq	coupling	was	confirmed.	The	 fraction	of	 IL-1ß	 less	 than	3	
kDa	induced	a	robust	calcium	signal	as	well	(data	not	shown).	
Utilizing	 JH	14102,	 it	was	decided	 to	 investigate	 the	Gs	and	Gi	 coupling	via	 cAMP	assays.	 JH	14102	
could	not	induce	any	cAMP	accumulation	at	1	µM	final	concentration,	which	means	that	MRGPRX4	is	
not	 Gs	 coupled	 (data	 not	 shown).	 The	 screening	 for	 Gi	 coupling	 was	 done	 twice	 at	 1	 µM	 final	
concentration	and	no	inhibition	of	10	µM	forskolin-induced	cAMP	accumulation	was	detected	(data	
not	shown).	
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Figure	43:	The	normalized	curve	of	three	independent	calcium	mobilization	assays	of	MSX-3	at	MRGPRX4	receptor.	The	EC50	
value	was	47.8	±	12.5	nM	
	
Herewith	 it	was	 possible	 to	 confirm	 the	 findings	 of	 Burstein	 et	 al.23	 for	 a	 sole	Gq	 coupling	 using	 a	
potent,	selective	pharmacological	tool	for	the	first	time.	While	conducting	these	experiments,	Kroeze	
et	 al.	 published	 nateglinide	 as	 an	 agonist	 at	MRGPRX4	 receptor.112	 Like	 our	 approach	 a	 ß-arrestin	
assay	was	employed	to	detect	 the	agonist	and	a	HEK	cell	 line	overexpressing	MRGPRX4	revealed	a	
sole	Gq	coupling	of	this	receptor	in	harmony	wiht	our	findings.	It	is	noteworthy	to	keep	in	mind	that	
the	calcium	assay	is	not	easy	to	conduct	using	the	CHO	ß-arrestin	cell	line	due	to	the	modest	increase	
in	signal,	which	could	be	inherent	to	CHO	cell	lines,	which	appears	to	express	only	a	small	level	of	Gq-
proteins	 (unpublished	 data).	 Therefore,	 ß-arrestin	 assays	 were	 further	 employed	 for	 investigating	
SAR	of	MRGPRX4	agonists.		
2.4.10	Structure-activity	relationships	of	MRGPRX4	receptor	agonists	
	
More	 than	 one	 series	 of	 compounds	 have	 been	 synthesized	 as	 agonists	 at	MRGPRX4	 receptor.	 It	
should	also	be	noted	that	in	all	assays	from	now	on	a	modified	protocol	for	the	ß-arrestin	assay	has	
been	used.	 This	 change	 resulted	 in	 a	 slight	 increase	 in	 the	EC50	 value	but	 the	 S/N	 ratio	 stayed	 the	
same.	For	example	the	phosphonate	JH	14102	showed	an	increase	in	EC50	value	from	17.4	±	5.6	nM	
with	the	old	buffer	to	76.1	±	12.5	nM	with	the	new	one.		
Since	dividing	the	compounds	should	have	a	reference	point,	it	was	decided	to	divide	them	according	
to	 the	 linker	 between	 the	 xanthine	moiety	 and	 the	 aromatic	 ring.	 Accordingly,	 four	 categories	 of	
ligands	have	been	synthesized;	1)	compounds	that	have	an	ethylene	linker,	2)	compounds	that	have	
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an	ethenyl	linker,	3)	compounds	with	methylene	as	a	linker,	4)	compounds	with	no	linker.	The	results	
are	shown	in	the	following	tables	(see	tables	26	to	29).	
Table	 26:	 The	 structures,	 the	 EC50	 values	 and	 S/N	 ratios	 (efficacy)	 of	 the	 synthesized	 compounds	 with	 an	
ethylene	linker		
Compounds	that	have	an	ethylene	linker	
Compound	 Structure	 EC50	value	±	SEM	(µM)*	 S/N	ratio**	
Yazh	473	
	
	
	
0.160	±	0.048	
	
	
4	
Yazh	479	
	
	
	
0.674	±	0.050	
	
	
3	
Yazh	438	
	
	
	
>>10	
	
	
2	
Yazh	449	
	
>>10	 	
	
	
Yazh	474	
	
>>10	 	
	
	
Yazh	599	
	
	
	
27.1	±	13	
	
	
1.4	
*:	Results	are	mean	±	SEM	of	at	least	three	independent	ß-arrestin	experiments	
**:	S/N	ratio	not	given	means	no	signal	induced	
	
The	results	showed	again	that	the	phosphate	is	essential	since	all	the	compounds	without	phosphate	
were	 inactive	 or	 weakly	 active.	 Yet	 the	 most	 important	 conclusion	 from	 these	 compounds	 is	 the	
importance	of	an	ethylene	linker.	Yazh	473	and	Yazh	479	with	an	S/N	ratio	of	4	and	3,	respectively,	
showed	the	best	efficacy	so	far.	Yazh	473	is	more	potent	than	MSX-3	as	well.	This	means	the	simple	
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bond	derivatives	are	more	potent	and	stable	than	double	bond	ones.	The	second	conclusion	 is	 the	
superiority	of	propargyl	to	propyl	as	shown	in	the	higher	potency	of	Yazh	473	compared	to	Yazh	479.		
Table	 27:	 The	 structures,	 the	 EC50	 values	 and	 S/N	 ratios	 (efficacy)	 of	 the	 synthesized	 compounds	 with	 an	
ethenyl	linker	
Compounds	that	have	an	ethenyl	linker	
Compound	 Structure	 EC50	value	±	SEM	(µM)*	 S/N	ratio	
Yazh	556	
	
	
	
	
	
4.34	±	0.99	 2	
Yazh	517A	
	
	
	
	
	
>100		 2.5	
Yazh	529	
	
	
	
	
	
>100	 1.6	
Yazh	466	
	
	
	
	
>10	 	
Yazh	562	
	
67.3	±	47.5	 2	
Yazh	436	
	
>10	 	
Yazh	552	
	
>100	 	
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Yazh	509	
	
>10	 2	
Yazh	516	
	
>>10	 3	
Yazh	519	
	
>100	 2	
Yazh	525	
	
>100	 	
Yazh	559	
	
8.79	±	3.57	 1.8	
Yazh	560	
	
>100	 	
Yazh	561	
 
>100	 	
Yazh	562	
	
	
>100	
	
*:	Results	are	mean	±	SEM	of	at	least	three	independent	ß-arrestin	experiments	
**:	S/N	ratio	not	given	means	no	signal	induced	
	
Keeping	 in	 mind	 that	 MSX-3	 and	 JH	 14102	 belong	 to	 this	 category	 as	 well,	 it	 is	 clear	 again	 that	
propargyl	is	better	than	propyl	(MSX-3	vs.	Yazh	466).	A	methyl	at	N7	seems	to	be	better	than	H,	since	
MSX-3	is	more	active	than	Yazh	556.	The	exact	EC50	value	of	Yazh	562	was	determined	since	it	is	the	
first	derivative	with	an	ethyl	at	N1.	The	ethyl	does	not	seem	to	be	beneficial	but	there	 is	no	direct	
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comparison	 since	 other	 compounds	 with	 propargyl	 or	 propyl	 have	 a	 methyl	 at	 N7.	 Intriguingly,	
Yazh	559	with	no	phosphate	but	acetyl	residue	showed	a	moderate	potency	but	it	should	be	noted	
that	many	compounds	have	demonstrated	variation	in	results,	which	necessitated	up	to	seven	assays	
sometimes	to	get	these	EC50	values	and	this	fact	is	reflected	in	the	high	SEM.		
Table	 28:	 The	 structures,	 the	 EC50	 values	 and	 S/N	 ratios	 (efficacy)	 of	 the	 synthesized	 compounds	 with	 a	
methylene	linker	
Compounds	that	have	a	methylene	linker	(8-benzyl	derivatives)	
Compound	 Structure	 EC50	value	±	SEM	(µM)*	 S/N	ratio	
Yazh	555	
	
>100	 	
Yazh	564	
 
14.8	±	3.4	 1.8	
*:	Results	are	mean	±	SEM	of	at	least	three	independent	ß-arrestin	experiments	
**:	S/N	ratio	not	given	means	no	signal	induced	
	
Only	two	8-benzyl	derivatives	have	been	synthesized.	Hence,	no	SAR	could	be	obtained	from	these	
derivatives.	
	
Table	29:	The	structures,	the	EC50	values	and	S/N	ratios	(efficacy)	of	the	synthesized	compounds	with	no	linker	
Compounds	that	have	no	linker		
Compound	 Structure	 EC50	value	±	SEM	(µM)*	 S/N	ratio	
MSX-155	
	
0.351	±	0.083	 1.7	
Yazh	499	
	
10.6	±	1.6	 3.5	
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Yazh	496	
	
11.9	±	2.2	 2.5	
Yazh	527	
	
Very	weak	antagonist!	
Maximal	inhibition	of	
12%	at	100µM	
	
	
	
*:	Results	are	mean	±	SEM	of	at	least	three	independent	ß-arrestin	experiments	
**:	S/N	ratio	not	given	means	no	signal	induced	
	
Both	Yazh	449	and	Yazh	496	are	phosphonates	and	 they	 indicate	 that	a	 cyclopentyl	 is	equally	well	
tolerated	 as	 an	 aryl	 group	 if	 the	 linker	 is	 omitted.	 Interestingly,	 Yazh	 449	 showed	 a	 considerably	
weaker	potency	than	MSX-155;	its	phosphate	analog.	This	means	that	the	phosphate	is	necessary	for	
the	compounds	without	a	 linker	whereas	phosphonates	 showed	better	potency	and	efficacy	when	
there	was	 linker	with	 a	 double	 bond	 (MSX-3	 vs.	 JH	 14102).	 This	 could	 implicate	 that	 omitting	 the	
linker	changes	 the	mode	of	binding	of	 the	 ligands	 to	MRGPRX4.	This	hypothesis	and	 its	 interesting	
consequence	were	 confirmed	 later	when	conducting	 calcium	mobilization	assays	 in	 LN229	cell	 line	
(see	chapter	2.4.12).		
In	 summary,	 several	 ligands	 have	 been	 synthesized,	 but	 only	 Yazh	 473	 and	 Yazh	 479	 were	
significantly	potent	and	efficacious.	The	elucidated	SARs	thus	far	are	summarized	in	figure	44.	
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Figure	44:	The	determined	SARs	from	the	available	lignds	synthesized	so	far.	(A)	The	structure-activity	relationships	of	the	
synthesized	compounds	with	a	linker	(B)	The	structure-activity	relationships	of	the	synthesized	compounds	without	a	linker	
	 	
2.4.11	Adenosine	monophosphate:	final	deorphanization	approach	
	
The	final	deorphanization	attempt	arose	out	of	the	structural	properties	of	the	synthetic	agonists	of	
MRGPRX4,	MSX-3	and	MSX-155,	discovered	by	screening.	Both	of	 them	were	designed	as	selective	
and	potent	water-soluble	prodrugs	at	adenosine	A2A	and	adenosine	A1	receptors,	respectively.	Both	
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of	them	activated	MRGPRX4	receptor	with	a	comparable	potency.	The	negatively	charged	phosphate	
appears	 to	 be	 essential	 for	 the	 activity.	 Both	 compounds	 are	 prodrugs	 and	 after	 hydrolysis	 they	
interact	with	adenosine	receptor.	Addition	of	a	phosphate	to	these	competitive	adenosine	receptors	
ligands	 produced	 potent	 MRGPRX4	 ligands.	 So	 what	 would	 happen	 if	 adenosine	 was	
phosphorylated?	This	approach	results	in	AMP.	Therefore,	AMP	was	screened	at	MRGPRX4	initially	in	
the	 suspension	 format	 of	 the	 calcium	 assay	 at	 1	 mM.	 AMP	 indeed	 induced	 a	 reproducible	 and	
selective	 signal	 at	MRGPRX4	 but	 not	 at	MRGPRX1,	MRGPRX2,	MRGPRX3	 or	 ß-arrestin	 empty	 cells	
(data	 not	 shown).	 AMP	 is	 a	 physiological	 metabolie	 that	 can	 be	 degraded	 by	 several	
ectonucleotidases	and	phosphatases	(see	chapter	2.4.14).	Moreover,	calcium	mobilization	assays	are	
difficult	 to	 conduct	 using	 CHO	 cells.	 Nevertheless,	 AMP	 considerably	 and	 reproducibly	 induced	 a	
signal	at	1	mM,	and	it	was	possible	to	obtain	a	complete	concentration-response	curve	as	shown	in	
figure	45.	The	determined	EC50	value	was	61.7	±	22.7	µM.	
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Figure	45:	The	mean	curve	of	three	independent	calcium	mobilization	assays	of	AMP	at	MRGPRX4	receptor.	The	EC50	value	
was	61.7	±	22.7	µM	
	
Testing	 of	 AMP	using	 the	 ß-arrestin	 assay	was	 subsequently	 attempted.	 Screening	 conducted	 at	 1	
mM	 showed,	 like	 in	 the	 calcium	assay,	 a	 clear	 signal	 (data	 not	 shown)	 but	 plotting	 dose-response	
curves	in	the	ß-arrestin	assay	showed	high	variability	as	expected	due	to	the	long	incubation	time	of	
90	min,	which	may	result	in	(partial)	hydroylsis.	The	first	assays	were	done	using	the	commercial	lysis	
buffer.	The	determined	EC50	value	was	19.4	±	4.8	µM	as	demonstrated	in	figure	46.	
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Figure	46:	 The	mean	normalized	 curve	of	 three	 independent	ß-arrestin	 assays	of	AMP	at	MRGPRX4.	 The	EC50	 value	was	
19.4	±	4.8	µM	
	
It	should	be	noted	that	incubation	in	the	presence	of	AMP-CP,	ecto-5ʹ-nucleotidase	inhibitor,	did	not	
have	 any	 effect	 on	 the	 results	 (data	 not	 shown).	 The	 results	 indicate	 a	 lower	 EC50	 value	 in	 the	 ß-
arrestin	 assay	 than	 in	 the	 calcium	assay.	 This	 is	 unexpected	because	 the	 incubation	 time	 in	 the	ß-
arrestin	assay	 is	 longer.	This	could	 indicate	that	an	optimization	of	calcium	assay	conditions	should	
be	done.	The	ß-arrestin	assays	were	 later	 switched	 to	another	protocol,	 in	which	 the	EC50	value	of	
AMP	was	214	µM	(see	table	30),	which	is	considerably	higher.	Radioligand	binding	experiments	using	
[3H]AMP	 were	 tried	 but	 were	 not	 successful	 probably	 due	 to	 the	 low	 affinity	 of	 the	 radioligand.	
Moreover,	an	unspecific	binding	of	[3H]AMP	to	the	GFB	filters	was	observed	(data	not	shown).	
Next	 we	 investigated	 other	 nucleotides	 and	 related	 compounds.	 ATP,	 ADP,	 cAMP,	 cGMP,	 UMP,	
dAMP	 and	AMPαS	were	 also	 screened	 at	 1	mM	but	were	 not	 active.	GMP	 showed	 an	 increase	 in	
signal	at	1	mM	but	a	complete	curve	could	not	be	plotted.	Several	AMP	derivatives	were	available	for	
screening	at	MRGPRX4	receptor.	All	of	 these	derivatives	were	 inactive	 (no	complete	curve	without	
extrapolation).	 However,	 the	 induced	 S/N	 ratio	 of	 9	 at	 maximal	 concentration	 for	 Ali	 909	 was	
exceptionally	high	(see	table	30).	This	could	mean	that	MRGPRX4	could	theoretically	be	activated	to	
such	a	high	S/N	ratio.	All	these	assays	were	done	using	the	new	lysis	buffer.	
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Table	30:	Structure	and	EC50	value	of	some	AMP	derivatives,	which	were	tested	at	MRGPRX4	receptor	using	ß-
arrestin	assay	
Compound	 Structure	 EC50	value	(µM)		 S/N	ratio	at	
2mM	
AMP	
	
214	 1.8	
8-Br-AMP	
	
40.9	±	11.3	 2	
Ali	901A	
	
>	2	mM	 3	
Ali	909	
	
>	2	mM	 9	
CHETP	
	
>	2	mM	 2	
Ali	900D	
	
>	2	mM	 2	
Ali	913	
	
>	2	mM	 2.5	
Ali	916	
	
	
>	2	mM	 2.5	
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The	 results	 showed	 that	only	 8-Br-AMP	 (figure	47)	 is	more	 active	 than	AMP	as	 shown	but	no	 SAR	
analysis	can	be	proposed	at	present	because	no	systematic	ligand	synthesis	of	AMP-derivatives	have	
been	conducted	yet.	
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Figure	47:	The	mean	normalized	curve	of	three	independent	ß-arrestin	experiments	of	8-Br-AMP	at	MRGPRX4.	The	EC50	
value	was	40.9	±	11.3	µM	
	
2.4.12	A	search	for	a	native	cell	line	expressing	MRGPRX4	receptor	
	
The	search	 for	a	cell	 line	 that	natively	expresses	MRGPRX4	went	 into	 three	directions	according	 to	
the	 information	 found	 in	 the	 literature	 about	MRGPRX4.	 Sensory	 neurons,	 CD8+	 lymphocytes	 and	
tumor	cell	lines	were	investigated	
2.4.12.1	Differentiation	of	stem	cells	to	DRG-like	sensory	neurons	
	
The	 expression	 of	 all	 MRGPRX	 receptors	 in	 the	 sensory	 neurons	 was	 described	 from	 the	 very	
beginning.17,18	In	order	to	investigate	this,	further	collaboration	with	Prof.	Brüstle	was	initiated.	The	
aim	was	to	differentiate	fibroblasts	 into	DRG-like	sensory	neurons,	which	express	MRGPRX4	on	the	
protein	level.	This	kind	of	differentiation	is	not	well	investigated	in	the	literature,	in	which	only	three	
relevant	 publications	 are	 found.202-204	 The	 protocol	 of	 Young	 et	 al.204	 was	 mainly	 adopted	 in	 the	
attempted	differentiation.	Two	different	variations	were	 tried,	 in	which	all	MRGPRX	subtypes	have	
been	detected	on	the	mRNA	 level.	The	 first	protocol	seemed	to	be	more	efficient	 than	the	second	
one	 beauce	 the	 DNA	 bands	 are	 clearer	 at	 the	 same	 number	 of	 qPCR	 cycles	 as	 demonstrated	 in	
figure	48.	 It	 seems	 that	 the	 expression	 is	 restricted	 in	 time	 since	 the	 fixation	 at	 day	 35	 did	 show	
mRNA	 of	 MRGPRX	 receptors	 but	 the	 fixation	 at	 day	 46	 did	 not	 demonstrate	 an	 expression	 of	
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MRGPRX	 receptors.	 These	 initial	 results	 are	 encouraging	 but	 further	 confirmation	 is	 required	 and	
detection	on	the	protein	level	should	be	carried	out.	It	should	be	noted	that	these	experiments	were	
done	by	Swetlana	Ritzenhofen	form	the	group	of	Prof.	Brüstle.	
	 	
Figure	48:	The	results	of	qPCR	experiments	from	two	different	differentiation	protocols	with	two	fixations	at	day	35	and	day	
46.	The	first	protocol	seems	to	be	more	efficient.	The	qPCR	data	were	thankfully	provided	by	Swetlana	Ritzenhofen.	
		
2.4.12.2	Investigating	different	lymphocytes	subpopulations	
	
The	 second	 direction	was	 focused	 on	 investigating	MRGPRX4	 in	 the	 immune	 system,	 especially	 in	
CD8+	lymphocytes.114	In	order	to	do	this,	collaboration	with	Prof.	Nattermann	was	started.	The	first	
step	was	to	confirm	the	finding	that	MRGPRX4	is	expressed	in	lymphocytes.	This	was	suggested	to	be	
performed	 by	 fluorescence-activated	 cell	 sorting	 (FACS),	 in	 which	 a	 limited	 number	 of	 cells	 will	
suffice.	 FACS	 is	 advantageous	 because	 these	 lymphocytes	 are	 native	 cells	 isolated	 from	blood	 and	
Western	 bloting	 (WB)	would	 be	more	material	 consuming.	 The	 problem	was	 the	 inavailibility	 of	 a	
commercial	FACS-validated	antibody	(Ab).	Therefore,	an	immunofluorescence	(IF)	Ab	was	employed	
in	 the	FACS	experiments	 (see	 chapter	4.6).	 The	 initial	 results	using	3	µg/ml	 from	 the	Ab	 showed	a	
small	shift	(expression)	in	T-cells	(blue),	NK	cells	(green)	and	B-cells	(orange).	The	expression	was	in	
the	following	order	as	demonstrated	in	figure	48:	T-cells	>	NK	cells	>	B-cells.	These	data	in	figure	49	
are	from	one	patient	with	hepatitis	C	virus	(HCV)	infection.	
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Figure	49:	FACS	results	showed	a	slight	expression	in	T-cells,	NK	cells	and	B-cells	
	
In	order	 to	 confirm	 the	 initial	 data	 the	peripheral	blood	mononuclear	 cells	 (PBMC)	 from	8	healthy	
subjects	were	investigated	via	FACS	and	the	results	showed	that	CD56Bright	NK	cells	have	the	highest	
expression	 whereas	 other	 lymphocytes	 subsets	 (NK,	 CD4,	 CD8	 and	 CD	 56Dim	 NK	 cells)	 have	 less	
expression	as	demonstrated	in	figure	50.	
	
Figure	50:	The	mean	expression	of	MRGPRX4	receptor	in	five	different	subsets	of	lymphocytes	from	8	healthy	subjects.	The	
results	show	an	increased	expression	of	MRGPRX4	in	CD	56Bright	NK	cells	compared	to	other	subsets	of	lymphocytes.	
	
These	data	are	highly	interesting	because	they	prove	that	MRGPRX4	may	play	a	role	in	the	immune	
system	and	 is	not	exclusively	expressed	 in	the	DRG	as	reported	 in	 literature.	This	could	 lead	to	the	
identification	of	novel	roles	of	this	receptor	in	the	immune	system.	The	different	expression	pattern	
between	the	HCV	patient	and	the	healthy	subjects	could	also	be	important	but	more	data	should	be	
collected	before	reaching	any	conclusion.		
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2.4.12.3	Investigating	different	tumor	cell	lines	
	
The	third	area	of	our	search	was	focused	on	cancer	cell	lines.	The	suggestion	that	MRGPRX4	receptor	
could	function	as	an	oncogene	in	colorectal	cancers113	was	the	rationale	behind	this	search.	There	are	
many	commercially	available	colorectal	cancer	cell	lines	but	we	have	been	interested	in	cancers	that	
are	 difficult	 to	 treat.	 Several	 mRNA	 samples	 of	 glioblastoma	 cell	 lines	 were	 obtained	 from	 Prof.	
Scheffler,	Life	&	Brain	(Bonn),	and	it	was	decided	to	investigate	the	expression	of	MRGPRX	receptors	
in	 these	 cell	 lines.	 The	 Cq	 values	 are	 given	 in	 the	 following	 table	 (results	 in	 table	 31	 are	 from	
Katharina	Sylvester).	
Table	31:	The	results	of	qPCR	experiments	performed	as	n=1	 in	duplicates.	The	expression	of	 the	4	MRGPRX	
members	and	ecto-5ʹ-nucleotidase		
Cell	line	 MRGPRX1	 MRGPRX2	 MRGPRX3	 MRGPRX4	 hNT5E	 hGAPDH*	 hß-actin*	
LN229	 >35	 >35	 32.19	 29.57	 27.0	 21.19	 19.35	
T98G	 >35	 >35	 >35	 >35	 31.6	 19.14	 18.52	
U138	 >35	 >35	 >35	 >35	 28.65	 20.80	 17.49	
106Z	 >35	 >35	 >35	 32.67	 28.06	 19.56	 18.14	
46Z	 >35	 >35	 >35	 34.68	 25.04	 19.56	 17.36	
78Z	 >35	 >35	 34.39	 >35	 25.04	 18.31	 17.26	
*:	hGAPDH	and	hß-actin	were	the	positive	control	
The	results	show	that	the	LN229	cell	line	is	the	most	suitable	one.	However,	the	expression	is	pretty	
low	on	the	mRNA	level.	It	is	also	notable	that	this	cell	line	also	expresses	mrgprX3	at	a	very	low	level	
but	not	mrgprX1	or	mrgprX2.	
Fortunately,	 the	 group	 of	 Prof.	 Scheffler	 provided	 us	 with	 an	 aliquot	 of	 the	 LN229	 cell	 line.	 This	
enabled	the	investigation	of	MRGPRX4	on	the	protein	level.	The	previously	mentioned	Ab	against	the	
C-terminus	 was	 used.	 Immunofluorescence	 experiments	 in	 an	 overexpressing	 cell	 line	 (ß-arrestin)	
and	the	native	LN229	glioma	cell	 line	were	conducted.	The	results	from	the	overexpressing	cell	 line	
indicate	that	this	Ab	is	able	to	detect	the	receptor	in	a	very	effective	manner.	The	experiment	in	the	
LN229	 cell	 line	 proved	 the	 expression	 of	MRGPRX4	 on	 the	 protein	 level	 and	 demonstrated	 a	 low	
expression	of	the	receptor	in	harmony	with	the	mRNA	data	as	shown	in	figure	51.	
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Figure	 51:	 Left,	 the	 expression	 of	 MRGPRX4	 receptor	 in	 the	 ß-arrestin	 cell	 line.	 The	 expression	 is	 very	 high	 in	 the	 cell	
membrane	as	expected.	Right,	the	expression	of	MRGPRX4	in	LN229	cell	line	is	low	as	predicted	from	the	mRNA	data.	
	
This	finding	is	important	because	it	represents	the	identification	of	an	immortalized	human	cell	 line	
with	a	native	expression	of	MRGPRX4,	which	can	easily	be	propagated	 in	culture.	This	 is	a	decisive	
difference	compared	to	neurons	and	native	lymphocytes.	
After	proving	that	LN229	cells	are	expressing	MRGPRX4	natively,	it	was	decided	to	establish	calcium	
mobilization	assay	using	this	cell	line.	The	calcium	assay	was	chosen	because	the	overexpressing	cell	
line	 showed	Gq	 coupling	 (see	 chapter	 4.2.9).	 By	 the	 same	 token,	 it	was	 decided	 to	 begin	with	 the	
suspension	cell	protocol	because	the	adherent	cell	protocol	had	not	shown	positive	results	in	the	ß-
arrestin	cell	line.	Yazh	473	(see	table	25)	was	initially	used	because	it	had	been	the	agonist	with	the	
best	efficacy	in	the	ß-arrestin	assay	with	an	S/N	ratio	of	4.	
The	 first	 experiments	were	 conducted	with	a	measurement	 time	of	60	 seconds	per	well.	 Yazh	473	
induced	 a	 weak	 calcium	 signal	 but	 the	 increase	 in	 signal	 was	 slow	 and	 not	 always	 reproducible.	
Therefore,	it	was	decided	to	increase	the	measurement	time	to	120	seconds	per	well.	In	this	case	the	
signal	of	Yazh	473	was	still	weak	but	reproducible,	whereas	PBS	as	a	negative	control	did	not	induce	
any	signal.	The	EC50	value	was	621	±	143	nM	as	shown	in	figure	52A.	In	the	suspension	cell	format,	
AMP	 and	 ATP	 did	 not	 show	 any	 increase	 in	 signal	 at	 1	 mM	 and	 MSX-3	 showed	 only	 a	 minimal	
increase	at	100	µM	and	it	was	not	possible	to	plot	a	curve.	
Results	and	Discussion	
112	
	
1 0 -1 0 1 0 -9 1 0 -8 1 0 -7 1 0 -6 1 0 -5 1 0 -4 1 0 -3
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0 A
Y a z h  4 7 3 , [M ]
D
F
lu
o
re
s
c
e
n
c
e
	
1 0 -9 1 0 -8 1 0 -7 1 0 -6 1 0 -5 1 0 -4
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
1 2 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0 B
Y a z h  4 7 3 , [M ]
D
F
lu
o
re
s
c
e
n
c
e
	
D
F
lu
o
re
s
c
e
n
c
e
Y a
z h
 4
7 3
 1
0 0
 µ
M
 
Y a
zh
 4
7 3
 1
0 0
 µ
M
 
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
1 0 0 0 0
1 2 0 0 0
1 4 0 0 0
1 6 0 0 0
1 8 0 0 0
2 0 0 0 0
s u s p e n s io n  c e ll fo rm a t
a tta c h e d  c e ll fo rm a t
C
	
	
Figure	52:	 (A)	Mean	dose-response	curve	of	 three	calcium	assays	of	Yazh	473	 in	LN229	cell	 line	using	the	suspension	cell	
format.	The	determined	EC50	value	was	621	±	143	nM.	(B)	Mean	dose-response	curve	of	three	calcium	assays	of	Yazh	473	in	
LN229	cell	line	using	the	attached	cell	format.	The	determined	EC50	value	was	234	±	13	nM.	(C)	A	comparison	of	the	induced	
signal	of	Yazh	473	at	100	µM	in	both	the	suspension	and	attached	cell	format	of	the	calcium	mobilization	assay.	
	
The	concentration-response	curve	reflects	an	MRGPRX4-dependent	signaling.	However,	the	ability	to	
conduct	a	curve	only	with	the	most	efficacious	compound	is	a	big	limitation.	Therefore,	the	attached	
cells	protocol	was	performed	in	both	60	seconds	and	120	seconds	formats.	Interestingly,	there	was	a	
robust	 increase	 in	 signal	 up	 to	 19,000	 units,	 which	 is	 comparable	 or	 even	 better	 than	 that	 in	 the	
overexpressing	cell	 lines.	The	120	seconds	per	well	was	initially	adopted	since	the	increase	in	signal	
continued	 for	 more	 than	 60	 seconds.	 Yazh	473	 demonstrated	more	 potency	 and	 the	 assay	 had	 a	
better	reproducibility	in	this	protocol	with	an	EC50	value	of	234	±	13	nM	as	shown	in	figure	52B.	
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It	should	be	noted	that	some	other	modification	has	been	adopted	to	get	an	optimal	signal	like	the	
increase	in	fluo-4	concentration	(an	aliquot	of	fluo-4	used	for	2	assays	only	instead	of	3	assays)	and	
as	 a	 rule	 of	 thumb:	 a	 confluent	 175	 cm2	 flask	 is	 enough	 for	 1.5	 96-well	 plates.	 The	 time	 of	
measurement	was	later	reduced	to	80	seconds	per	well.	
After	 reaching	 suitable	 conditions,	 several	 compounds	 were	 investigated	 using	 this	 new	 cell	 line.	
These	compounds	have	already	been	characterized	via	ß-arrestin	assay	and	have	been	shown	to	be	
active,	 including	8-Br-AMP,	MSX-3	and	MSX-155,	but	also	newly	 suggested	P2X	 receptor	agonist	 (a	
locked	AMP	analog)	MRS2339	was	also	 tested.205	All	 of	 these	 compounds	were	active	as	 shown	 in	
figure	53.	The	EC50	values	for	MSX-3,	MRS2339	and	8-Br-AMP	were	460	±	13	nM,	257	±	28	and	152	±	
23	µM,	respectively.		
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Figure	53:	Mean	dose-response	curves	of	three	calcium	assays	of	8-Br-AMP,	MSX-3	and	MRS2339	in	LN229	cell	 line	using	
the	attached	cell	format.	The	determined	EC50	values	for	8-Br-AMP,	MSX-3	and	MRS2339	were	152	±	23	µM,	460	±	13	nM,	
and	257	±	28	µM,	respectively.			
	
These	results	show	the	same	rank	order	of	potency	as	in	ß-arrestin	assay.	The	EC50	values	are	higher	
than	 in	 the	 ß-arrestin	 assay	 due	 to	 the	 lower	 expression	 levels.	 In	 accordance	with	 the	 ß-arrestin	
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results,	UMP,	GMP,	cAMP,	cGMP,	AMPαS,	dAMP	and	AMP-CP	were	all	 inactive	at	1	mM	(data	not	
shown).			
The	phosphonate	compound	 JH	14102	 showed	an	unexpectedly	high	potency	and	efficacy	with	an	
EC50	value	of	11.6	±	1.3	nM	as	demonstrated	 in	figure	54.	 Intriguingly,	 this	value	 is	higher	than	the	
potency	determined	in	the	overexpressing	ß-arrestin	cell	line.	
10-10 10-9 10-8 10-7 10-6
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
[JH 14102], M
Fl
uo
re
sc
en
ce
N
N N
H
N
O
O
OMe
P
O
OH
OH
	
Figure	54:	Mean	dose-response	curves	of	three	calcium	assays	of	JH	14102	in	LN229	cell	line	using	the	attached	cell	format.	
The	determined	EC50	value	was	11.6	±	1.3	nM.	
	
The	most	interesting	finding	might	well	be	the	result	of	MSX-155	(figure	40),	which	had	an	EC50	value	
of	351	nM	 in	ß-arrestin	assay.	 Suprisingly,	 this	 compound	did	not	 induce	any	 signal	 in	 the	 calcium	
mobilization	assay	in	three	independent	experiments	and	in	concentrations	up	to	100	µM	(see	figure	
57).	The	stability	of	MSX-155	was	confirmed	and	the	activity	in	ß-arrestin	assay	was	reproduced	(data	
not	shown).	This	could	only	be	explained	by	MSX-155	being	a	biased	agonist	capable	of	activating	the	
ß-arrestin	 signaling	pathway	but	not	 the	Gq	pathway	due	 to	a	distinct	binding	mode	 to	MRGPRX4.	
The	distinct	binding	mode	could	be	explained	by	the	considerable	differences	regarding	the	chemical	
structure	compared	to	MSX-3.	In	addition,	this	explains	the	previous	finding	that	Yazh	499	(see	table	
28),	the	phosphonate	analog	of	MSX-155,	is	much	weaker	at	MRGPRX4	than	MSX-155,	whereas	the	
phosphonate	analog	of	MSX-3	(like	JH14102)	is	considerably	more	potent.	The	binding	mode	of	MSX-
155	requires	the	oxygen	of	the	phosphate	for	interacting	with	the	receptor	and	replacing	this	oxygen	
with	methine	(CH)	results	in	a	much	weaker	interaction	(probably	loss	of	an	H-bond).	Moreover,	the	
MSX-155-induced	 conformation	 of	 the	 receptor	 appears	 not	 to	 allow	 the	 engagement	 of	 the	 Gq	
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signaling	 pathway.	 To	 the	 contrary,	 in	 the	 distinct	 binding	 mode	 of	 MSX-3	 the	 oxygen	 of	 the	
phosphate	is	apparently	not	 involved	in	an	important	 interaction	with	the	receptor	and	replacing	it	
with	a	carbon	(like	 in	JH	14102)	results	 in	a	more	potent	compound	(may	be	due	to	a	hydrophobic	
interaction).	The	conformational	change	 induced	by	MSX-3	and	JH	14102	 leads	to	the	activation	of	
both	ß-arrestin	and	Gq	singaling	pathways.	
AMP	was	also	investigated	using	the	LN229	cell	line.	AMP	induced	a	robust	signal	at	1	mM	but	then	
the	signal	considerably	decreased	at	300	µM	and	disappeared	at	further	dilutions.	Therefore,	it	was	
not	feasible	to	plot	a	concentration-response	curve	and	determine	an	EC50	value	for	AMP.	This	could	
be	 due	 to	 ectonucleotidase/phosphatase	 activities	 in	 this	 cell	 line.	 Ecto-5´-nucleotidase	 is	 more	
highly	expressed	on	the	mRNA	level	in	this	cell	line	than	MRGPRX4	as	shown	in	table	30.	It	was	tried	
to	use	HBSS	buffer	with	50	µM	final	 concentration	of	 the	Ecto-5´-nucleotidase	 inhibitor	AMP-CP	 in	
the	assay	but	this	did	not	have	an	effect	on	the	signal	of	AMP	in	the	calcium	mobilization	assay	(data	
not	shown).	The	active	 fraction	of	 IL-1ß	 induced	a	 robust	signal	at	a	concentration	of	10	µl/100	µl.	
This	 indicates	clearly	that	the	active	moiety	 in	the	IL-1ß	is	not	the	nucleotide,	AMP,	due	to	the	 low	
concentration	in	this	fraction.	ATP	(1	mM)	induced	a	signal,	whereas	adenosine	(1	mM)	and	the	non-
selective	 adenosine	 receptor	 agonist	 NECA	 (100	 µM)	 did	 not	 induce	 any	 signal	 (data	 not	 shown).	
Keeping	in	mind	that	native	adenosine	A2B	receptor	induce	a	delayed	calcium	singal	in	Jurkat	cells206,	
the	lack	of	adenosine	receptor	agonism	is	important	because	it	demonstrates	that	the	observed	slow	
increase	in	the	calcium	signal	in	LN229	cell	line	could	not	be	an	indication	that	the	phosphates	were	
hydrolyzed	and	the	adenosine	ligands	induced	the	observed	signal	(see	figure	57).	 It	should	also	be	
mentioned	 that	 no	 binding	 of	 Yazh	 473	 was	 found	 in	 radioligand	 binding	 experiments	 at	 all	 four	
subtypes	of	human	adenosine	receptors	(data	not	shown).	This	confirms	that	the	detected	signals	in	
LN229	cell	experiments	are	MRGPRX4-dependent.		
The	susceptibility	of	MRGPRX1	and	MRGPRX2	receptors	to	sensitization	and	endocytosis	has	proven	
controvertial,	 with	 some	 groups	 suggesting	 no	 sensitization54,101	 and	 other	 groups	 suggesting	 the	
opposite.55,94	 Since	 these	 findings	 have	 been	 reported	 using	 cell	 lines	 with	 overexpression,	 we	
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intended	to	investigate	this	point	using	natively	expressed	MRGPRX4	receptor	in	LN229	cell	line.	The	
cells	were	preincubated	with	200	nM	of	Yazh	473	 for	20,	25	and	30	min	and	 then	challenged	with	
1	µM	 Yazh	 473	 (EC80	 value).	 The	 change	 in	 the	 signal	was	 compared	 to	 the	 signal	 induced	 by	 cell	
preincubated	 with	 PBS.	 Our	 results	 show	 a	 time-dependent	 decrease	 in	 signal	 (sensitization)	 of	
MRGPRX4	receptor	as	shown	in	figure	55.		
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Figure	55:	The	results	of	unpaired	t-test	of	the	induced	calcium	assay	signals	after	preincubation	with	PBS	(control)	or	with	
200	nM	of	Yazh	473	and	then	challenged	with	1	µM	of	Yazh	473	after	20,	25,	30	min.		
	
The	results	showed	no	significant	decrease	in	signal	after	20	min	of	preincubation	but	the	decrease	
was	significant	after	25	and	30	min	of	preincubation.	Thus	our	data	suggest	that	MRGPRX4	receptor	
is	susceptible	to	endocytosis	and	sensitization,	and	this	process	is	slow.	
Another	aspect	which	was	observed	during	calcium	mobilization	assays	was	the	ability	of	Yazh	473	to	
induce	 a	prolonged	 increase	 in	 the	 signal	 as	 shown	 in	 figure	56.	 The	 signal	 of	 Yazh	473	 tended	 to	
decrease	with	considerably	more	delay	compared	to	other	agonists	at	MRGPRX4	receptor	like	MSX-3.	
This	prolonged	duration	of	signal	and	the	higher	efficacy	(also	in	the	case	of	ß-arrestin	signal)	could	
be	an	indication	that	Yazh	473	has	a	longer	residence	time	at	MRGPRX4	receptor	than	MSX-3.207	
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Figure	56:	The	profiles	of	real-time	changes	in	the	calcium	mobilization	signal	induced	by	10	µM	Yazh	473,	a	derivative	with	
an	ethylene	linker,	and	10	µM	MSX-3,	a	derivative	with	ethenyl	linker.	Yazh	473	showed	an	EC50	value	of	234	±13	nM,	while	
MSX-3	showed	an	EC50	value	of	460	±	13	nM.	The	duration	of	measurement	was	two	minutes	and	the	maximal	signal	was	
reached	after	10	seconds.	
	
This	observation	 led	us	 to	 shorten	 the	measurement	 time	 to	80	 sec	per	well	 as	mentioned	above.	
Figure	 57	 shows	 the	 fluorescence	 tracks	 of	 the	 most	 important	 agonists	 at	 MRGPRX4	 in	 calcium	
assays	using	the	LN229	cell	line.	
	
	
Figure	57:	The	fluorescence	tracks	of	the	most	important	agonists	at	MRGPRX4.	(A)	The	most	important	synthetic	agonists	
(B)	AMP,	8-Br-AMP,	adenosine	and	NECA	as	a	potent	non-selecive	AR	agonist.	
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All	in	all,	these	results	show	the	importance	of	the	LN229	cell	line	as	a	tool	to	investigate	MRGPRX4	in	
a	native	setting.	
2.4.13	Screening	of	compound	libraries	in	search	for	antagonists	at	MRGPRX4	
receptor	
	
The	next	step	in	investigating	MRGPRX4	was	to	screen	compound	libraries	with	the	goal	to	identify	
an	 antagonist.	 The	 compound	 libraries	 1,	 2,	 7	 and	 12	 were	 screened	 using	 ß-arrestin	 assay.	
Interestingly,	 several	 hits	 have	 been	 identified	 in	 our	 search,	 which	 indicates	 that	 finding	 an	
antagonist	will	be	easier	 than	 finding	an	agonist.	 In	 the	compound	 library	7	 the	non-steroidal	anti-
inflammatory	 drug	 oxyphenbutazone	 was	 identified208,209;	 in	 the	 compound	 library	 2	 KD162	 and	
KD165	 were	 identified;	 in	 the	 compound	 library	 1,	 the	 serotonin	 receptor	 antagonist	 and	 ß3-
adrenoceptor	partial	 agonist	 (S)-(-)-Pindolol210,211,	 the	ß3-adrenoceptor	partial	 agonist	BRL	37344212,	
the	NMDA	receptor	antagonist	SDZ	220-040213,	the	competitive	c-Jun	kinase	inhibitor	BI	78D3214	and	
the	protein	kinase	C	suppressor	Oncrasin	1215	were	identified	(for	structures	see	figure	58).	
	
	
Figure	58:	Chemical	structure	of	the	antagonistic	hits	at	MRGPRX4	receptor	identified	using	ß-arrestin	assay	
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Some	 of	 these	 antagonists	 were	 further	 investigated.	 Oxyphenbutazone	 showed	 an	 IC50	 value	 of	
2.18	µM	 in	 ß-arrestin	 assays;	 KD162	 and	 KD165	 demonstrated	 IC50	 values	 of	 1.05	 and	 1.77	 µM,	
respectively	(all	IC50	values,	n=1).		
Utilizing	the	LN229	cell	line,	it	was	possible	to	confirm	the	antagonistic	activity	of	oxyphenbutazone,	
KD165,	(S)-(-)-Pindolol	and	SDZ	220-040	in	calcium	mobilization	assay.	Oxyphenbutazone	showed	an	
IC50	 value	 of	 38.6	 µM,	 KD165	 demonstrated	 an	 IC50	 value	 of	 20	 µM.	 SDZ	 220-040	 was	 the	 best	
investigated	 antagonist	 at	 MRGPRX4	 receptor	 in	 calcium	mobilization	 assay	 with	 an	 IC50	 value	 of	
6.36	±	0.96	µM	as	shown	in	figure	59.	
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Figure	59:	Mean	dose-response	curve	of	three	calcium	mobilization	assays	of	SDZ	220-040	in	the	LN229	cell	line		
	
Although	these	results	are	encouraging,	it	should	be	stressed	that	those	are	preliminary	results	and	
should	be	further	investigated	and	confirmed.	Pindolol	for	instance	seems	to	be	active	but	there	was	
no	opportunity	to	further	investigate	this	drug.	These	antagonists	seem	to	be	selective	because	they	
have	 already	 been	 screened	 at	 the	 related	MRGPRX1	 and	MRGPRX2	 and	 showed	 no	 activity	 (see	
above).	 In	 addition,	 screening	 at	 GPR143	 in	 the	 same	 testing	 system	 showed	 also	 no	 antagonistic	
activity	(data	not	shown).	
	
2.4.14	Discussion	II	
	
After	 the	 different	 unsuccessful	 deorphanization	 and	 screening	 attempts,	 a	 second	 screening	
approach	 led	 to	 the	 identification	 MSX-3	 as	 an	 agonist	 at	 MRGPRX4.	 This	 prodrug	 at	 the	 A2A	
adenosine	receptor197	 is	a	relatively	potent	MRGPRX4	agonist	with	an	EC50	of	175	nM.	This	enabled	
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us	 to	 test	 related	 compounds	 to	 investigate	 the	 activation	 of	 the	 MRGPRX4	 receptor.	 The	 most	
important	 finding	was	 that	 a	 phosphate	 or	 phosphonate	 is	 essential	 for	 potency.	 Investigating	 the	
linker	of	MSX-3	revealed	that	the	higher	the	rigidity	of	the	linker,	the	lower	were	both	potency	and	
efficacy.	 Thus	 the	 8-ethinylxanthine	 derivative	 JH	 14021	 was	 virtually	 inactive	 and	 the	 8-
styrylxanthine	derivative	MSX-3	was	considerably	more	potent.	Moreover,	the	8-phenethylxanthine	
derivative	 Yazh	 473	 was	 the	 most	 potent	 and	 efficacious	 phosphate	 derivative	 so	 far.	 These	
observations	 are	 tempting	 to	 suggest	 that	 Yazh	473,	due	 to	 the	 linker	with	 an	ethylene	bond,	 can	
rotate	freely	and	bind	with	the	highest	affinity	in	the	binding	pocket	of	the	receptor.	MSX-3	can	only	
form	 E/Z	 isomers	 and	 this	 limited	 flexibility	 is	 responsible	 for	 the	 lower	 potency	 and	 efficacy	
compared	to	Yazh	473.	JH	14021	with	the	rigid	triple	bond	has	the	least	ability	to	fit	into	the	binding	
pocket	 of	 MRGPRX4	 and	 consequently	 the	 lowest	 potency	 and	 efficacy.	 This	 SAR	 is	 particulary	
important	 because	 it	 distinguishes	MRGPRX4	 receptor	 from	 the	 A2A	 receptor,	 for	 which	 both	 the	
double	and	triple	bond	seem	to	have	comparably	high	potency.198,199	MSX-155	was	also	identified	as	
an	 agonist	with	 an	 EC50	 value	 of	 351	 nM.	 This	was	 highly	 unexpected	based	on	 the	 SARs	 of	 other	
agonists	 since	 the	 linker	 is	 omitted	 and	 the	 aryl	 at	 position	 8	 is	 substituted	 by	 a	 cyclopentyl	 ring.	
MSX-155	provides	a	 clue	 that	activating	MRGPRX4	 is	 feasible	without	a	 linker	and	an	 indication	of	
possibly	distinct	interactions	with	the	amino	acids	of	the	receptors.	In	fact,	MSX-155	is	a	prodrug	of	
DPCPX,	a	potent	A1	adenosine	receptor	antagonist.	DPCPX	can	also	bind	to	A2A	adenosine	receptor	
but	with	much	 lower	 affinity.200,216	 The	 ability	 of	 these	 prodrugs	 to	 bind	 to	MRGPRX4	 could	 be	 of	
interest	 for	 a	 future	 mutagenesis	 experiments	 for	 defining	 the	 binding	 pocket	 of	 this	 receptor.	
Phylogenetically	MRGPRX4	is	more	related	to	the	P2Y12	receptor	since	both	are	in	the	δ	group	of	the	
Rhodopsin	 receptor	 family	 of	 the	 7TMR	 tree2,4	 but	 for	 identifying	 the	 binding	 pocket	 not	 only	 the	
P2Y12	X-ray	structure	but	also	those	of	adenosine	A2A	and	possibly	the	A1	receptor	could	be	used	as	a	
template	despite	a	lower	relatedness.	The	rationale	is	the	ability	of	MSX-2	and	DPCPX	to	bind	to	A2A	
and	not	P2Y12	 receptor.	 Several	 crystal	 structures	of	both,	P2Y12	and	A2A	adenosine	 receptors	have	
been	previously	published.217-221		
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However,	the	identified	phosphoric	acid	esters	may	show	enzymatic	instability.	Phosphonates	seem	
to	 represent	 a	 stable	 alternative	 to	 the	 phosphates.	 Thus	 far	 only	 few	 phosphonates	 have	 been	
synthesized	due	to	the	challenging	synthesis	and	purification.	The	phosphonate	JH	14102	exhibited	
the	best	potency	at	MRGPRX4	in	both	ß-arrestin	and	calcium	assay	thus	far.	It	represents	a	valuable	
tool	 in	 investigating	this	orphan	receptor.	A	 future	phosphonate	analog	of	Yazh	473	would	be	very	
interesting.	 Unfortunately,	 such	 an	 analog	 could	 not	 be	 synthesized	 within	 the	 timeframe	 of	 this	
thesis.	 Taking	 the	determined	SAR	 so	 far	 into	 consideration,	 it	would	be	appealing	 to	assume	 that	
such	a	ligand	could	be	a	radioligand	candidate.	Since	establishing	a	radioligand	is	a	future	aim,	some	
points	should	be	kept	in	mind.	The	increase	of	EC50	value	of	JH	14102	in	ß-arrestin	assay	from	17.4	to	
76.1	nM	upon	changing	the	lysis	buffer	demonstrates	the	difficulty	in	deciding	which	value	is	a	more	
accurate	estimation	of	a	Ki	value.	 In	addition,	 synthesis	of	more	derivatives	could	also	be	a	way	 to	
find	more	potent	compounds	as	radioligand	candidates.	For	example	the	substitution	of	the	aryl	at	
position	8	of	the	xanthine	ring	was	not	investigated	thoroughly.	An	allyl	group	instead	of	a	propargyl	
residue	at	N1	could	also	be	an	option.	
The	agonists	were	utilized	to	reveal	the	G	protein	coupling	of	MRGPRX4,	which	turned	out	to	be	sole	
coupling	to	Gq.	The	ligands	neither	induced	nor	inhibited	cAMP	accumulation.	It	should	be	noted	that	
the	 effect	 of	 pertussis	 toxin	 on	 the	 calcium	 signal	 has	 not	 been	 tested,	 which	 could	 be	 a	 further	
confirmation	 of	 the	 sole	 Gq	 coupling.	 Further	 optimization	 of	 the	 calcium	 mobilization	 assay	 is	
urgently	needed	 in	 the	 future.	 The	overexpressing	CHO	ß-arrestin	 cell	 line	was	not	an	optimal	 cell	
line	for	conducting	calcium	assays	because	the	induced	signal	was	weak	and	not	easily	reproducible.	
Therefore,	generating	a	new	cell	 line,	e.g	HEK	cells	overexpressing	MRGPRX4,	 could	 result	 in	more	
reproducible	and	robust	calcium	mobilization	assay	signals.		
Since	the	only	DRG	neuronal	 immortalized	cell	 line	 is	 from	the	rat222,	our	aim	to	 identify	a	cell	 line	
natively	 expressing	MRGPRX4	 led	 us	 to	 three	 approaches.	 The	 first	 one	 was	 to	 differentiate	 iPSC	
(induced	pluripotent	stem	cells)	 into	DRG-like	sensory	neurons.	The	results	 in	this	phase	show	that	
two	differentiation	protocols	were	able	to	 induce	the	expression	of	the	four	MRGPRX	receptors	on	
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the	mRNA	level.	The	findings	are	encouraging	but	further	investigations	are	necessary	to	detect	the	
MRGPRX	 receptors	 on	 the	 protein	 level.	 This	 could	 be	 done	 using	 Ab	 for	 an	 IF	 or	WB	 approach.	
Further	steps	could	be	investigating	the	functionality	of	the	receptors	using	a	neuron	calcium	imaging	
method.223	 Further	 more	 complicated	 steps	 could	 be	 fusing	 the	 DRG-like	 neurons	 with	
neuroblastoma	cells	in	order	to	establish	an	immortalized	cell	line	in	a	similar	way	to	establishing	the	
F11	cell	 line	from	rat	DRG	neurons.224	This	would	enable	even	more	sophisticated	procedures	like	a	
co-culture	for	investigating	communication	between	different	kind	of	cells	like	those	of	the	immune	
system	and	neurons.	Such	an	approach	has	already	been	described	for	rat	DRG	neurons	and	human	
keratinocytes.225			
The	second	search	for	a	native	expression	of	MRGPRX4	was	carried	out	in	the	immune	system,	more	
precisely	in	the	different	lymphocyte	subpopulations.	The	search	was	based	on	FACS	(i.e	on	protein	
level)	via	a	new	Ab	against	the	C-terminus	of	MRGPRX4	receptor.	Initially,	it	was	expected	to	detect	
an	 expression	 in	 CD8+	 lymphocytes	 as	 described	 previously.114	 Our	 preliminary	 data	 suggest	 that	
MRGPRX4	 is	 represented	 in	 all	 different	 lymphocytes	 subpopulations	 with	 a	 higher	 expression	 in	
CD56Bright	NK	cells.	The	reason	behind	the	expanded	expression	detected	in	our	approach	could	be	
due	to	the	use	of	an	affinity	based	method	for	detection	of	7TMRs.	This	 is	more	sensitive	than	the	
mass	spectrometry	method	used	in	by	Kim	et	al.114	because	7TMRs	possess	a	poor	solubility	and	are	
difficult	to	detect	 in	mass	spectrometry.226	NK	cells	represent	ca.	10%	of	blood	 lymphocytes.	These	
cells	could	be	subdivided	 into	two	subpopulations	based	on	the	density	of	CD56	marker	 (bright	vs.	
dim)	 and	 presence	 or	 absence	 of	 CD16.227	 CD56Bright	NK	 cells	 are	 a	minority	 of	NK	 cells	 in	 blood	
(10%)	 but	 a	 majority	 in	 secondary	 lymphoid	 tissues.	 CD56Bright	 NK	 cells	 are	 abundant	 cytokine	
producers	 but	 exhibit	 a	 weak	 cytotoxicity.228	 The	 wide	 expression	 could	 be	 a	 manifestation	 of	
unknown	 roles	 of	 the	MRGPRX4	 in	 the	 immune	 system,	 which	 have	 yet	 to	 be	 characterized.	 Our	
novel	pharmacological	tools	would	enable	future	 investigation	of	possible	roles	of	MRGPRX4	 in	the	
different	cell	types.	The	expression	in	other	immune	cells	like	macrophages,	mast	cells	and	dendritic	
cells	 could	 be	 interrogated	 in	 the	 future	 as	 well.	 In	 general,	 cytokine	 production	 and	 activation	
Results	and	Discussion	
123	
	
markers	should	be	 investigated	before	being	able	 to	put	 forward	any	hypothsis	 regarding	a	 role	of	
MRGPRX4	 in	 the	 immune	system.	Another	perspective	 for	a	potential	physiological	 role	could	be	a	
change	 in	 the	 expression	 pattern	 of	MRGPRX4	 in	 immune	 cells	 in	 health	 and	 disease	 (e.g.	 HIV	 or	
HCV).	
Tumor	cell	lines	were	our	last	area	for	searching	a	cell	line	with	native	expression.	The	motive	behind	
this	 search	 was	 the	 finding	 that	 MRGPRX4	 was	 proposed	 as	 a	 candidate	 oncogene	 in	 colorectal	
cancer.113	This	is	apparently	a	vast	area	for	searching	since	more	than	35	human	colorectal	tumor	cell	
lines	 are	 commercially	 available	 according	 to	 the	 ATCC®	 database.	 In	 addition,	 the	 search	 could	
theoretically	 include	all	human	tumor	cell	 lines.	That	could	be	very	time-consuming	and	expensive.	
Luckily,	 the	 glioblastoma	 cell	 line	 LN229	 was	 already	 available	 and	 upon	 investigation	 it	 showed	
positive	 results	 both	 on	 mRNA	 and	 protein	 level.	 The	 LN229	 cell	 line	 is	 usually	 used	 to	 study	
apoptosis.229	
The	 most	 interesting	 aspect	 in	 this	 cell	 line	 was	 the	 excellent	 calcium	 mobilization	 assay	 signal	
regarding	 reproducibility	and	amplitude.	The	 reason	behind	 this	exceptional	 signal	despite	 the	 low	
expression	(see	figure	50)	was	not	clear	but	could	be	due	to	an	efficient	coupling	to	G	protein230	 in	
this	 cell	 line	or	because	of	a	higher	expression	of	Gq	protein	and	a	better	 signal	amplification.	The	
implication	is	that	LN229	is	a	novel	tool	for	MRGPRX4	investigation.	Capitalizing	on	this	new	cell	line	
it	was	possible	to	demonstrate	clearly	that	MRGPRX4	is	subject	to	sensitization	and	endocytosis.	But	
here	it	should	be	noted	that	showing	the	endocytosis	using	an	Ab	would	be	a	good	confirmation	as	
well.	 It	was	also	feasible	to	show	that	MSX-155	is	a	biased	agonist	towards	ß-arrestin	signaling	and	
completely	 lacks	 Gq	 protein	 signaling.	 The	 lack	 of	 G	 protein	 coupling	 implicates	 a	 distinct	 binding	
mode	 to	MRGPRX4	 as	well	 as	 a	 different	 induced	 conformation	 of	 the	 receptor	 compared	 to	 the	
conformation	 induced	by	MSX-3	 and	 related	 compounds.	 The	different	binding	mode	 can,	 in	 turn,	
shed	light	on	SAR	and	explain	the	decreased	potency	of	the	phosphonate	analog	of	MSX-155	(Yazh	
499)	 despite	 the	 increased	 potency	 of	 the	 phosphonate	 analog	 of	 MSX-3	 (JH	 14102).	 All	 these	
insights	 provide	 an	 evidence	 of	 the	 importance	 of	 the	 LN229	 cell	 line.	 In	 the	 future	 a	 further	
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confirmation	using	ERK1/2	phosphorylation	assays	could	provide	more	insights	into	the	downstream	
singaling	of	these	ligands.	MSX-155	should	actually	function	as	an	antagonist	in	calcium	mobilization	
assays	since	it	does	not	cause	a	calcium	signal	but	evidently	binds	to	the	receptor	because	of	the	ß-
arrestin	 signal.	 The	 signal	 bias	 could	 have	 important	 implications	 like	 eliminating	 a	 side-effect.	
Activating	the	ß-arrestin	signal	of	the	opioid	receptors	for	instance	results	in	respiratory	depression.	
Hence,	a	biased	opioid	agonist	towards	the	G	protein	signaling	could	be	advantageous.231,232	On	the	
other	 hand,	 the	 biased	 angiotensin	 ligand	 TRV	 120027	 blocks	 G	 protein	 coupling	 but	 activates	 ß-
arrestin	pathway-bound	benefits	 like	the	increase	in	cardiac	performance.233-235	A	further	possibility	
is	 to	 investigate	 if	 MRGPRX4	 is	 a	 real	 oncogene	 as	 suggested	 by	 Gylfe	 et	 al.	 and	 to	 investigate	
possible	mutations	like	the	proposed	Ser114Arg	and	Ala115Thr113	mutations	(both	at	the	end	of	TM3	
according	 to	 uniprot.org)	 and	 a	 potential	 role	 of	 such	mutations	 in	 increasing	 their	 signaling	 that	
would	 explain	 the	 exceptionally	 efficient	 Gq	 coupling	 observed	 in	 the	 calcium	 mobilization	 assay.		
Proliferation	assays	could	be	a	good	starting	point.	
Taken	together,	all	three	approaches	to	identify	a	native	cell	line	expressing	MRGPRX4	are	promising	
and	have	led	to	positive	results,	but	more	efforts	are	still	needed	and	many	questions	are	yet	to	be	
answered.	
The	 search	 for	 antagonists	was	 initiated	 and	 some	 preliminary	 results	 have	 been	 obtained.	 It	was	
interesting	to	find	several	hits,	although	not	all	available	compound	libraries	have	been	screened	yet.	
This	 is	 an	 advantage	 because	 several	 scaffolds	 could	 be	 obtained	 and	 more	 room	 for	 chemical	
synthesis	 would	 be	 available.	 These	 antagonists	 should	 be	 investigated	 by	 plotting	 concentration-
response	curves	 in	both	ß-arrestin	and	calcium	mobilization	assay.	MSX-155	should	be	 investigated	
as	an	antagonist	in	calcium	assay	only,	as	mentioned	previously.	The	most	interesting	antagonists	for	
now	are	oxyphenbutazone,	 KD165,	 (S)-(-)-Pindolol	 and	 SDZ	220-040.	According	 to	Gaucher	 et	 al.209	
oxyphenbutazone	 reaches	 as	 high	 as	 0.75	µg/ml	 in	 CSF	 i.e	 2.31	 µM,	which	 is	 higher	 than	 the	 EC50	
value	in	the	overexpressing	ß-arrestin	cell	line	of	2.18	µM	but	considerably	lower	than	38.6	µM,	the	
EC50	 value	 of	 calcium	 assay	 in	 LN229	 cell	 line.	 These	 findings	 are	 interesting	 because	
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oxyphenbutazone	 is	 an	 analgesic	 and	 anti-inflammatory	 drug.	 However,	 this	 high	 concentration	 in	
CSF	 should	 be	 critically	 judged.	 All	 in	 all,	 it	 is	 tempting	 to	 suggest	 that	 finding	 and	 optimizing	 an	
antagonist	is	possible	but	more	efforts	should	be	done	in	this	direction	in	the	future.	
The	SAR	of	our	new	agonists	 led	us	 to	a	 fourth	and	 last	deorphanization	attempt	of	 the	MRGPRX4	
receptor.	 The	 suggested	 physiological	 ligand	 is	 adenosine	 monophosphate	 (AMP)	 because	 it	
represents	 all	 characteristics	 necessary	 to	 activate	 MRGPRX4	 (adenosine	 plus	 phosphate)	 as	
discussed	previously	 (see	chapter	4.2.11).	The	nature	of	 the	agonist	as	a	nucleotide	 is	distant	 from	
the	originally	assumed	peptide	as	in	the	second	and	third	deorphanization	approaches	and	closer	to	
the	first	deorphanization	attempt	with	adenine.	That	means	MRGPRX1	and	MRGPRX2	have	evolved	
to	be	peptide	receptors	while	MRGPRX4	evolved	to	bind	a	nucleotide.	An	explanation	could	be	the	
pronounced	 positive	 selection	 in	 the	 extracellular	 loops	 of	 MRGPRX	 receptors	 that	 has	 been	
previously	reported.21	In	fact,	members	of	MRGPR	receptor	family	have	been	described	as	sequence	
related	 7TMR	 with	 structurally	 dissimilar	 ligands.122	 Nevertheless,	 proving	 AMP	 as	 a	 physiological	
ligand	 is	 a	 very	 formidable	 task	 for	 several	 reasons.	 AMP	has	 already	 been	 screened	 at	MRGPRX4	
receptor	by	DiscoverX®	 in	 their	deorphanization	campaign	and	 failed	 to	be	 identified	as	a	hit.95	No	
precise	concentration,	at	which	AMP	was	screened,	has	been	given	but	the	inability	to	detect	AMP	as	
an	agonist	could	have	been	due	to	the	low	concentration	used	(usually	1	or	10	µM),	which	results	in	
an	 S/N	 ratio	 below	 1.4	 (to	 be	 considered	 as	 a	 hit).	 To	make	matters	worse,	 there	 have	 been	 two	
previous	 deorphanizations	 in	 the	 literature	 proposing	 AMP	 as	 a	 physiological	 ligand.	 GPR99	 was	
suggested	 to	 be	 a	 novel	 nucleotide	 receptor,	 suggested	 to	 be	 renamed	 to	 P2Y15,	 which	 could	 be	
activated	by	both,	adenosine	and	AMP.	[32P]AMP	was	shown	to	bind	GPR99	with	a	Kd	value	of	18.8	
µM.236	This	deorphanization	was	discredited	and	α-ketoglutarate	was	subsequently	shown	to	be	the	
native	 ligand.237-239	 In	 2012	 AMP	 was	 suggested	 to	 activate	 A1	 adenosine	 receptors.240	 	 This	
deorphanization	has	not	been	discounted	in	a	publication	but	results	from	our	lab	indicate	no	binding	
of	 AMP	 to	 A1	 adenosine	 receptor	 (data	 not	 shown).	 Although	 AMP	 was	 reported	 to	 have	
physiological	 effects,241-244	 it	 is	mainly	 through	 its	degradation	 to	adenosine	or	 to	 its	 conversion	 to	
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ADP	 or	 ATP,	 all	 of	which	 have	 their	 defined	 7TMRs.245,246	 The	metabolism	 of	 extracellular	 AMP	 to	
adenosine	is	physiologically	regulated	by	different	ecto-phosphohydrolases	like	ecto-5'-nucleotidase	
(NT5E),	 prostatic	 acid	 phosphatases	 and	 more	 than	 one	 type	 of	 alkaline	 phosphatases.247,248	 The	
pattern	of	expression	of	these	enzymes	in	different	tissues	and	cells	represents	a	further	complexity	
for	 determining	 a	 role	 for	 AMP.	 Among	 the	 AMP-degrading	 phosphatases,	 NT5E	 is	 the	 best	
investigated	one	and	the	rate-limiting	enzyme	in	generating	extracellular	adenosine.	NT5E	has	a	Km	
value	in	the	lower	micromolar	range.247	NT5E	is	upregulated	by	IL-1ß,	TNF-α	and	downregulated	by	
INF-γ	 and	 IL-4.249,250	 Therefore,	 it	 would	 be	 useful	 to	 look	 at	 its	 expression	 in	 the	 DRG,	 immune	
system	and	tumor	cells	(the	three	areas	natively	expressing	MRGPRX4	that	were	found	in	this	thesis).	
In	the	DRG	it	was	found	that	the	small	diameter	neurons	(peptidergic	and	non-peptidergic)	express	
NT5E	 and	 that	 this	 enzyme	 is	 responsible	 for	 regulating	 AMP	 in	 nociceptive	 circuits	 and	 thus	
inhibiting	 pain	 by	 producing	 adenosine.251,252	 In	 the	 immune	 system,	 NT5E	 is	 a	 known	maturation	
marker	of	T	and	B	cells	and	has	also	been	found	in	many	other	 immune	cells.114,247,253	 Interestingly,	
the	 expression	 of	 this	 enzyme	 in	 CD56bright	 NK	 cells	 has	 recently	 been	 described.	 The	 role	 of	
CD56bright	cells	as	cytokine	releasers	has	already	been	reported	but	there	are	indications	that	these	
cells	 play	 a	 regulartory	 role	 in	 the	 immune	 system.	 Morandi	 et	 al.	 proposed	 this	 regulatory	 role	
(inducing	 proliferation	 of	 CD4+	 T-cells)	 to	 be	 mediated	 via	 adenosine	 receptors.	 To	 address	 this	
hypothesis,	 the	 expression	 of	 NT5E	 and	 its	 ability	 to	 efficiently	 degrade	 AMP	 to	 adenosine	 was	
demonstrated	in	these	cells	in	contrary	to	CD56dim	cells.	Moreover,	patients	with	juvenile	idiopathic	
arthritis	showed	CD56bright	NK	cells	with	a	reduced	NT5E	activity	and	adenosine	production	in	the	
synovial	 fluid.254	Chatterrjee	et	al.	proposed	that	the	percentage	of	NT5E-expressing	NK	cells	 is	 low	
(ca.	1%)	but	upon	contact	with	mesenchymal	 stem	cells	 the	NT5E-expressing	NK	cells	 increased	 to	
10%	and	the	ability	to	degrade	AMP	increased	as	well.	Therefore,	a	subpopulation	of	NK	cells	aquire	
NT5E	 and	 the	 ability	 to	 convert	 AMP	 to	 adenosine	 upon	 contact	 with	 mesenchymal	 stem	 cells.	
Characterization	of	this	subpopulation	(bright	or	dim)	has	not	been	performed.255		
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Tumor	 cells	 and	 their	 expression	 of	 NT5E	 were	 thoroughly	 investigated.	 NT5E	 demonstrated	 an	
overexpression	in	bladder	cancer,256	leukemia,257	melanoma,258	ovarian	cancer,259	thyroid	cancer,260	
esophageal	cancer,261		prostate	and	breast	cancer262		and	glioblastoma	(LN229	for	instance)	cancer.263	
NT5E	is	associated	with	poor	prognosis	for	ovarian	and	glioma	cancers.264,265	The	catabolism	of	AMP	
in	 glioma	 cell	 lines	 showed	 a	 pronounced	 efficiency	 via	 NT5E.266	 All	 these	 findings	 indicate	 that	
MRGPRX4	is	probably	co-expressed	with	NT5E.	Our	results	as	well	showed	higher	expression	of	NT5E	
in	LN229	cell	line	than	MRGPRX4	receptor	on	the	mRNA	level	(see	table	30).	Our	data	together	with	
the	published	data	prove	on	one	side	that	MRGPRX4	is	expressed	at	the	same	sites	where	AMP	and	
NT5E	are	available	and	on	the	other	side	this	co-expression	may	explain	the	weak	signal	of	AMP	in	
the	LN229	cell	line.	Nevertheless,	the	co-expression	and	the	reported	AMP	degradation	could	be	an	
indication	of	preferred	adenosine	signaling	and	not	MRGPRX4	signaling	on	these	cancer	cells.	In	this	
regard	it	is	interesting	to	further	investigate	MRGPRX4	in	NK	cells	since	these	cells	seem	not	to	have	
a	basal	expression	of	NT5E,	which	could	mean	 that	under	 some	conditions	AMP	could	accumulate	
and	activate	MRGPRX4	and	upon	inducing	NT5E	MRGPRX4	signaling	would	dwindle.	
The	 International	 Union	 of	 Basic	 and	 Clinical	 Pharmacology	 (IUPHAR)	 published	 recently	
recommendations	 for	 deorphanizing	 a	 7TMR.	 The	 deorphanization	 should	 ideally	 include	 a	
radioligand	 binding	 assay	 plus	 functional	 assays,	 both	 in	 vitro	 and	 in	 native	 tissues.	 The	 putative	
ligand	should	be	present	in	the	tissues	in	appropriate	concentration.	Further	evidence	could	be	from	
anatomical	 level,	 and	plausible	mechanisms	 for	 ligand	 to	 reach	physiological	 concentrations	 in	 the	
tissues.	Deleting	the	gene	encoding	the	receptor	in	mice,	exploiting	a	naturally	occurring	deletion	in	
human	tissues,	or	RNA	silencing	should	abolish	receptor	characteristics,	such	as	radioligand	binding	
or	 physiologic	 and/or	 pharmacological	 actions	 of	 the	 endogenous	 ligand	 in	 functional	 assays.	
Conversely,	receptor	overexpression	may	be	expected	to	potentiate	these	actions.267	Since	AMP	as	a	
radioligand	did	not	work	due	to	its	too	low	affinity	(see	chapter	2.4.11),	it	is	possible	to	show	binding	
using	 another	potent	 ligand.	We	have	performed	 two	 functional	 assays	 in	 an	 artificial	 system	 that	
showed	 the	 activity	 of	 AMP.	 The	 determined	 EC50	 value	was	 in	 the	micromolar	 range.	 The	 actual	
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concentration	of	AMP	 in	 the	DRG,	 the	microenvironment	of	 tumor	or	on	 the	surface	of	NK	cells	 in	
secondary	lymphoid	tissues	is	difficult	to	measure.	In	the	literature,	AMP	in	the	plasma	was	reported	
to	be	between	1.3	to	0.6	µM.268,269	The	concentration	of	AMP	in	the	CSF	according	to	Eells	et	al.	is	<	
0.2	 µM.270	 The	 CSF	 metabolome	 database	 (www.csfmetbolome.ca)	 provides	 useful	 information	
about	metabolites	in	the	CSF.	In	this	database,	more	or	less	the	same	values	for	AMP	in	plasma	and	
CSF	are	reported.271	Rodríguez-Núñez	et	al.	estimated	the	AMP	concentration	to	be	as	high	as	1.86	±	
1.11	mM	in	CSF	of	children	suffering	from	sepsis.	This	value	seems	to	be	too	high.272	Most	reported	
concentrations	are	lower	than	our	determined	EC50	values	but	they	do	not	represent	the	local	AMP	
concentration	 at	 the	 site	 of	 action.	 Another	 point	 is	 the	 inability	 to	 perform	 calcium	moblilization	
assays	using	AMP	in	the	native	LN229	cell	line	because	the	signal	was	detected	only	at	1	mM.	These	
are	formidable	barriers	for	a	deorphanization	proposing	AMP	as	a	cognate	ligand.	Nevertheless,	our	
deorphanization	proposal	 could	 be	 substantiated.	 The	 first	 step	 is	 to	 develop	 a	 radioligand	 and	 to	
demonstrate	a	specific	binding	of	AMP	at	MRGPRX4	receptors.	The	phosphonate	analog	of	Yazh	473	
could	 be	 a	 suitable	 candidate.	 The	 second	 step	 is	 to	 synthesize	 a	 non-hydrolysable	 phosphonate	
analog	 of	 AMP,	 for	 which	 the	 EC50	 should	 be	 determinable.	 Such	 a	 compound	 can	 be	 a	 plausible	
argument.	For	now	8-Br-AMP	seems	to	be	the	most	potent	AMP-derivative.	It	would	be	plausible	to	
systematically	 synthesize	 such	derivatives	with	 small	modifications	of	AMP,	 in	a	 similar	way	 to	 the	
adenine	 derivatives,273	 because	 they	 would	 probably	 not	 be	 degraded	 as	 efficiently	 as	 the	
physiological	AMP.	The	third	step	is	to	find	a	physiological	function	for	native	MRGPRX4	which	could	
be	 induced	by	AMP	or	a	very	similar	derivative	of	AMP	and	then	to	demonstrate	that	this	 function	
could	 be	 abolished	 via	 a	 selective	 antagonist	 (unfortunately	 till	 now	 we	 do	 not	 have	 one)	 or	 via	
siRNA.	 Lymphocytes	 could	 be	 candidates	 for	 a	 physiological	 function	 like	 increasing	 the	 release	 of	
cytokines,	 and	 LN229	 cells	 could	 also	 be	 candidates	 for	 proliferation	 assays	 or	 inducing	 apoptosis.	
DRG-like	 neurons	would	 probably	 be	more	 difficult	 to	 handle.	Moreover,	 generating	 an	MRGPRX4	
overexpressing	cell	line	for	calcium	mobilization	assays	should	be	carried	out	in	order	to	get	a	better	
reproducibility,	and	HEK	cells	could	be	a	suitable	Gq-expressing	cell	line.			
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3.	Summary	and	Outlook	
The	human	MRGPRX	receptors	belong	to	the	orphan	7TMRs	within	the	Rhodopsin	family	of	7TMRs.	
The	MRGPRX	receptor	subfamily	is	exclusively	expressed	in	primates,	which	represents	a	hurdle	for	
elucidating	 the	 (patho)physiological	 roles	 of	 these	 receptors.	 In	 this	 PhD	 thesis	 the	 four	 human	
MRGPRX	 receptors	were	pharmacologically	 investigated.	The	primary	assay	employed	 in	 this	 study	
was	 the	 ß-arrestin	 assay	 using	 ß-galactosidase	 complementation	 due	 to	 its	 high	 specificity	 for	 the	
expressed	 receptor.	 Additional	 assays	 like	 calcium	mobilization	 and	 cAMP	 accumulation	were	 also	
employed.	
MRGPRX1	 is	 the	 best	 investigated	member	 of	 the	MRGPRX	 subfamily	 of	 7TMRs.	Our	 efforts	were	
focused	 on	 screening	 several	 compound	 libraries	 in	 order	 to	 identify	 new	 antagonists	 for	 this	
receptor	 subtype.	 Only	 one	 compound,	 MIRA-1,	 was	 found	 to	 have	 an	 antagonistic	 activity	 at	
MRGPRX1	 in	the	performed	ß-arrestin	assays.	However,	 the	chemical	structure	(instable	ester)	and	
the	 steep	 concentration-response	 curve	 made	 us	 refrain	 from	 further	 investigation	 of	 this	 hit	
compound.	 Screening	of	 further	 compound	 libraries	 should	be	performed	 in	 the	 future	 to	 identify	
ligands	that	are	more	suitable	for	drug	development.		
	
MRGPRX2	was	paired	to	the	peptide	agonist	CST-14,	but	several	other	agonists	have	been	described	
in	the	literature.	However,	no	antagonists	have	been	described	so	far.	In	our	screening	approach	for	
antagonists	using	the	ß-arrestin	assay	several	hits	were	identified,	e.g.	vitamin	K3	(menadione)	from	
compound	library	7.	One	hit	from	compound	library	3,	designated	CB8,	with	a	tricyclic	benzimidazole	
scaffold	showed	an	IC50	value	of	2.42	µM.	It	was	decided	to	develop	this	hit	further.	Our	efforts	led	to	
an	 establishment	 of	 SARs	 and	 to	 successive	 optimization	 of	 the	 parent	 compound.	 The	 best	
antagonist	so	far	(CD63)	exhibited	an	IC50	value	of	6.38	nM	as	shown	in	figure	60.	The	mode	of	action	
of	 these	 antagonists	 was	 determined	 to	 be	 competitive	 versus	 CST-14.	 In	 addition,	 initial	
pharmacokinetic	data	of	the	best	three	antagonists	were	determined.	Lastly,	the	recently	proposed	
functional	 ortholog	 of	 MRGPRX2	 receptor,	 the	 mouse	 MRGPRB2	 receptor,	 was	 cloned	 and	 a	 ß-
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arrestin	cell	line	was	established.	The	aim	was	to	test	our	novel	antagonists	at	the	mouse	receptor	as	
well.	This	could	not	be	carried	out	so	far	due	to	the	low	potency	of	the	agonist	CST-14	at	the	mouse	
receptor	in	the	ß-arrestin	assay.		
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Figure	60:	The	 curve	of	CB8,	 the	 first	hit	 found	at	MRGPRX2	 receptor,	with	an	 IC50	 value	of	2.42	µM	and	CB6,	 the	most	
potent	antagonist	so	far,	with	an	IC50	value	of	6.38	nM.	Both	curves	are	from	three	independent	ß-arrestin	assays	
	
Our	results	provide	valuable	tools	for	investigating	the	MRGPRX2	receptor.	CB63	is	a	good	candidate	
for	developing	a	radioligand	or	obtaining	a	co-crystal	structure	of	MRGPRX2	due	to	its	high	potency.	
Given	the	newly	elucidated	role	of	this	receptor	in	chronic	urticaria	and	pseudoallergic	reactions,	our	
antagonists	 may	 contribute	 as	 tool	 compounds	 to	 expand	 the	 research	 and	 deepen	 the	
understanding	of	this	receptor	and	its	functions.	These	antagonists	could	be	of	crucial	importance	for	
animal	 experiments	 if	 they	 keep	 their	 affinity	 for	 the	 murine	 MRGPRB2	 receptor.	 In	 the	 future,	
further	 improvement	 could	 result	 in	 compounds	 with	 improved	 properties.	 Some	 issues	 like	 low	
water	solubility,	and	metabolic	instability	have	to	be	addressed.	Developing	a	radioligand	should	not	
be	 far	 from	 reach.	 Most	 importantly	 establishing	 a	 suitable	 MRGPRB2	 cell	 line	 for	 calcium	
mobilization	assays	could	be	of	significance	for	testing	our	novel	antagonists.	A	HEK	cell	line	may	be	
used	for	expression	due	to	high	Gq-protein	content.	
	
The	MRGPRX3	receptor	 is	an	orphan	receptor	with	no	reported	pharmacological	 tool	 for	now.	This	
receptor	 was	 cloned	 and	 a	 ß-arrestin	 cell	 line	with	 high	 expression	was	 established.	 Screening	 all	
available	compound	libraries	during	the	time	of	this	thesis	resulted	in	no	hit.	The	MRGPRX3	receptor	
remains	an	enigmatic	receptor.	Taking	into	account	that	an	MRGPRX3	cell	 line	is	not	available	from	
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DiscoverX®	 for	 undisclosed	 reasons	 and	 that	 the	 MRGPRX3	 receptor	 is	 probably	 Gq-coupled,	 it	 is	
advisable	to	adopt	calcium	mobilization	assays	for	new	compound	library	screening	in	the	future.	
	
MRGPRX4	is	an	orphan	receptor.	The	drug	nateglinide	was	reported	at	the	final	stage	of	this	thesis	to	
act	as	a	weak,	non-selective	agonist.	Several	screening	and	deorphanization	approaches	in	the	course	
of	 this	 thesis	 resulted	 in	 no	 progress	 until	 MSX-3	 was	 identified	 as	 an	 artificial	 agonist.	 Related	
compounds	 subsequently	 were	 tested	 and	 initial	 SARs	 were	 established.	 Our	 efforts	 led	 to	 the	
optimization	 of	 both,	 efficacy	 and	 potency	 of	 the	 agonists.	 The	 best	 stable	 phosphonate	 agonist,	
JH	14102,	 shows	 EC50	 values	 in	 the	 nanomolar	 range	 in	 both,	 ß-arrestin	 and	 calcium	mobilization	
assays.	 Using	 these	 agonists	 we	 demonstrated	 only	 Gq	 coupling	 for	 this	 7TMR.	 Further	 synthesis	
resulted	in	the	phosphate	derivative	Yazh	473,	which	demonstrated	the	best	signal-to-noise	ratio	in	
the	ß-arrestin	assay	so	far	 indicating	high	efficacy	of	the	compound.	For	a	deeper	understanding	of	
this	 receptor	a	 search	 for	a	native	cell	 line	 led	us	 to	 stem	cells	differentiated	 to	DRG-like	neurons,	
detection	of	MRGPRX4	in	several	lymphocyte	subpopulations	and	to	a	tumor	cell	line,	LN229,	which	
expresses	the	receptor	natively.	The	obtained	information	proved	the	expression	and	consequently	a	
potential	physiological	role	of	MRGPRX4	in	the	immune	system.	This	could	be	of	high	significance	for	
a	better	understanding	of	the	(patho)physiological	role	of	this	receptor.	The	tumor	cell	line,	LN229,	is	
an	 evidently	 invaluable	 tool	 for	 investigating	 MRGPRX4,	 which	 enabled	 us	 to	 demonstrate	 the	
susceptibility	 of	 this	 7TMR	 to	 agonist-induced	 desensitization	 and	 endocytosis.	Moreover,	 calcium	
mobilization	 assays	 showed	 a	 high	 signal	with	 efficient	 Gq	 coupling.	 These	 natively	 expressing	 cell	
lines	 are	 important	 for	 elucidating	 the	 role	 of	MRGPRX4.	 Screening	 for	 antagonists	 has	 also	 been	
carried	out	and	several	hits	with	different	scaffolds	have	been	identified.	This	opens	up	the	door	for	
the	development	of	more	potent	and	selective	antagonists.	Lastly,	a	pairing	proposal	of	MRGPRX4	to	
AMP	as	 its	physiological	agonist	based	on	the	structure	of	our	novel	agonists	has	shown	promising	
results.	AMP	exhibited	the	activation	of	both,	ß-arrestin	and	Gq	pathways.	Figure	61	shows	the	most	
important	agonists	discovered	and	developed	within	this	study.		
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Figure	61:	The	curves	of	MSX-3,	the	first	identified	hit	at	MRGPRX4	receptor,	with	an	EC50	value	of	175	nM	and	JH	14102	as	
the	most	potent	agonist	so	far	with	an	EC50	value	of	17.4	nM.	Based	on	the	similarity	in	structure,	AMP	was	proposed	as	a	
physiological	 ligand	and	showed	an	EC50	value	of	19.4	µM.	Each	curve	 is	the	mean	curve	of	three	 independent	ß-arrestin	
assays	
	
Further	steps	are	needed	to	support	our	proposal.	Open	questions	remain	due	to	inherent	instability	
of	 AMP	 and	 regarding	 physiological	 and	 pathophysiological	 concentration	 of	 this	 nucleotide.	 In	
addition,	 improving	 the	 potency	 of	 our	 agonists	 with	 the	 goal	 to	 prepare	 a	 radioligand	 should	 be	
pursued.		
All	 in	 all,	 the	 results	 of	 this	 thesis	 enrich	 our	 understanding	 of	 the	 so	 far	 not-well	 characterized	
MRGPRX	receptor	subfamily	and	provide	important	tools	for	further	investigations.	
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4.	Experimental	part	
4.1	General	
4.1.1	Chemicals	
2-Propanol,	technical		 ZVE	Bonn-Endenich	
2’-desoxy-AMP	disodium	salt	 Sigma-Aldrich,	D6375	
8-Br-AMP	disodium	salt	 Sigma-Aldrich,	B3131	
Adenine		 Sigma-Aldrich,	A8626	
Adenosine		 Sigma-Aldrich,	A9251	
ADP	disodium	salt	 Sigma-Aldrich,	A2754	
Agarose		 Roth,	2267	
Ali	901A,	Ali	909,	Ali	900D,	Ali	913,	Ali	916	 Synthetic	 compound	 from	 lab	 of	 Prof	 Christa	
Müller	
AMP	disodium	salt	 Sigma-Aldrich,	01930	
AMP-CP	 Sigma-Aldrich,	M3763	
Ampicilline	sodium	salt		 Roth,	K029	
APVRSLNCTLRDSQQKSLVMSGPYE	 (synthetic	
peptide)	
ProteoGenix	SAS	
APVRSLNCTLRD	(synthetic	peptide)	 Genosphere	Biotechnologies	
ATP	disodium	salt		 Sigma-Aldrich,	A26209	
BAM-22	 Genscript,	RP10424	
BI03		 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	
BMS	191011		 TOCRIS	Bioscience,	2665		
Calcium	chloride	dihydrat	 Fluka,	21097;	Sigma,	C3306	
cAMP	 Enzo	Life	Science,	80-0056	
Cantharidin	 TOCRIS	Bioscience,	1548	
CB	compounds	 Synthetic	 compounds	 from	 lab	 of	 Steven	 De	
Jonghe	
Chloroquine	diphosphate	 Sigma-Aldrich,	C6628	
Ciprofloxacin	 Sigma-Aldrich,	17850	
Cortistatin-14	 Genscript,	RP10972	
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D-(+)-Glucose		 Sigma-Aldrich,	G-7021	
DMSO		 Roth,	4720	
DMSO,	steril	 AppliChem,	A3672	
EDTA,	disodium	dihydrate		 Roth,	X986.1	
Ethanol,	p.A.		 Merck,	1.00983	
Fetal	calf	serum		 Sigma-Aldrich,	F-0804	
Fluo-4-AM	 Lifetechnologies,	F-14201	
Forskolin		 Enzo	Life	Sciences,	BML-CN100	
G418		 AppliChem,	A2167	
GelRed™		 Biotrend,	41002	
Glycerol		 Acros,	158920010	
GMP	disodium	salt		 Sigma-Aldrich,	G8377	
Hepes		 Sigma-Aldrich,	H3375	
Hydrochloric	acid	37%		 Sigma-Aldrich,	30721	
Hygromycine	B		 InvivoGen,	ant-hm-5	
Interleukin	1	beta	(IL-1ß)	 R&D	Systems,	201-LB-005/CF	
Lifetechnologies,	10139-HNAE-5	
Istradefylline	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	
JH	14102,	JH	14021	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	
KD162,	KD165	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Kiec-
Kononowicz	
Magnesium	chloride		 Fluka,	63068	
Magnesium	sulfate		 Sigma-Aldrich,	M2643	
Matrix	metalloproteinase	3	(MMP3)	 Lifetechnologies,	10467-HNAE-25	
Sigma-Aldrich,	SRP7783	
MIRA-1	 TOCRIS	Bioscience,	3362	
Morphine,	hydrochloride	 Sigma-Aldrich,	Y000451	
MSX-2,	MSX-3,	MSX-4,	MSX-155	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	
NECA		 Sigma-Aldrich,	E2387	
NT	021071,	NT	021033,	NT	02109,	NT	02005	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	
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Oregon	Green®	488	BAPTA-1	AM	 Molecular	Probes,	O6807	
Penicilline/Streptomycin	solution		 Cambrex,	DE17-602E	
Pluronic®	F-127		 Sigma-Aldrich,	P2443	
Polyclonal	MRGPRX4	antibody	 Aviva	Systems	Biology,	OAAF04989	
Potassium	chloride		 Fluka,	60128	
Potassium	dihydrogenphosphate		 Sigma-Aldrich,	P9791	
Prin01	 Princeton	BioMolecular	Research,	OSSL_790375	
Ro20-1724		 Hoffmann	la	Roche	
Saponin		 Fluka,	84510	
SDZ-220-040	 TOCRIS	Bioscience,	1251	
Sodium	carbonate		 AppliChem,	A1881	
Sodium		chloride		 Roth,	3957.1	
Sodium		hydrogencarbonate		 Sigma-Aldrich,	S5761	
Sodium		hydroxid		 Merck,	109959	
Soybean	trypsin	inhibitor	(STI)	 Sigma-Aldrich,	T9003	and	T9767	
Triton™	X-100		 Sigma-Aldrich,	X-100	
UMP	disodium	salt	 Sigma-Aldrich,	U6375	
Yazh	compounds	 Synthetic	 compounds	 from	 lab	 of	 Prof	 Christa	
Müller	
ZM39923	 TOCRIS	Bioscience,	1367	
	
4.1.2	Instruments	and	Software	
Autoclave		
	
VX-95,	Systec	
3850	ELV,	Systec	
Balance,	precision		
	
SBC	42,	SCALTEC	
440-47N,	KERN	
Benches	
	
NUNC®	Safe	flow	1.2	
NUNC®	MICROFLOW	
Cell	culture	flasks	 25	cm²,	75	cm²,	175	cm²	steril,	Sarstedt	
Cell	scraper	 Josef	Peske	GmbH	und	Co.	
Centrifugal	filters	 Amicon®	Ultra,	Merck	Millipore	
Centrifuges		
	
Mikro	200,	Hettich	
AllegraTM	21	R,	Beckman	Coulter	
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AvantiTM	J-201,	Beckman	
Rotofix	32,	Hettich	
Cryovials	steril	 Starsedt	
Dismozon®	pur		 Bode	Chemie	
Drying	cabinet	 Heraeus	Instruments	
Glass-fiber	filters		 Whatman®,	Schleicher	und	Schüll	(GF/B)	
Filters	(sterile)	 Filtropur	0,22	μm,	Sarstedt	
Fluorimeter	 NOVOstar®,	bmg	Labtech	
Mithras	Research	II	LB	940,	Berthold	
Technologies	
Harvester		
	
Brandel	M24	Gaithersburg,	MD,	USA	
Brandel	M48	Gaithersburg,	MD,	USA	
Incubator	 Jouan	IG	650	
Heraeus	HERAcell®	240	
Inc	240,	Memmert	
Incubator	shaker		
	
Innova	4200	Incubator	shaker,	
New	Brunswick	Scientific	
Liquid	scintillation	analyzer		 Tri-Carb	2810	TR,	Perkin-Elmer	
Topcount	NXT™,	Packard	
Liquid	scintillation		 cocktail	LumaSafe®,	Perkin-Elmer	
Microscope		
	
Wilovert,	Hund	Wetzlar	
Axiovert	25,	Zeiss	
Microscope	for	fluorescence	images		 Leica,	DM	IL	LED	Fluo	
Microwave	 Micorwave	800,	Severin	
Neubauer	cell	chamber	 Marienfeld,	Germany	
pH	meter		
	
691	pH	Meter,	Metrohm	
Seven	Easy,	Mettler	Toledo	
Pipettes		 Eppendorf	Research	
Pipette	tipps	 Greiner	Plastibrand®,	Brand;	Sarstedt	
Pipette	tipps	(electronical	pipets)	 Ritips®	professional,	Ritter	
Photometer		 DU-530,	Beckman	
Serological	pipets	 Starsedt	
Software	 BLAST®	Protein	Alignment	
GraphPad	Prism®,Version	6.0	und	5.0	
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ChemBiodraw	Ultra	11.0	
Microsoft	Excel	und	Microsoft	Word	2007	
Clone	Manager,	Version	9	
DNA	Translator	2.0,	Dr.	Anke	Schiedel/	
J.	Bosmann	
Chromas	Version	1.45,	Conor	McCarthy	
OligoAnalyser	3.1,	IDT,	Scitools	
ClustalW2,	European	Bioinformatics	Institute	
Thermal	block		 Thermomixer	comfort,	Eppendorf	
Thermocycler	 Px2	Thermal	Cycler,	Thermo	Scientific	
Biometra	
Ultraturrax	 T25	basic,	IKA	Labortechnik	
Vaccume	pump	 MD	4C	Vario,	Vaccubrand	
Vortexer		 MS	1	Minishaker,	IKA	Labortechnik	
Water	bath	 GFL®	1083,	Gesellschaft	für	Labortechnik	GmbH	
WWB	14,	Memmert	
Well-plates	(96)	 Starsedt	
Nunc	
Greiner	
Corning	3340	
Well-plates	(24)	 Starsedt	
	
4.1.3	Buffers	
PBS	buffer		
8.0	g	NaCl	(150	mM),	0.2	g	KCl	(2.5	mM),	1.3	g	Na2HPO4	and	0.2	g	KH2PO4	(1.5	mM)	are	dissolved	in	1	
l	of	deionized	water.	Buffer	is	then	sterilized	via	autoclave	and	stored	at	RT.	
0.05	%	Trypsin	/	0.6	mM	EDTA	solution		
6	ml	of	a	0.1	M	EDTA	stock	solution	are	added	to	1	l	PBS	buffer	and	autoclaved	subsequently.	20	ml	
of	a	sterile	2.5	%	trypsin	solution	and	750	µl	of	a	sterile	0.5	%	phenol	red	solution	are	added	under	a	
laminar	flow	bench.	The	solution	is	stored	at	4	°C	in	100	ml	aliquots.	
HEPES	buffer		
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2.38	g	HEPES	(10	mM),	4.68	g	NaCl	(80	mM),	0.27	g	KCl	(3.6	mM),	0.11	g	MgCl2	·	6	H2O	(0.53	mM)	,	
0.18	g	CaCl2	·	2	H2O	(1.2	mM)	were	added	to	deionized	1	l	water,	pH	is	adjusted	to	7.4	at	4	°C	with	
saturated	NaOH	solution.	The	buffer	is	stored	at	4	°C.	
HBSS	buffer	
8	g	NaCl	(13	mM),	4.77	g	Hepes	(20	mM),	1	g	Glucose	(5.5	mM),	0.1	g	MgSO4	(0.8	mM),	0.1	g	MgCl2	(1	
mM),	 0.185	 g	CaCl2	 (1.25	mM),	 0.35	 g	NaHCO3	 (4.2	mM),	 0.4	 g	KCl	 (5.4	mM),	 0.06	 g	KH2PO4	 (0.44	
mM),	 0.048	 g	Na2HPO4	 (0.34	mM)	were	 added	 to	 1.0	 l	 deionized,	 autoclaved	water	 and	 the	 pH	 is	
adjusted	to	7.3.	The	buffer	is	stored	at	4	°C.	
Lysis	buffer	for	cAMP	assay	
1.48	g	EDTA	(4	mM)	und	100	μl	Triton	(0.01	%)	were	dissolved	in	1.0	l	of	deionized,	autoclaved	water.	
The	pH	is	adjusted	to	7.3.	
	5X	Krebs-Hepes	buffer	(KHB)	
16.85	g	NaCl	(118.6	mM),	0.875	g	KCl	(4.7	mM),	0.4	g	KH2PO4	(1.2	mM),	0.875	g	NaHCO3	(4.2	mM),	
5.25	g	D-Glucose	(11.7	mM)	und	5.95	g	HEPES	(10	mM)	were	added	to	500	ml	deionized	water	and	
the	pH	is	adjusted	to	7.3.	The	buffer	is	stored	at	-20°C.	
	1X	Krebs-Hepes	buffer	(KHB)	
100	ml	of	5X	KHP	buffer	were	added	 to	650	μl	of	1	mM	CaCl2	 solution	 (f.c	1.3	mM)	and	600	μl	of	
1	M	MgSO4	solution	(f.c	1.2	mM)	and	then	completed	with	deionized	water	to	500	ml.	The	pH	was	
again	adjusted	to	7.3	and	aliquots	of	25	ml	were	frozn	in	-20°C.	
Oregon-Green	Solution	
50	μg	of	Oregon	Green	were	dissolved	in	39.7	μl	DMSO	(f.c	1	mM).	The	solution	was	divided	to	3	μl	
aliquots	 and	 these	 aliquots	 were	 stored	 in	 -20°C.	 The	 preparation	 should	 be	 done	 under	 light	
protection	since	Oregon	Green	is	light-sensitive.	
Fluo-4	AM	Solution	
50	μg	of	 Flou-4	AM	were	dissolved	 in	45	μl	DMSO.	The	 solution	was	divided	 to	15	μl	 aliquots	and	
these	aliquots	were	stored	in	-20°C.	
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Pluronic®-F127	solution	
200	mg	of	Pluronic	were	dissolved	in	800	μl	DMSO.	The	solution	was	kept	in	room	tempetature	and	
approximately	15	min	prior	to	use	the	solution	was	heated	to	37°C	in	a	water	bath.	
50x	TAE	buffer	for	molecular	biology	
242	 g	 TRIS	 (2	M),	 14.61	 g	 EDTA	 (50	mM)	 and	 57.1	ml	 acetic	 acid	 (glacial)	 are	 added	 to	 deionized	
water	 yielding	 a	 total	 volume	 of	 1	 l.	 	 Buffer	 is	 sterilized	 via	 autoclave,	 stored	 at	 RT	 and	 is	 diluted	
appropriately	prior	to	usage.	
4	%	Paraformaldehyd	in	PBS	
1	g	Paraformaldehyd	is	added	to	20	ml	of	80°C	heated	water.	1	N	NaOH	solution	is	added	dropwise	
until	 the	 solution	 becomes	 clear.	 2.5	 ml	 10X	 PBS	 are	 added	 to	 the	 solution	 and	 the	 volume	 is	
completed	to	25	ml	with	deionized	water.	After	cooling	pH	was	adjusted	to	7.4	and	the	solution	was	
stored	at	-20°C.	
1	%	BSA	in	PBS	
Dissolve	1	g	of	BSA	in	100	ml	PBS	and	store	the	25	ml	aliquots	in	-20°C.	
4.2	Cell	culture	
4.2.1	Cells	and	Media	
PathHunter®	CHO-K1	β-Arrestin	Parental	Cell	
Line	
DiscoveRx,	93-0164	
PathHunter®	 CHO-K1	 MRGPRX1	 β-Arrestin	 Cell	
Line	
DiscoveRx,	93-0919C2	
PathHunter®	 CHO-K1	 MRGPRX2	 β-Arrestin	 Cell	
Line	
DiscoveRx,	93-0309C2	
PathHunter®	 CHO-K1	 MRGPRX3	 β-Arrestin	 Cell	
Line	
Cloned	within	this	thesis	
PathHunter®	 CHO-K1	 MRGPRX4	 β-Arrestin	 Cell	
Line	
DiscoveRx,	93-0541C2A	
PathHunter®	 CHO-K1	 MRGPRB2	 β-Arrestin	 Cell	
Line	
Cloned	within	this	thesis	
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LN229	Glioblastoma	Cell	line	 ATCC®	CRL-2611™	
Provided	by	AK	Prof.	Dr.	Björn	Scheffler	
	
ß-arrestin	cell	lines	were	cultured	using	the	following	media	
Basal	medium	 Culture	medium	 Selection	medium	
DMEM-F12	(1:1)	
FCS	10%	
Penicillin	100	U/ml	
Streptomycin	100	µg/ml	
Hygromycin	300	µg/ml	
DMEM-F12	(1:1)	
FCS	10%	
Penicillin	100	U/ml	
Streptomycin	100	µg/ml	
Hygromycin	300	µg/ml	
G418	200	µg/ml	
DMEM-F12	(1:1)	
FCS	10%	
Penicillin	100	U/ml	
Streptomycin	100	µg/ml	
Hygromycin	300	µg/ml	
G418	800	µg/ml	
	
LN229	cell	line	was	cultured	using	the	following	medium	
Basal	medium	
DMEM-F12	(1:1)	
FCS	10%	
Penicillin	100	U/ml	
	
	
Generally	all	cells	are	maintained	in	cell	culture	flasks	at	37	°C	in	a	humidified	atmosphere	of	90	%	air	
and	10	%	CO2.	Once	adherent	cells	have	grown	into	a	monolayer	of	approx.	90	%	confluence	they	are	
passed	 into	 new	 flasks.	 This	 is	 done	 by	 decanting	 the	 medium	 and	 rinsing	 the	 cells	 with	 PBS	 to	
remove	residual	medium.	A	0.05	%	trypsin	/	0.6	mM	EDTA	solution	is	added	and	cells	are	incubated	
for	 3-5	 minutes	 at	 37	 °C.	 In	 order	 to	 adhere	 to	 surfaces	 cells	 require	 integrin	 structures.	 These	
structures	are	digested	by	 trypsin	which	belongs	 to	 the	 family	of	 serine	proteases.	 In	addition,	 the	
concentration	 of	 divalent	 cations	which	 are	 crucial	 for	 integrin	 stability	 is	 reduced	 by	 EDTA.	Once	
cells	 are	 detached	 they	 are	 suspended	 in	 basal	medium	 and	 separated	 by	 passing	 the	 suspension	
through	a	sterile	pipette	several	times.	Depending	on	the	required	amount	of	cells,	a	certain	volume	
of	cell	suspension	is	transferred	to	a	new	flask	containing	preheated	medium.	
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It	should	be	noted	that	prior	to	seeding	cells	for	a	ß-arrestin	assay	the	cell	should	not	be	dissociated	
via	 a	 detachment	 buffer	 without	 trypsin.	 Hence,	 PBS	 buffer	 containing	 2	 mM	 EDTA	 and	 10	 mM	
Glucose	was	used	in	this	case.	
4.2.2	Membrane	preparation	
Once	 cells	 have	 reached	 a	 confluence	 of	 ~90	 %	 the	 content	 of	 one	 175	 cm2	 flask	 is	 passed	 into	
twenty	sterile	150	mm	dishes.	After	the	cells	have	grown	into	a	monolayer	of~90	%	confluence	again	
the	medium	is	decanted	and	dishes	are	rinsed	with	5	ml	PBS.	After	freezing	the	dishes	at	-20	°C	or	-80	
°C	for	at	least	15	min,	1	ml	of	ice-cold	5	mM	TRIS	/	2	mM	EDTA	/	pH	7.4	buffer	are	added	and	dishes	
are	scraped	with	a	cell	scraper.	This	step	is	repeated	to	ensure	that	all	cells	are	collected	from	each	
dish.	 Once	 the	 content	 of	 all	 dishes	 is	 unified	 in	 a	 beaker,	 the	 cell	 suspension	 is	 treated	 with	 an	
ultraturrax	for	1	min	at	24,000	/	min	and	homogenized	via	a	dounce	homogenizer	subsequently.	To	
remove	nuclei	and	other	 larger	organelles	and	cell	debris	 the	homogenate	 is	centrifuged	at	1000	g	
for	10	min	(4	°C).	The	supernatant	is	collected	and	centrifuged	at	48,400	g	for	1	h	(4	°C).	The	resulting	
pellets	 are	 resuspended	 in	 0.1	 ml	 /	 Dish	 of	 50	 mM	 TRIS	 /	 pH	 7.4	 buffer	 and	 crude	 membrane	
solutions	are	stored	at	-80	°C.	All	steps	should	be	carried	out	swiftly	at	a	temperature	of	4	°C	to	avoid	
receptor	internalization.		
4.2.3	Reagents	for	protein	determination	(Lowry)	
Reagent	A:	10	g	of	Na2CO3	are	dissolved	in	500	ml	of	0.1	N	sodium	hydroxide	solution.		
Reagent	B:	0.25	g	CuSO4	x	5H2O	are	dissolved	in	20	ml	of	deionized	water.	0.5	g	of	disodium-	tartrate	
are	dissolved	in	another	20	ml.	Solutions	are	unified	and	deionized	water	is	added	to	a	final	volume	
of	50	ml.		
Reagent	 C:	 Reagent	 C	 always	 needs	 to	 prepared	 freshly	 prior	 to	 usage.	 It	 is	 prepared	 by	 mixing	
reagent	A	and	B	in	a	ratio	of	50:1.		
Reagent	D:	Deionized	water	is	added	to	18	ml	of	folin	reagent	to	a	final	volume	of	90	ml.	Solution	has	
to	be	stored	protected	from	light.	
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1	mg/ml	bovine	serum	albumin	(BSA)	solution	is	prepared	and	its	OD	is	measured	in	a	quartz	cuvette	
at	a	wavelength	of	280	nm.	Since	 there	 is	a	 linear	correlation	between	the	BSA	concentration	of	a	
solution	and	its	OD	the	actual	BSA	concentration	can	be	calculated	using	the	following	formula:																	
BSA	(mg/ml)	=	1	(mg/ml)	*	measured	OD/reference	OD	
	
Reference	OD	equals	0.66	
Dilutions	from	50	to	500	µg/ml	of	the	BSA	solution	are	prepared.	Protein	concentrations	have	to	be	
adjusted	according	to	the	calculated	BSA	concentration.	
Two	dilutions	(1:10	and	1:20)	of	crude	membrane	samples	are	prepared	with	50	mM	TRIS	/	pH	7.4	
buffer	yielding	a	total	volume	of	200	µl.	Blank	value	is	determined	as	200	µl	of	50	mM	TRIS	/	pH	7.4	
buffer.	1	ml	of	 reagent	C	 is	added	 to	each	 sample	and	 incubated	 for	20	min	at	 room	temperature	
(RT).	Another	period	of	30	min	incubation	follows	after	addition	of	100	µl	of	reagent	D.	All	samples	
are	subsequently	transferred	to	semi	micro	cuvettes	and	ODs	are	measured	at	550	nm.	OD	values	of	
the	BSA	dilution	are	plotted	against	their	concentration	and	a	linear	regression	analysis	is	performed	
using	Microsoft	 Excel	 2007.	 Protein	 concentrations	 of	 crude	membrane	 samples	 can	be	 calculated	
according	to	the	results	of	the	aforementioned	linear	regression	analysis.	
4.3	Molecular	biology	
4.3.1	Kits,	enzymes	and	reagents	
6x	Gel	Loading	Dye,	blue	 New	England	BioLabs,	N3026S	
ΦX174	DNA-HaeIII	Digest	 New	England	BioLabs,	B7021S	
NheI	 New	England	BioLabs,	R0131S	
HindIII	 New	England	BioLabs,	R0104S	
DNA	Clean	&	Concentrator™-25	Kit	 Zymo	Research,	D4033	
Lambda	DNA/EcoRI+HindIII	marker	 Fermentas,	SM0191	
LipofectamineTM	2000	Transfection	Reagent	 Invitrogen,	11668019	
PathHunter®	Detection	Kit	 DiscoveRx,	93-0001L	
PureLink®	HiPure	Plasmid	Filter	Midiprep	Kit	 Life	Technologies,	K2100-15	
Pyrobest	ploymerase	 TaKaRa,	R005	
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Zymoclean™	Gel	DNA	Recovery	Kit	 Zymo	Research,	D4002	
Zyppy™	Plasmid	Maxiprep	Kit	 Zymo	Research,	D4028	
Zyppy™	Plasmid	Miniprep	Kit	 Zymo	Research,	D4020	
	
DNA	 midipreparation:	 	 Invitrogen™,	 PureLink™	 HiPure	 Plasmid	 Filter	 Purification	 Kits.	 The	
components	 of	 the	 kit	 were	 resuspension	 buffer	 with	 RNase	 A,	 Lysis	 buffer,	 precipitation	 buffer,	
equilibration	 buffer,	 wash	 buffer,	 elution	 buffer,	 TE	 buffer	 and	 HiPure	 Filter	 Midi	 Columns.	 The	
midipreparations	were	performed	according	to	the	manufacturer	instructions.	
DNA	minipreparation:	ZYMO	RESEARCH	CORP.	ZR	Plasmid	Miniprep™-Classic.	The	components	of	the	
kit	were	P1	buffer,	P2	buffer,	P3	buffer,	Endo-Wash	buffer,	Plasmid	Wash	buffer,	DNA	elution	buffer,	
RNase	A,	Zymo-Spin™	IIN	columns	and	collection	tubes.	The	DNA	minipreparations	were	performed	
according	to	the	manufacturer	instructions.	
Both	mini-	 and	midipreparations	 aim	 at	 extracting	 the	 plasmid	 DNA	 from	 the	 bacteria.	 The	most	
utilized	principle	is	the	alkaline	lysis	of	the	bacterial	cell	wall.	
DNA-Recovery:	ZYMO	RESEARCH	CORP.	Zymoclean™	Gel	DNA	Recovery	Kit.	This	kit	is	used	to	extract	
the	 DNA	 from	 the	 agarose	 gel	 and	 it	 consists	 of	 the	 following	 components	 the	 ADB	 (Agarose	
Dissolving	Buffer),	DNA	wash	buffer,	Zymo-Spin™	I	columns	and	collection	tubes.	The	DNA	recovery	
was	performed	according	to	the	manufacturer	instructions.	
DNA-Recovery:	ZYMO	RESEARCH	CORP.	DNA	clean	&	concentrator™-5	Kit.	This	kit	is	used	to	extract	
the	DNA	from	PCR	digestion,	cell	lysate,	etc	and	it	consists	of	the	following	components	DNA	binding	
buffer,	 DNA	 wash	 buffer,	 Zymo-Spin™	 columns	 and	 collection	 tubes.	 The	 DNA	 recovery	 was	
performed	according	to	the	manufacturer	instructions.	
4.3.2	PCR	DNA	amplification	
4.3.2.1	human	MRGPRX3	receptor	
The	following	PCR	program	was	adopted	to	amplify	the	cDNA	of	human	MRGPRX3	from	the	vector	
pCMV6-Entry	provided	by	OriGene	Company	US.	
98	°C	 	 10	s	
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98	°C	 	 10	s*	
67	°C	 	 1	min*	 	 	
72	°C	 	 3	min*	
72	°C	 	 10	min	
*	=	30	cycles	
1	µl	template	DNA	(~	20	ng)	
2	µl	f-primer											(~	10	pM)	
2	µl	r-primer											(~	10	pM)	
5	µl	10X-pyrobest-buffer	
4	µl	dNTP	
0.5	µl	pyrobest-polymerase	
35.5	µl	PCR-H2O	
−−−−−−−−−−−−−−−−	
50	µl	total	volume	
Table	32	The	restriction	enzymes	(bold)	and	the	primer	sequences	used	to	amplify	hMRGPRX3	
Primer	 Sequence	5`	-	3`	
f-hMRGPRX3-NheI			 GCATAATGCTAGCACCATGGATTCAACCATCCCAGTCTTG	
r-	hMRGPRX3-HindIII	 TTCGAAGCTTGACTGCTCCAATCTGCTTCCCGAC	
	
4.3.2.2	mouse	MRGPRB2	receptor	
The	following	PCR	program	was	adopted	to	amplify	the	cDNA	of	murine	MRGPRB2	from	the	vector	
pCMV6-Entry	provided	by	OriGene	Company	US.	
98	°C	 	 10	s	
98	°C	 	 10	s*	
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62	°C	 	 1	min*	 	 	
72	°C	 	 3	min*	
72	°C	 	 10	min	
*	=	30	cycles	
1	µl	template	DNA	(~	20	ng)	
2	µl	f-primer											(~	10	pM)	
2	µl	r-primer											(~	10	pM)	
5	µl	10X-pyrobest-buffer	
4	µl	dNTP	
0.5	µl	pyrobest-polymerase	
35.5	µl	PCR-H2O	
−−−−−−−−−−−−−−−−	
50	µl	total	volume	
Table	33	The	restriction	enzymes	(bold)	and	the	primer	sequences	used	to	amplify	mMRGPRB2	
Primer	 Sequence	5`	-	3`	
f-mMRGPRB2-NheI			 GCAATGCTAGCACCATGAGTGGAGATTTCCTAATCAAG	
r-	mMRGPRB2-HindIII	 CTAAGCTTGAGCTGCAGCTCTGAACAGTTTCC	
	
4.3.3	ß-arrestin	vectors	
pCMV-ProLink™1	vector	 93-0167	
pCMV-ProLink™2	vector	 93-0171	
pCMV-ARMS1-ProLink™2	vector	 93-0489	
pCMV-ARMS1-ProLink™2	vector	 93-0490	
	
ARMS	 means	 Arrestin	 Recruitment	 Modifying	 Sequence	 and	 it	 facilitates	 the	 G	 protein	 receptor	
kinase	(GRK)	recruitment.	
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4.3.4	Subcloning	of	the	cDNA	
In	order	to	subclone	the	cDNA	in	the	vectors	of	interest	(in	this	case	the	four	ß-arrestin	plasmids)	the	
recognition	sites	of	the	restriction	enzymes	have	to	be	introduced	adjacent	to	the	genes.	This	can	be	
achieved	by	the	specific	design	of	the	primers.	Chapters	4.3.2.1	and	4.3.2.2	contain	the	names	of	the	
restriction	 enzymes	 (bold)	 used	 for	 each	 gene	 as	 well	 as	 the	 recognition	 sites	 of	 these	 enzymes	
(underlined).	 The	 pCMV-ProLink™	 series	 are	 suitable	 for	 subcloning	 the	 7TMR	 of	 interest	 and	 the	
resulting	plasmid,	when	expressed	in	a	mammalian	cell,	will	have	a	ProLink	tag	on	the	C-terminus	of	
the	 7TMR.	 It	 is	 important	 to	 design	 the	 primer	 sothat	 the	 stop	 codon	 of	 the	 7TMR	 is	 omitted.	
Moreover,	the	7TMR	should	be	in	frame	with	the	ProLink	tag.	
The	gene	and	the	vector	of	interest	were	then	digested	with	the	restriction	endonuclease	enzymes.	
The	 total	 volume	was	 20	µl	 and	 the	 reaction	was	 performed	 according	 to	 the	manufacturer	 (New	
England	 Biolabs)	 protocol	 for	 1	 hour	 in	 the	 room	 temperature.	 The	 digested	 genes	 were	 then	
subjected	to	the	gel	electrophoresis	 in	order	to	separate	them	from	the	restriction	enzymes	and	to	
estimate	 their	 amount.	 The	 agarose	 gel	 was	 then	 excised	 and	 the	 digested	 PCR	 products	 were	
extracted	with	the	Zymoclean™	Gel	DNA	Recovery	Kit.	
4.3.5	Ligation	
After	the	digestion	of	the	vector	and	the	PCR	products,	they	were	ligated	using	the	enzyme	T4	DNA	
ligase.	 This	 reaction	 was	 performed	 at	 room	 temperature	 for	 2	 hours	 according	 to	 the	 following	
protocol	
X	µl	vector	DNA	(~50	ng)	
Y	µl	Insert	DNA	(~150	ng)	
2	µl	100nM	ATP	solution	
2	µl	10X	T4-DNA	ligase	Buffer	
1	µl	T4-DNA	ligase	
Z	µl	PCR	water	
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−−−−−−−−−−−−−−−−	
20	µl	total	volume	
4.3.6	Agarose	gel	electrophoresis	
Agarose	is	added	to	TAE	buffer	yielding	a	concentration	of	1	%	and	suspension	is	heated	until	agarose	
is	 completely	 dissolved.	 In	 order	 to	 avoid	 thermal	 degradation	 GelRed™	 nucleic	 acid	 stain	 from	
Biotium,	Inc.	is	added	as	a	final	concentration	of	1:10,000	after	the	solution	has	cooled	down	to	~50	
°C.	The	solution	is	then	transferred	to	a	gel	holder.	After	the	gel	has	hardened	the	comb	is	removed	
and	the	gel	is	put	into	the	electrophoresis	chamber	containing	1x	TAE	buffer.	Samples	mixed	with	6x	
loading	dye	are	 loaded	 into	the	pockets	and	the	gel	 is	run	at	a	100	V.	DNA	bands	are	visualized	by	
exposure	to	UV	light	using	the	Bio-Rad	Gel	doc	system.	
4.3.7	LB	medium	
25	 g	 of	 LB	 medium	 are	 dissolved	 in	 1	 l	 deionized	 water	 according	 to	 manufacturer’s	 protocol.	
Medium	 is	 sterilized	 subsequently	 and	 stored	 at	 4	 °C	 until	 further	 use.	 If	 the	medium	 is	 used	 to	
cultivate	bacteria	transformed	with	the	four	ß-arrestin	vector	constructs,	kanamycin	is	added	to	give	
a	final	concentration	of	100	µg	/ml.		
4.3.8	Preparation	of	competent	bacteria	
E.Coli	 genotype	 TOP10	was	 used,	 from	which	 50	 μl	 of	 a	 glycerol	 culture	 were	 given	 into	 4	ml	 LB	
medium	 (without	 antibiotics),	which	was	 incubated	 in	 the	 bacteria	 shaker	 at	 37	 °C,	 220	 rpm	 over	
night.	The	following	day,	500	μl	of	this	preculture	were	transferred	into	40	ml	LB	medium	(without	
antibiotics)	and	again	incubated	in	the	bacteria	shaker	(37	°C,	220	rpm).	After	approximately	45	min,	
the	optical	density	of	this	suspension	at	550	nm	(OD550)	was	measured	against	a	blank	(LB	medium	
without	bacteria).	If	necessary	the	incubation	time	was	extended	until	an	OD550	of	0.5	was	obtained.	
At	 this	 time,	 it	 can	be	 assumed	 that	 bacterial	 reproduction	 is	within	 the	 exponential	 phase	of	 the	
bacteria	growth	curve.	The	suspension	was	centrifuged	(1700	g,	4	°C,	20	min)	and	the	resulting	pellet	
resuspended	in	20	ml	cold	CaCl2	solution	(0.1	M).	After	incubation	on	ice	for	30	min,	the	suspension	
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again	was	centrifuged	(1700	g,	4	°C,	20	min).	The	obtained	pellet	was	resuspended	in	2	ml	cold	CaCl2	
solution	 (0.1	M).	 After	 addition	 of	 0.5	ml	 glycerol	 and	 quick	 homogenization,	 the	 suspension	was	
aliquoted	à	100	μl	and	stored	at	-80	°C.	
4.3.9	Transformation	of	competent	bacteria	
100	µl	of	competent	bacteria	are	kept	on	ice	until	thawed	completely.	The	ligation	mixture	is	added	
to	 the	 thawn	 bacteria	 and	 the	 resulting	mixture	 is	 incubated	 on	 ice	 for	 30	min.	 Bacteria	 are	 then	
subjected	to	heat	shock	treatment	at	37	°C	for	2	min	and	another	2	min	of	incubation	on	ice	directly	
thereafter.	300	µl	of	LB	medium	are	added	and	the	suspension	is	incubated	at	37	°C	and	600	rpm	for	
2	h.	Within	this	incubation	period	successfully	transformed	bacteria	are	able	to	express	the	proteins	
coded	in	the	plasmids	resistance	gene.	Bacteria	are	then	transferred	to	a	Kanamycin	containing	agar	
plate	 and	 distributed	 evenly	 using	 a	 Drigalski	 spatula.	 Plates	 are	 incubated	 upside	 down	 at	 37	 °C	
overnight.	
4.3.10	Bacterial	cultures	
Depending	on	the	required	downstream	application	bacteria	can	be	cultured	in	4	ml	or	100	ml	of	LB	
medium	plus	kanamycin	100	µg/ml.	To	obtain	bacteria	cultures,	a	small	amount	of	bacteria	is	taken	
either	 from	 agar	 colonies	 or	 previous	 bacterial	 cultures	 and	 transferred	 to	 the	 desired	 amount	 of	
medium.	Cultures	are	then	incubated	at	37	°C	and	220	rpm	overnight.	
4.3.11	Sequencing	
All	 sequencing	 analyses	 were	 performed	 by	 GATC	 Biotech	 AG,	 Germany.	 Samples	 were	 prepared	
according	to	the	manufacture’s	specifications.	
4.3.12	Glycerol	Stocks	
In	 order	 to	 preserve	 the	 bacterial	 clones	 carrying	 the	 desired	 gene	 in	 vector	 construct	 for	 long	
periods	of	time,	they	can	be	kept	as	glycerol	stocks.	These	are	prepared	by	adding	200	µl	of	sterile	
glycerol	to	800	µl	of	bacterial	suspension	in	LB	medium.	Stocks	are	stored	at	either	-20	°C	or	-80	°C.	
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4.4	Cell	counting	
To	determine	the	number	of	cells	in	a	given	solution,	a	Neubauer	cell	chamber	was	used.	Therefore,	
a	glass	slide	was	put	on	the	chamber	and	the	cell	suspension	was	pipeted	between	the	slide	and	the	
champer.	Cells	within	a	square	of	the	dimension	1	x	1	mm	were	counted	under	the	microscope.	Since	
a	 square	 of	 these	 dimensions	 –	 due	 to	 a	 depth	 of	 0.1	mm	–	 contains	 100	 nl,	 the	 number	 of	 cells	
counted	in	this	square	multiplied	by	10,000	corresponds	to	the	number	of	cells	per	ml.	To	increase	
the	accuracy	of	the	determination,	cells	within	two	or	more	of	these	squares	were	counted	and	the	
mean	was	used	for	calculation	of	cells	per	ml.	
4.5	Transfection	
The	 term	 transfection	 refers	 to	 the	 introduction	 of	 nucleic	 acids	 into	 eukaryotic	 cells	 by	 non-viral	
methods.	If,	as	a	result	thereof,	the	nucleic	acid	molecule	is	integrated	into	the	host	genome	(stable	
transfection),	 the	transfected	nucleic	acid	will	be	replicated	along	with	 the	host	genome	with	each	
cell	cycle	and	the	gene	product	will	be	stably	expressed.	If	the	nucleic	acid	molecule	is	not	integrated	
into	the	host	genome	(transient	transfection),	it	will	only	temporarily	remain	within	the	cell	and	will	
get	lost	during	mitosis	or	will	be	degraded	by	time.	Several	different	transfection	methods	are	known	
at	present,	which	make	use	of	various	electrical,	chemical	or	physical	principles.	
4.5.1	Lipofection	
In	 general,	 lipofection	with	 LipofectamineTM	 2000	was	 performed	 according	 to	 the	manufacturer’s	
protocol,	 as	 described	 in	 the	 following:	 one	 day	 before	 transfection,	 1-2	 106	 cells	were	 seeded	 in	
seeding	medium	using	25	cm2	flask	and	cultivated	over	night	 (1).	On	the	following	day,	 the	culture	
medium	was	exchanged	against	F12	plus	FCS	(no	antibiotic)	several	hours	before	transfection	(2).	In	a	
tube	 600	 µl	 LipofectamineTM	 2000	 was	 added	 to	 25	 µl	 F12	 without	 any	 supplements,	 mixed	 by	
inverting	and	 incubated	 for	5	min	 (3).	 In	 the	meanwhile,	 the	DNA	solution	 (containing	10	µg	DNA)	
was	prepared	by	adding	the	required	amount	of	DNA	into	F12	without	any	supplement	in	a	second	
tube	sothat	the	final	volume	is	625	µl	(4).	Subsequently,	the	LipofectamineTM	2000	solution	was	given	
into	 the	 DNA	 solution,	 mixed	 by	 inverting	 and	 the	 mixture	 was	 incubated	 for	 20	 min	 at	 room	
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temperature.	At	the	end	of	the	incubation	time,	liposome-DNA	complexes	have	formed,	which	were	
given	drop-bydrop	onto	the	cells.	After	 incubation	till	next	day	the	medium	was	exchanged	against	
basic	culture	medium	(5).	One	the	following	day	the	selection	medium	was	used	till	a	stable	growth	
of	cells	(usually	14	days)	is	evident	(6).	Thereafter,	the	culture	medium	should	be	continually	used.	
4.6	Immunofluorescence	experiments	
On	the	day	preceding	the	experiment,	cells	are	seeded	on	coverclips	in	a	12	well-plate.	On	the	day	of	
experiments	the	following	steps	were	done:	(1)	washing	the	cells	3X	with	PBS	(2)	removal	of	PBS	and	
addition	of	500	µl	of	4%	Paraformaldehyde	in	PBS	for	15	min	(3)	removal	of	PBS	and	washing	3X	with	
25mM	glycine	(4)	removal	of	glycine,	washing	with	PBS	and	solubilizing	the	cells	with	1%	saponin	in	
PBS	solution	for	10	min	(5)	removal	of	saponin	solution,	washing	3X	with	PBS	and	blocking	with	1%	
BSA	in	PBS	solution	for	15	min	(6)	taking	of	coverclips	and	addition	of	primary	Ab	(30-40	µl)	diluted	in	
PBS	according	to	instruction	of	the	manufacturer	(7)	washing	2X	with	PBS	and	addition	of	secondary	
Ab	for	20-50	minutes	(8)	washing	2X	with	PBS.	The	overclips	are	then	ready	to	be	investigated.	
In	the	case	of	the	primary	Ab	against	C-terminus	of	MRGPRX4,	the	dilution	was	1/250	in	PBS.	
4.7	Competition	radioligand	binding	assays	
In	order	to	investigate	the	binding	of	adenine	at	MRGPRX4,	[3H]adenine	was	used	as	a	radioligand	as	
shown	in	the	protocol	below.		
50	mM	TRIS	/	pH	7.4	buffer	 190	µl	
DMSO	/	Adenine	 10	µl	
[3H]Adenine	 100	µl	
Membrane	preparation	 100	µl	
Total	volume	 400	µl	
		
DMSO	100%	was	used	to	determine	the	total	binding;	adenine	in	DMSO	to	final	concentration	of	100	
µM	was	 used	 to	 determine	 the	 unspecific	 binding.	 The	 incubation	 time	was	 60	minutes.	 The	 final	
concentration	of	the	radioligand	was	10	nM.	The	filtration	took	place	under	reduced	pressure	over	
GF/B	 filter	 directly	 after	 the	 incubation	 time	 has	 finished	 and	 was	 performed	 3	 times	 each	 with	
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approx.	3	ml	50	mM	TRIS.	This	 filtration	aims	at	removing	the	unbound	radioactivity	after	reaching	
the	equilibrium;	the	filters	were	then	punched	out	and	put	into	mini	scintillation	vials	and	2.5	ml	of	
scintillation	 cocktail	 Lumasafe	 from	 PerkinElmer	 Inc.	 are	 added.	 The	 counting	 of	 the	 radioactivity	
takes	place	in	a	Tri-Carb	liquid	scintillation	counter,	after	an	initial	waiting	period	of	at	least	6	hours.	
The	following	formulas	were	applied	to	determine	the	concentration	of	the	protein	and	the	RL	
 Protein	[ml]	=	(Anzahl	Vials	+	6)	*	csoll	Protein	[µg]	
																																							cist	Protein	[µg/ml]	
Puffer			[ml]	=	(Anzahl	Vials	+	6)	*	0,1	ml	–	Protein	[ml]	
	
Ligand		[µl]	=	(Anzahl	Vials	+	6)	*	spez.	Aktivität	[Ci/mmol]	*	csoll	Ligand	[nM]	*	Gesamtvolumen	[ml]									
1000	*	cist³H[Ci/L]	
Puffer			[ml]	=	(Anzahl	Vials	+	6)	*	0,1	ml	
4.8	Pharmacological	assays	
4.8.1	ß-Arrestin	assay	
The	 β-arrestin	 recruitment	 assay	 is	 based	 on	 the	 detection	 of	 the	 interaction	 of	 a	 7TMR	 with	 β-
arrestin	 by	 β-galactosidase	 fragment	 complementation	 (β-arrestin	 Path	 Hunter	 assay,	 DiscoverX,	
Fremont,	 CA,	 U.S.A.).	 The	 7TMR	 of	 interest	 is	 fused	 to	 the	 ProLink	 tag,	 the	 N-terminal	 part	 of	 β-
galactosidase,	 and	β-arrestin	 is	 fused	 to	 the	enzyme	acceptor,	which	 is	β-galactosidase	 lacking	 the	
first	41	amino	acids.	Upon	receptor	activation,	β-arrestin	is	recruited	to	the	receptor	which	leads	to	
the	 complementation	 of	 both	 β-galactosidase	 fragments.274	 The	 activity	 of	 the	 functional	 β-
galactosidase	is	measured	by	chemiluminescence.	
CHO	cells	stably	expressing	the	respective	receptor	were	seeded	in	a	volume	of	90	μL	into	a	96-well	
plate	and	incubated	at	a	density	of	20,000	cells/well	in	Opti-MEMTM	for	24	h	at	37	°C.		
After	the	incubation,	test	compounds	were	diluted	in	PBS	buffer	containing	10%	DMSO	and	added	to	
the	 cells	 in	 a	 volume	 of	 10	 μL,	 followed	 by	 incubation	 for	 90	min	 at	 37	 °C.	 For	 determination	 of	
baseline	 luminescence,	 PBS	 buffer	 (containing	 10%	 DMSO)	 in	 the	 absence	 of	 test	 compound	 was	
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used.	 During	 the	 incubation	 period,	 the	 detection	 reagent	 was	 prepared.	 For	 determination	 of	 β-
arrestin	 recruitment	 the	 detection	 reagent	 for	 the	 respective	 receptor	 was	 prepared	 (see	 below).	
After	 the	 addition	 of	 50	 μL/well	 detection	 reagent	 to	 the	 cells,	 the	 plate	 was	 incubated	 for	 an	
additional	 60	 min	 at	 room	 temperature.	 Finally	 luminescence	 was	 determined	 in	 a	 luminometer	
(TopCount	NXT,	Packard/Perkin-Elmer).	
For	 the	determination	of	antagonistic	properties	of	 tested	compounds	the	assay	was	performed	as	
described	 for	 agonists	 except	 that	 the	 test	 compounds	 were	 added	 to	 the	 cells	 in	 a	 volume	 of	 5	
μL/well	60	min	prior	to	addition	of	the	agonist	(532	nM	Yazh	473	final	concentration,	corresponding	
to	EC80,	for	MRGPRX4;	1000	nM	CST-14	final	concentration,	corresponding	to	EC80,	for	MRGPRX2	and	
10	µM	BAM22	final	concentration,	corresponding	to	EC80,	 for	MRGPRX1).	Data	were	obtained	from	
three	independent	experiments	performed	in	duplicate.	Data	were	analyzed	using	Graph	Pad	Prism,	
version	6.02	(San	Diego,	CA,	U.S.A.). 
	
	
For	human	MRGPRX1-4	 receptor	and	mouse	MRGPRB2:	The	plating	reagent	was	Opti-MEM™	and	
the	commercial	detection	reagent	kit	was	used.	
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4.8.2	cAMP	assay	
Cells	 were	 removed	 from	 a	 confluent	 175-cm2	 flask,	 transferred	 into	 a	 50-ml	 Falcon	 tube,	 and	
centrifuged	at	200g,	for	5	minutes.	After	removal	of	the	supernatant,	the	cell	pellet	was	resuspended	
in	DMEM-F12	medium.	The	cell	suspension	(500	µl,	∼200,000	cells	per	well)	was	transferred	to	24-
well	 plates	 and	 incubated	 for	 24	 hours	 at	 37°C.	 After	 removal	 of	 the	 culture	medium,	 cells	 were	
washed	 HBSS	 buffer	 and	 then	 incubated	 with	 230	 µl	 HBSS	 buffer	 for	 2	 h	 at	 37°C.	 The	
phosphodiesterase	 inhibitor	Ro20-1724	 (final	 concentration	40	μM)	dissolved	 in	100%	HBSS	buffer	
was	added	 to	each	well	and	 incubated	 for	10	min.	Thereafter,	25	μl	of	 the	agonist	was	added	and	
incubated	for	20	min.	After	incubation	with	the	agonist,	the	final	DMSO	concentration	did	not	exceed	
1.4%.	For	investigating	the	Gi	coupling	cAMP	production	was	stimulated	by	addition	of	forskolin	(final	
concentration	 10	 µM)	 for	 10	 min.	 The	 reaction	 was	 stopped	 by	 removal	 of	 the	 reaction	 buffer	
followed	by	the	addition	of	a	hot	lysis	buffer	(250	μl;	90°C;	4	mM	EDTA,	0.01%	Triton	X-100).	The	24-
well	plates	were	kept	at	room	temperature	for	5	min	and	then	kept	at	minus	20°C.	For	competition	
binding	experiments,	50	μl	of	the	cell	lysates	were	transferred	into	2.5-ml	tubes.	[3H]cAMP	(30	μl)	(3	
nM	final	concentration)	 in	 lysis	buffer	and	40	μl	of	cAMP-binding	protein	 in	the	same	buffer	(75	μg	
protein	 per	 vial)	 were	 added.	 Total	 binding	 was	 determined	 with	 50	 μl	 of	 lysis	 buffer,	 30	 μl	 of	
[3H]cAMP	solution,	and	40	μl	of	cAMP-binding	protein	containing	solution.	Nonspecific	filter	binding	
was	determined	with	90	μl	of	lysis	buffer	and	30	μl	of	[3H]cAMP	solution.	For	a	cAMP	standard	curve,	
50	μl	of	known	cAMP	concentrations	were	used	 instead	of	50	μl	of	 cell	 lysate.	After	an	 incubation	
time	of	1	hour	on	ice,	the	assay	mixture	was	filtered	through	GF/B	glass	fiber	filters	using	a	Brandel	
harvester.	Filters	were	washed	three	times	with	ice-cold	50	mM	Tris-HCl	buffer,	pH	7.4.	Then	filters	
were	transferred	into	minivials,	incubated	for	9	h	with	2.5	ml	of	scintillation	cocktail	and	counted	in	a	
liquid	scintillation	counter.	
4.8.3	Calcium	mobilization	assay	
Calcium	mobilization	assays	have	been	conducted	only	with	MRGPRX4	receptor.	Two	cell	lines	have	
been	 used.	 The	 ß-arrestin	 CHO	 and	 LN229	 glioblastoma	 cell	 line.	 For	 the	 former	 cell	 line	was	 the	
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suspension	 format	 suitable	 while	 for	 the	 latter	 the	 attached	 cell	 format	 was	 more	 appropriate.	
Novostar®	microplate	reader	was	used	for	the	measurements.	
4.8.3.1	The	suspension	cell	format	of	calcium	mobilization	assay	
Two	confluent	flasks	of	MRGPRX4	ß-arrestin	cells	were	harvested	using	3	ml	0.05	%	trypsin	/	0.02	%	
EDTA	and	the	volume	was	completed	to	30	ml	with	culture	medium.	The	cells	were	kept	under	5	%	
CO2	at	37°C	for	45	min	and	then	centrifuged	at	200	x	g	for	5	min.	The	cells	were	resuspended	in	994	
µl	KHB	(see	chapter	4.1.3)	and	transferred	to	an	Eppi.	3	μl	Oregon	Green	and	3	µl	1	%	Pluronic®	F127	
were	added	to	the	cells	and	rotated	via	a	shaker	for	1	h	at	room	temperature	under	light	protection.	
The	cells	were	added	to	a	V-shaped	basin	and	19	ml	of	KHB	were	added	mixed	thoroughly.	180	µl	of	
cell	suspension	were	pipetted	in	each	well	of	a	96-well	plate	(Greiner	655096)	and	left	for	10	min	in	
room	 temperature	 under	 light	 protection.	 In	 the	mean	 time	 a	 dilution	 of	 the	 test	 compound	was	
prepared.	Fluorescence	intensity	was	measured	at	520	nm	for	60	s	at	0.4	s	intervals.	PBS	was	used	as	
a	 negative	 control	 and	 ATP	 100	 µM	 was	 used	 as	 a	 positive	 control.	 At	 least	 three	 independent	
experiments	were	performed	in	duplicates	for	each	compound.	
4.8.3.2	The	attached	cell	format	of	calcium	mobilization	assay	
The	cells	were	harvested	using	3	ml	0.05	%	trypsin	/	0.02	%	EDTA.	The	volume	was	completed	to	10	
ml	 using	 the	 culture	medium.	 The	 volume	 of	 cell	 suspension	 corresponding	 to	 5	million	 cells	 was	
transferred	into	a	sterile	solution	basin	and	sufficient	nutrient	medium	added	to	give	a	final	volume	
of	21	ml.	Using	an	8-channel	pipette	and	sterile	filtered	tips,	200	µl	of	cell	suspension	were	pipetted	
into	 each	well	 of	 a	 sterile	 96-well	 corning	 3340	microplate	with	 clear	 bottom	 and	 incubated	 over	
night	(37	°C,	5	%	CO2,	96	%	rel.	humidity).	
The	 cells	 at	 the	 bottom	 of	 the	 96-well	 microplate	 were	 examined	 under	 a	 microscope.	 If	 they	
appeared	viable,	the	experimental	set-up	was	proceeded	with	by	inverting	the	microplate	on	tissue	
paper	 to	 remove	 the	 nutrient	medium.	A	 solution	 containing	 4970	µl	 of	HBSS	 buffer,	 15	µl	 of	 the	
detergent	Pluronic®	F-127	and	15	µl	of	the	fluorescent	dye	fluo-4	was	prepared	under	reduced	light	
conditions.	With	the	aid	of	a	stepper	pipette,	40	µl	of	this	solution	was	placed	into	each	well	of	the	
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microplate.	 The	plate	was	 incubated	 for	1	h	 at	 room	 temperature	under	 light	protection	and	with	
gentle	shaking	(200	rpm).	Meanwhile,	the	test	compounds	were	diluted	in	DMSO	in	a	V-shaped	96-
well	microplate.		
Following	the	removal	of	the	dye	solution	by	inversion	over	tissue	paper,	178	µl	of	HBSS	buffer	were	
transferred	into	each	well	using	a	multiple-channel	pipette.	Each	well	was	subsequently	loaded	with	
2	 µl	 of	 the	 antagonist	 dilution	 and	 the	 microplate	 incubated	 at	 room	 temperature	 under	 light	
exclusion.	During	this	time,	the	reagent	plate	was	prepared	by	pipetting	40	µl	of	Yazh	473	solution	
(5.32	µM)	or	HBSS	buffer	into	each	well	of	a	V-shaped	96-well	microplate.	For	agonist	assays,	180	µl	
HBSS	buffer	were	 transferred	 into	wells	and	 the	serial	dilution	of	 the	agonist	was	prepared	 in	a	V-
shaped	 96-well	 plate.	 Following	 10	min	 of	 incubation,	 the	measurement	 and	 reagent	 plates	were	
transferred	into	a	fluorescence	reader	with	pipettor	function	and	the	measurement	initiated.	
4.9	Digestion	of	IL-1ß	
In	order	to	get	digest	 IL-1ß	with	MMP-3	the	protocols	 in	Schönbeck	and	Ito	et	al.	were	taken	as	an	
example.170,171	 In	 the	 case	 of	 the	 less	 pure	 IL-1ß,	 the	 5	 µg	 of	 IL-1ß	 were	 dissolved	 in	 water	 and	
subjected	 to	 filtration	 using	 a	 3	 kDa	 cutoff	 Amicon®	 Ultra	 according	 to	 the	 instructions	 of	 the	
manufacturer.	 The	 two	 fractions	 were	 then	 immediately	 freezed	 using	 liquid	 nitrogen	 and	 then	
lyophilized.	The	fraction	of	less	than	3	kDa	was	active	and	could	be	directly	dissolved	and	used	in	a	
functional	assay.	
The	inactive	fraction	of	more	than	3	kDa	of	IL-1ß	and	MMP-3	were	dissolved	in	250	µl	H2O	each.	Both	
solutions	were	combined	and	incubated	at	37°C	at	least	for	2	h	(for	more	details	for	each	experiment	
see	 chapter	 2.4.5).	 The	 solution	 was	 then	 filtrated	 using	 a	 3	 kDa	 cutoff	 Amicon®	 Ultra.	 The	 two	
fractions	were	then	 immediately	 freezed	using	 liquid	nitrogen	and	then	 lyophilized.	The	 lyophilized	
fractions	were	then	dissolved	in	PBS	and	tested	in	a	functional	assay.	
In	the	experiment	with	the	highly	pure	IL-1ß	and	MMP-3	the	first	filtration	step	was	not	performed	
since	the	highly	pure	IL-1ß	was	not	active.	The	subsequent	steps	were	identical	with	the	exception	of	
incubating	4	µg	of	IL-1ß	and	5	µg	of	MMP-3.	
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4.10	Compound	libraries	
Number	 Name	 Composition	 Characteristics	
1	 TOCRIS	 1120	 small	molecules	with	proven	
physiological	activities	
2	 Xanthine	 352	 Drug-like	xanthine	derivatives	
3	 ChemBridge	 689	 Drug-like	small	molecules	
4	 ChemDiv	 555	 Drug-like	small	molecules	
5	 Herdewijn	 354	 Drug-like	small	molecules	
6	 Interbioscreen	 346	 Drug-like	small	molecules	
7	 Approved	drugs	 440	 Commercially	available	approved	
drugs	
8	 Dipeptides	 53	 Nitrile	amino	acid	derivatives	
9	 Briel	and	RaghuPrasad	 38	 Drug-like	small	molecules	
10	 Natural	products	 88	 Natural	products	with	reported	
physiological	activity		
11	 Lipid	 49	 Lipids	with	reported	physiological	
activity	
12	 Anthraquinones	 222	 Anthraquinones	with	
physiological	activity	
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5.	Abbreviations	
7-TMR	 Seven	transmembrane	receptor	
Ab	 Antibody	
ADP		 Adenosine	diphosphate	
AMP		 Adenosine	monophosphate	
ATP	 Adenosine	triphosphate	
BAM	 Bovine	adrenal	medulla	
bp		 Basenpaare	
°C		 Grad	Celsius	
cAMP		 cyclic	Adenosine	monophosphate	
cDNA	 copy	DNA	
CFA	 Complete	Freund's	adjuvant	
CHAPS	 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate	hydrate	
CHO		 Chinese	hamster	ovary	
CNS		 Central	nervous	system	
CSF	 Cerebrospinal	fluid	
CST-14	 Cortistatin-14	
DAG	 Diacylglycerine	
dAMP		 deoxyadenosine	monophosphate	
DMSO		 dimethyl	sulfoxide	
DMEM		 Dulbecco´s	modified	Eagle	Medium	
DNA		 deoxyribonucleic	acid	
DRG	 Dorsal	root	ganglia	
EC50		 half	maximal	excitatory	concentration	
E.coli		 Escherichia	coli	
EDTA		 Ethylendiamintetraacetic	acid	
GABA	 gamma-Aminobutyric	acid	
e.g.		 exempli	gratia	(for	example)	
ERK	 Extracellular-signal	regulated	kinase	
et	al.		 et	alii	(and	others)	
IC50		 half	maximal	inhibitory	concentration	
IF	 Immunofluorescence	
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IL-1ß	 Interleukin-1	beta	
f		 forward	
FCS		 fetal	calf	serum	
g		 gram	
G418		 geneticin	
GMP	 Guanosine	monophosphate	
GPCR		 G	protein-coupled	receptor	
h	 human	or	hour	
hBD	 human	beta	defensin	
HBSS	 Hancks'	Buffered	salt	solution	
HEK		 Human	Embryonic	Kidney	
HEPES		 N-(2-hydroxyethyl)piperazine-N'-(2-
ethanesulfonic	acid)	
HPLC		 high	performance	liquid	chromatography	
KD		 equilibrium	dissociation	constant	
Ki		 equilibrium	inhibition	constant	
KO		 knockout	
M		 Molar	
min		 minute(s)	
MMP	 Matrix	metalloproteinase	
MRG	 Mas-related	gene	
MRGPR	 Mas-related	gene	protein	receptor	
mRNA		 messenger	RNA	
MS		 mass	spectroscopy	
NMR		 nuclear	magnetic	resonance	
NGF	 Nerve	growth	factor	
OD	 Optical	density	
PAMP	 Proadrenomedullin	N-terminal	peptide	
PBS		 phosphate	buffered	saline	
PCR		 polymerase	chain	reaction	
PKA	 Protein	kinase	A	
PKC	 Protein	kinase	C	
POMS	 proopiomelanocortin	
PS		 Penicilline-Streptomycin	solution	
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r		 reverse	
RNA		 ribonucleic	acid	
rpm		 rounds	per	minute	
s		 second(s)	
s.c.		 subcutaneous(ly)	
SEM		 standard	error	of	the	mean	
SNSR	 Sensory	neuron	specific	receptor	
SST	 Somatostatin	
TNF-α	 Tumor	necrosis	factor	α	
TRPA1	 Transient	receptor	potential	A1	
TRPV1	 Transient	receptor	potential	V1	
TTX	 Tetrodotoxin	
UMP	 Uridine	monophosphate	
WB	 Western	blotting	
wt	 wild-type	
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